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ABSTRACT 
 
Ductal carcinoma in situ (DCIS) is characterised as neoplastic cells confined to the 
mammary duct system of the breast.  DCIS initially develops within and has the 
potential to extend along these ducts.  When these neoplastic cells spread outside the 
ducts into the tissue, the lesion becomes invasive ductal carcinoma. Whilst the cause of 
DCIS has not been confirmed, there is a close association between DCIS and invasive 
ductal breast cancer, with approximately half of reported invasion found at or close to 
the original DCIS site. It is therefore important to ensure all the DCIS has been removed 
during the first operation. Yet the literature varies between 5 to 72% of cases require a 
second operation to obtain adequate margins. This additional surgery has implications 
for the patient’s quality of life and an impact on the health service in terms of cost and 
management. 
 
The hypothesis for this thesis was a preoperative radiopharmaceutical injection and the 
use of an intraoperative positron emission tomography (PET) probe would accurately 
(≥80%) determine the margin status during breast conserving therapy (BCT) for DCIS. 
The significance of this study was the ability to determine adequate margin clearance 
during surgery would reduce the need for a second operation (re-excision) and 
potentially reduce subsequent breast cancer events (defined as a recurrence or invasion). 
 
This study recruited 39 patients at a private hospital in Perth, Western Australia, who 
were planned to undergo BCT for primary DCIS. The distance between the edge of the 
DCIS and the edge of the excised tumour is measured to determine the width of normal 
tissue. This distance is referred to as the clearance of the margin. The probe findings 
were compared against the pathology findings, with a 10mm clearance of the margin 
used as the gold standard and a 2mm clearance of the margin as a reference against 
other intraoperative assessment techniques. The probe was 89.7% accurate at assessing 
the surgical margin in the cavity at a 10mm clearance of margins and 92.5% at a 2mm 
clearance of margins. It was 94.5% accurate at assessing the surgical margin on the 
excised specimen at a 10mm clearance of margins and 96.5% at a 2mm clearance of 
margins.  Compared to other intraoperative margin assessment methods the PET probe 
performed better in accuracy, sensitivity and specificity. The one exception was frozen 
section analysis that was more accurate but delayed the result (~20-30 minutes). Using 
simple and multiple linear regression modelling the study was able to confirm the 
viii 
hypothesis that the PET probe could accurately determine the margin status 
intraoperatively during DCIS surgery. An ideal protocol for future studies has been 
established, including a recommendation that the injected dose of FDG should be 
≥80MBq, used within two hours of injection and whilst the probe can be applied within 
the surgical cavity and on the excised specimen it is recommended to be used on the 
excised specimen. 
 
This research was able to demonstrate the PET probe has a high accuracy when used to 
determine the status of the surgical margin in DCIS surgery. The probe performed better 
than all identified technologies when compared by accuracy, sensitivity, specificity and 
time to apply and return a result. The implications is, when additional margins are taken 
based on the probe findings, the rate of second operations will be reduced having 
improved quality of life, health service management and healthcare cost implications. 
Potentially this will reduce the rate of women experience a subsequent breast cancer 
event, thus reducing the invasive ductal carcinoma of the breast rate. Further research is 
required where additional shavings are taken based on the probe results, in a multi-
centre study with a larger sample size, to further test the capability of the probe. This 
future research should include a substantial follow-up of a minimum of ten years to 
determine the effect of the probe on subsequent breast cancer event rates. An economic 
analysis is also recommended.  
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CHAPTER 1 INTRODUCTION 
 
1.1 Introduction 
Ductal carcinoma in situ (DCIS) is characterised as neoplastic cells confined to the 
mammary duct system of the breast.  Whilst DCIS remains within, or extends along 
these ducts, it is still a non-invasive tumour. However it has the potential to spread 
outside of the ducts into the surrounding tissue and become invasive ductal carcinoma.1 
It is important to ensure all the DCIS has been removed during the first operation as 
approximately half of reported invasions are found at or close to the original DCIS site. 
The literature varies between 5 to 72% of cases require a second operation to obtain 
adequate margins which impacts on the patient quality of life and health service 
management.2-4 Adequate excision of DCIS during the first operation may also reduce 
the number of cases that progress to invasive ductal carcinoma of the breast. 
 
 
1.2 Statement of the problem 
In breast conserving therapy (BCT) for DCIS the literature has reported failure to 
achieve adequate margins can result in the need for a second operation and there is a 
significant rate of subsequent breast cancer events, specifically recurrence or invasion.4  
 
 
1.3 Research question 
The main research question is whether a preoperative radiopharmaceutical injection and 
the use of an intraoperative positron emission tomography (PET) probe can accurately 
(≥80%) determine the margin status during BCT surgery for DCIS. To test this 
hypothesis, this study was developed in a staged approach: (1) literature review to 
identify the accuracy of existing intraoperative margin assessment (IMA) methods, (2) 
epidemiological study of DCIS in Western Australia (WA), (3) radiopharmaceutical 
testing, (4) laboratory testing and phantom study for the PET probe, and (5) clinical 
testing of the PET probe in surgery. 
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1.4 Research aim and objectives 
The National Breast Cancer Centre (NBCC) recognises that further research in DCIS is 
needed in the area of treatment.  An intraoperative device that is able to accurately 
assess the extent of DCIS remaining within the surgical margin during the first 
operation, thus allowing additional shavings to be taken where necessary, can 
potentially reduce the need for a second operation and the risk of a subsequent breast 
cancer event/s. This validation study aimed to identify a suitable radiopharmaceutical 
tracer for DCIS and determine the accuracy (≥80%) of a PET probe to evaluate the 
margin status during BCT for DCIS. 
 
The five objectives of this thesis are outlined below. 
 
(1) Systematic literature review: 
1. Identify published academic literature, using a systematic method, that reports 
the use of an intraoperative method to determine margin status in BCT; 
2. Identify the level of concordance in margin assessment between reported IMA 
methods and standard assessment; and 
3. Determine the accuracy of such methods. 
 
(2) Epidemiological study: 
1. Identify the characteristics of women who have been diagnosed with DCIS in 
WA between January 1996 and December 2005;  
2. Determine the rate of second operations and breast cancer events (BCE) 
(recurrence or invasion) in the study population; and  
3. Identify risk factors for a breast cancer event in the study population. 
 
(3) Radiopharmaceutical testing: 
1. Determine if both 18F-fluorodeoxyglucose (FDG) PET and 18F-
fluoromethylcholine (FCH) PET can detect newly diagnosed DCIS; 
2. Identify the tumour to background (TTB) ratio for each radiopharmaceutical in 
DCIS; and 
3. Determine the best radiopharmaceutical to use with the PET probe.  
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(4) Laboratory testing and phantom study: 
1. Identify the sensitivity and linearity, specific activity, spatial resolution, source 
detector distance and depth response of the PET probe in a laboratory setting, 
and  
2. Determine the ideal level of activity correlating the probe response with PET 
standardised uptake value (SUV). 
 
(5) Clinical testing: 
1. Determine if the use of a PET probe can accurately assess the surgical margins 
intraoperatively in women undergoing BCT for DCIS,  
2. Determine if there is an association between PET probe findings and 
histological factors such as DCIS size, nuclear grade or necrosis, 
3. Compare the results of this study with those identified in the systematic 
literature review, and  
4. Determine the level of radiation exposure for the surgeon excising and 
handling the excised tissue. 
 
 
1.5 Definition of terms 
For the purpose of this thesis, the following definitions are used. 
 
Investigator: the PhD candidate. 
 
Ductal carcinoma in situ (DCIS): the confinement of neoplastic cells within the 
mammary duct system of the breast. 
 
Second operation: the re-excision of DCIS where inadequate margins were obtained 
during the first operation. This is undertaken within four months of the first operation. 
 
Surgical margin: the edge or rim of the tissue within the breast from where the tumour 
has been removed. On the excised tissue the surgical margin is the outside edges of the 
tissue. There are therefore six possible surgical margins: superior (top), inferior 
(bottom), medial (towards the middle), lateral (towards the side), superficial (towards 
the surface) and deep (away from the surface). 
 
Clearance of margins: The distance between the edge of the tumour and the edge of the 
excised tissue to determine the width of normal tissue 
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Breast cancer event: any recurrence of DCIS within the same breast as the primary 
DCIS diagnosis, defined as a morphology behaviour code of ‘2’, or invasive ductal 
carcinoma, defined as a morphology behaviour code of ‘3’, that occurred more than four 
months after the diagnosis of DCIS. 
 
Shavings: when the surgeon removes an additional thin strip of tissue during surgery 
after the tumour has been excised. This is performed when the surgeon believes an 
adequate margin has not been achieved with the removal of the tumour. 
 
Radiopharmaceutical: a pharmaceutical or nuclide that contains a radioactive 
compound. 
 
 
1.6 Significance of the study 
The significance of this study was the validation of the PET probe in accurately 
determining the margin status both within the surgical cavity and on the excised tissue 
during breast conserving surgery for DCIS. Where further shavings are taken based in a 
positive PET probe result, it would reduce the need for a second operation. By more 
accurately assessing the margins and as such ensuring all of the DCIS had been 
removed from the breast during the first operation, this would reduce the risk of a 
subsequent breast cancer event. Potentially this could reduce the rate of invasive breast 
cancer where DCIS is detected. 
 
 
1.7 Limitations of the study 
As this was a validation study, no additional shavings were taken during the DCIS 
operation. Although the accuracy of the probe was determined, the impact of the probe 
on the second operation rate and rate of subsequent breast cancer events cannot be 
quantified.  
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1.8 Thesis organisation 
This thesis has been organised into the following chapters. 
 
Chapter 2: Ductal carcinoma in situ. 
This chapter provides the reader with a brief introduction to DCIS. It includes an 
overview of the anatomy of the breast, the histology of DCIS, incidence rates, risk 
factors, detection, diagnosis, treatment, breast cancer event rates and the importance of 
adequate surgical margins. This chapter is designed to provide the non-clinically 
orientated reader with sufficient knowledge to understand the implications of residual 
DCIS and current treatment methods. 
 
Chapter 3: Literature review: intraoperative assessment of surgical margins for breast 
cancer. 
A systematic literature review was undertaken on intraoperative margin assessment 
methods to identify the accuracy of existing methods in breast cancer surgery. The 
results of this study were used as a basis of comparison with the PET probe. 
 
Chapter 4: Epidemiology of ductal carcinoma in situ in Western Australia 1996 – 2005. 
Whilst chapter 2 provides the clinical background to this study, chapter 4 provides the 
epidemiological evidence to support this study. The chapter discusses the rate of DCIS 
in WA, the rate of second operations and the rate of subsequent BCEs. This chapter 
supports the need for IMA technology in WA in the surgical treatment of DCIS. 
 
Chapter 5: Comparison of radiopharmaceuticals in the detection of ductal carcinoma in 
situ with positron emission tomography. 
There has been little information available on the use of PET imaging for DCIS. 
Therefore it is unknown which radiopharmaceutical tracer is suitable to use with the 
PET probe. This chapter compares FDG against FCH in two case studies to determine 
how well each is taken up by DCIS. 
 
Chapter 6: Positron emission tomography (PET) probe laboratory testing and phantom 
study. 
As there has also been minimal published research on how the PET probe functions and 
the most appropriate protocol to use in surgery, a number of laboratory tests were 
performed to identify the sensitivity and linearity, specific activity, spatial resolution, 
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source detector and depth response of the probe. A phantom study was also developed 
to ascertain the appropriate injected dose to use in surgery. This chapter concludes with 
the best protocol to use in surgery. 
 
Chapter 7: Intraoperative positron emission tomography (PET) probe for margin 
assessment of DCIS. 
This chapter discusses the results and findings from using the PET probe in BCT for 
DCIS. It outlines the accuracy, sensitivity and specificity of the probe, determines if 
histological factors impact on this accuracy, compares the results against the other 
studies identified in chapter 3 and examines the radiation exposure for the surgeon. 
 
Chapter 8: Conclusion and recommendations. 
This final chapter discusses the findings from the present study and the tentative 
conclusions drawn. Recommendations for future research are identified at the 
conclusion of this thesis. 
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CHAPTER 2 DUCTAL CARCINOMA IN SITU 
 
2.1 Introduction 
Ductal carcinoma in situ (DCIS) is a heterogeneous disease characterised as a 
proliferation of neoplastic cells confined to the mammary duct system of the breast.  
Normal breasts contain lobules, and ducts that take the milk from the lobules to the 
nipple.  These are surrounded by a fibrofatty tissue.  DCIS initially develops within 
these ducts and has the potential to extend along these ducts.  When these neoplastic 
cells spread outside the ducts into the tissue, the lesion becomes invasive ductal 
carcinoma.1 
 
This chapter aims to provide a detailed background about DCIS. The anatomy and 
pathophysiology of DCIS is outlined, including the natural history of the disease. The 
risk factors of DCIS, including age, family history and reproductive factors, are 
examined. The incidence of DCIS in Australia will be discussed in this chapter, but the 
epidemiology of the disease in Western Australia (WA) shall be examined and 
discussed in detail in Chapter 4. Methods of detecting and diagnosing DCIS are 
reviewed, including explanations for recommended methods of detection and diagnosis. 
The treatment methods and Australian treatment guidelines are examined and predictors 
of subsequent breast cancer events (BCE) (recurrence or invasion) outlined. At the 
conclusion of this chapter the reader should have an adequate understanding of DCIS 
and an introduction to the problem of this research study: the difficulties in ensuring 
adequate margins have been achieved and the implications of not ensuring complete 
excision of the DCIS during surgery.  
 
 
2.2 Abbreviations 
Below is a list of abbreviations used in this chapter: 
ABBI advanced breast biopsy instrument 
ANZBCTG Australian and New Zealand Breast Cancer Trial Group 
BCE breast cancer event 
BCT breast conserving therapy 
CI confidence interval 
CNB/CNA  core needle biopsy/aspiration 
DCIS ductal carcinoma in situ 
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EORTC European Organization for Research and Treatment of Cancer 
ER oestrogen receptor 
FNB/FNA/FNAB fine needle biopsy/aspiration 
HRT hormone replacement therapy 
mg milligrams 
MIBB minimally invasive breast biopsy 
MRI magnetic resonance imaging 
NBCA National Breast Cancer Audit 
NBCC National Breast Cancer Centre 
NSABP National Surgical Adjuvant Breast and Bowel Project 
OR odds ratio 
PAH  polycyclic aromatic hydrocarbons  
RACS Royal Australasian College of Surgeons 
RR relative risk 
VNPI Van Nuys prognostic index 
WA Western Australia 
WLE wide local excision 
 
 
2.3 Breast anatomy 
The breasts are a number of sebaceous glands within the superficial fascia of the 
anterior wall of the chest, weighing on average 200-300 grams and comprised of 20% 
glandular tissue and 80% fat and connective tissue.2 Within the breast and extending 
from the nipple in a radial manner are 15-20 lobes, each containing one collecting duct 
measuring 2-8mm in size. Within each lobe are 20-40 lobules, each containing 10-100 
alveoli.2 The anatomical positioning of these ducts and their lobe is important when 
assessing the location and extent of breast disease. Figure 2.1 shows a sagittal cross-
section of the breast, including a cross-section sketch of a lobe. Figure 2.2 shows a 
galactogram image of the breast, which highlights the ductal system. 
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Figure 2.1: Sagittal cross-section of the breast 
 
Source: http://www.bci.org.au/public/guides/breast.jpg  
 
Figure 2.2: Ductal structure of the breast including ducts 
 
Source: http://www.radiologyinfo.org/en/photocat/gallery3.cfm?pid=1&image=brst-xr-galacto1.jpg&pg=galactogram 
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Lymphatic fluid drains to the axillary nodes (approximately 75% of drainage) or to the 
internal mammary nodes and skin lymphatics.2 The axillary contains 30-60 lymph 
nodes that are anatomically found in one of three levels that determine the sequential 
lymphatic draining and potential metastasis pathway. Commencing at level 1 nodes, 
these are located lateral to the pectoralis minor muscles. Draining is then to the level 2 
nodes located beneath the pectoralis minor muscles, then to level 3 nodes located medial 
to the pectoralis minor muscles.2 
 
2.4 Histopathology 
The key histological feature of DCIS of the breast is that it contains malignant cells that 
do not have the capacity to invade the basement membrane or to metastasise outside of 
the breast. Instead the malignant cells can spread along the duct system. DCIS develops 
when dysplastic cells within the ducts of the breast become malignant cells. Generally 
only one duct is involved, but multiple ducts may contain the malignant cells thereby 
involving several quadrants, known as multifocal disease. Unfortunately there is a high 
level of inter-observer variability amongst pathologists when examining breast tissue, 
largely due to the small samples obtained through biopsy and the continuum of change 
from normal epithelium to DCIS.3-5 DCIS accounts for approximately 15-30% of 
mammographically detected breast cancers.5-8 
 
2.4.1 Architecture 
Historically, DCIS was classified according to architectural pattern. There are five 
general architectural growth patterns of DCIS:2 
1. Comedo: rod-shaped or branching epithelial cells that are rapidly proliferating. This 
is the most common form detected by mammography, in approximately 50% of 
cases. 
2. Solid: disorderly proliferation of epithelial cells. 
3. Cribriform: sieve-like or geometric lacy. Most common form to be detected 
symptomatically.  
4. (Micro) Papillary: papillary projections into the lumen of the epithelial cells. More 
often multisectional. 
5. Mixed type 
 
In many cases pathologists see a mixture of architectural patterns. Other types of DCIS 
have been identified, such as neuroendocrine, cystic hypersecretory, small cell solid, 
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encysted papillary DCIS and clinging variants, but these are rarer subtypes and 
infrequently reported.9 
 
2.4.2 Grading 
It has been agreed that classification based on architecture alone has poor 
reproducibility amongst even experienced pathologists.9, 10 Today, DCIS is generally 
classified by cytonuclear grade of the nuclei, as low, intermediate or high grade disease. 
This is grouped based on the architecture and size of the cells and nuclear abnormalities 
seen by the pathologist, as outlined in Table 2.1. 
 
Table 2.1: Pathological classification of ductal carcinoma in situ 
High grade Intermediate grade Low grade 
 Large cells with profuse 
cytoplasm, 
 Marked nuclear 
pleomorphism, 
 Increased mitosis, 
 Often central comedo-type 
necrosis in the lumen, 
 Typically a solid architecture 
with rod-shaped calcifications 
but can be (micro)papillary or 
cribriform, 
 Nuclear membranes are 
irregular, chromatin coarse 
and often multiple prominent 
nucleoli, 
 Cellular polarization is 
infrequent. 
 Moderately sized cells, 
 Usually solid architecture, 
(micro)papillary or cribriform, 
 Nuclear polarization is usually 
at a moderate degree, with a 
degree of atypia and nuclear 
uniformity between the two 
grades, 
 Some evidence of cellular 
polarization and mitosis, 
 Single cell necrosis are 
infrequent, 
 Psammoma-like or 
amorphous calcification.  
 
 Small, uniform cells, 
 Often cribiform or 
(micro)papillary architecture, 
 Round calcifications often 
seen, 
 Smooth nuclear membrane, 
fine chromatin, and 
unremarkable nucleoli, 
 Indication of cellular 
polarization, with the cellular 
apex oriented towards the 
intercellular spaces, 
 Infrequent mitoses, 
 Central necrosis and 
psammoma-body like 
calcifications can be seen. 
Sources: Dervan (2001)5; Pinder & Provenzano (2010)6 
 
Using the grading system allows greater reproducibility in diagnostic results by 
pathologists.7,9,11 Other systems have been proposed but most pathologists use nuclear 
grade as a basis. A general consensus has been reached that DCIS should be classified 
using nuclear grade, necrosis, cellular polarization and architecture.9 
 
It has been noted that DCIS follows a continuous spectrum from low to high grade, with 
an increase in growth pattern.12 The growth pattern of DCIS appears to correlate with 
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the nuclear grade, whereby high grade DCIS shows continuous growth along the ducts 
and low grade DCIS are composed of discontinuous foci.7, 9 High grade DCIS has a 
higher risk of recurrence, which impacts on the management plan for the patient.9, 11, 13 
 
2.4.3 Natural history 
The natural history of DCIS is not fully understood, with many studies based on 
historical information or case studies of low grade DCIS. A sub-study analysed the data 
for 28 women diagnosed with small, non-comedo DCIS who did not undergo any 
treatment, with 25-35 years follow-up data.14, 15 The purpose of the longitudinal study 
was to understand the natural history of low grade, noncomedo DCIS, commencing in 
the 1970s with follow-up in 1982, 1995 and 2005. The study found eleven (39.3%) 
cases developed ipsilateral (same breast) invasive breast cancer, all located at the 
original biopsy site. The majority of cases progressed to invasive carcinoma within 15 
years of the initial biopsy. The study concluded that untreated low grade, noncomedo 
DCIS will eventually progress to invasive breast carcinoma in approximately a third of 
cases within 15 years.15 Given these findings, the risk of progression for high grade 
DCIS is much higher, with studies reporting approximately 50% of high grade DCIS 
cases will progress to invasive breast carcinoma.15-17 
 
2.4.4 Other histological factors 
It is difficult to reliably predict the biological behaviour of DCIS.7 One possible 
predictor of outcome is specific genetic alterations. Identification of any biological 
factors, such as histological or genetic factors that could accurately predict the 
likelihood of progression to invasive breast cancer, would allow better tailoring of 
treatment for the initial DCIS diagnosis.7 Similar to invasive breast cancer, 
amplification of several specific chromosomal regions are involved with the 
development of the cancer and usually one or more oncogenes are identified.7 10-25% 
of invasive breast cancers have identified amplified regions. Research has suggested the 
same chromosomal regions are amplified in DCIS with comparable frequencies.7 The 
three oncogenes that have been identified in DCIS are HER-2, cyclin D1 and C-MYC. 
Amplification of several other chromosomal regions have been identified. Genetic 
studies have inferred that high and low grade DCIS have different alterations.10 Another 
predictor is hormonal status, with oestrogen receptor (ER) negative cell clusters having 
a higher expressing frequency of multiple growth related genes than ER positive cell 
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clusters. This suggests greater potential for a subsequent BCE (recurrence or invasion) 
in the same breast.11, 18 
 
 
2.5 Incidence 
Between 1993 and 1998, the incidence of DCIS in Australia increased by over 80%.19 
This may be due to an increase in the number of women having screening 
mammograms and improved data collection.  The most recent Australian data reported 
there were 13,749 new cases of DCIS diagnosed in Australia between 1995 and 2005, 
with 1,558 new cases diagnosed in 2005.20  
 
In WA only 10 cases of DCIS without invasion were diagnosed in 1982, yet there were 
120 cases diagnosed in 1997 for reasons described above.21 Since 2000, the number of 
cases has remained steadily around 200.21 
 
The incidence of DCIS compared to invasive breast cancer varies by state and 
mammography services, between 1:4 to 1:10.19 Incidence peaks at an earlier age, with 
the mean age in Australia of 59 years.19 More than a third of new DCIS cases in 2005 
were women in the 50-59 years age group.20 
 
 
2.6 Risk factors 
There has been no research to successfully identify the cause of DCIS. Research has 
identified a number of associated risks, which are similar to those for invasive breast 
cancer.  
 
2.6.1 Family history and age 
Similar to invasive breast cancer, family history has a strong association with DCIS.22-25 
In a large population-based case-control study, a family history of breast cancer was 
identified as the greatest risk factor for developing DCIS with an odds ratio (OR) of 
1.48, with other studies reporting an OR up to 2.4.22, 24 A first-degree family member 
who was diagnosed at a young age with breast or ovarian cancer further increased this 
risk. Research has identified the link between the presence of the BRCA1 and BRCA2 
alleles and an increased risk of invasive breast-ovarian cancer, yet this has not been 
extended to DCIS. This may be due to in situ cancers being unstable genetically with 
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alterations shared with synchronous invasive cancer.26 There was also an inverse 
relationship between family history of breast cancer and age of onset, with an OR 2.4 
for cases diagnosed under 50 years of age versus 1.4 for cases diagnosed 50 years or 
older.23 Women under 45 years of age, with a first-degree family member with a history 
of breast cancer, have the highest risk factor (relative risk [RR] = 2.50).23 
 
2.6.2 Reproductive factors 
A number of reproductive factors have been associated with DCIS, including older age 
at time of first full term pregnancy, or fewer full-term pregnancies or nulligravida 
(never been pregnant).22-25, 27 The risk was halved in women who had four or more full-
term pregnancies when compared to women with a single birth.23 Women who were 
nulligravida had a RR of 2.31. Later menarche reduced the risk of DCIS whilst an older 
age at menopause increased the risk of DCIS, supporting the argument that long 
uninterrupted periods of exposure to oestrogen and progesterone can increase the risk of 
developing DCIS.22, 25 However, research has found there is no significant increase in 
risk of DCIS when assessing postmenopausal serum levels of sex hormones (estradiol, 
estrone, testosterone, androstenedione, DHEAS and SHBG).28 Within mammary tissue 
the degree of ER expression peaks during the DCIS stage and hormone dependence is 
diminished.29 
 
Most studies have found no association between the use of oral contraceptives or the 
use of hormone replacement therapy (HRT) and an increased risk of DCIS, with the OR 
0.92 and 1.22 respectively.22 Longnecker found an OR of 1.47 for use of HRT after 
excluding cases with an imputed age at menopause, but the 95% confidence interval 
(CI) was very wide (0.82-2.63). When adjusted for frequency of mammography and 
number of physician visits, there was no difference in risk to the control group. A 
similar result was found in the group who had ever used oestrogen replacement 
therapies.25 Only two studies suggested a positive association between HRT and DCIS, 
but there were significant flaws in study design or statistical results and therefore these 
results cannot be accepted. The first study identified a statistically significant 
relationship (p=0.0004), yet there is no mention of adjusting for any confounding 
factors and the primary aim of this research was to examine the association between 
alcohol consumption and DCIS.30 The second study identified a RR of 1.51 for DCIS in 
the oestrogen-only HRT use group, but the p value was not statistically significant 
(p=0.1).31 
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2.6.3 Body and breast density 
Although obesity has been associated with an increased risk of invasive breast cancer, 
no such association has been found with DCIS.23 In fact, research has found that a body 
mass index of 25 kg/m2 or higher was associated with a decreased risk of DCIS 
(OR=0.4-0.66).24, 25 Breast density has been identified as a risk factor for DCIS.32 
Measured as the percentage density and size of dense area, mammographic breast 
density was found to have an OR of 2.86 when the mean percentage density was over 
50% (p=0.001). The OR became 1.70 where the mean breast dense area was 30-
44.9cm2, and 2.59 where over 45cm2 (p=0.0026).32 However, the factors that affect 
breast density are unknown and could be the actual risk factors for DCIS.  
 
2.6.4 Social factors 
Although there is little evidence linking diet to DCIS, research has linked diet to early 
menarche, which has been shown above to increase the risk of DCIS.29  Vitamin D 
stores (or plasma 25-hydroxyvitamin D [25-OHD] levels) decrease the invasive breast 
cancer risk, but a significant association was not observed in DCIS.33 
 
The association with alcohol consumption and cigarette smoking has been extensively 
established for invasive breast cancer but these risk factors are debatable for DCIS. 
Whilst a number of studies 22, 23, 30, 31 found no association between either risk factor and 
DCIS, some websites still list these as risk factors (MayoClinic, DCIS Info and 
Macmillan Cancer Support). Polycyclic aromatic hydrocarbons (PAH) may play a role 
in the development of breast cancer.34 PAH are a class of chemical carcinogens found in 
the environment due to fossil fuel combustion, tobacco smoke and foods including 
charred or broiled meats. A study that measured PAH-DNA adducts in both diagnosed 
women and controls found that after controlling for known risk factors PAH-DNA 
adducts was significantly associated with breast cancer (OR=4.43).34 But the research 
also identified that neither smoking status (including passive smoking) nor diet were 
significantly associated with PAH-DNA adducts or breast cancer status. The study did 
not provide separate DCIS data but did include DCIS cases in the analysis.  
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2.6.5 Other factors 
‘Environmental factors’ are also listed as risk factors on a number of websites yet are 
not detailed as to what these are. An extensive literature search could not locate any 
published article to support this potential association, other than the occasional 
reference to it being a risk factor. 
 
Another area of debate is the association between a history of atypical hyperplasia of the 
breast (benign breast disease) and DCIS, and a history of breast biopsy and DCIS. A 
breast biopsy does not necessarily imply a positive result. However, a history of any 
breast disease could result in more frequent surveillance, thereby increasing the 
likelihood of early detection. The risk of invasive breast cancer following a diagnosis of 
benign breast disease is well documented, attributed to the natural history of the 
disease.22, 23, 25 
 
The measles virus was identified in 64% of invasive breast cancer tumours excised as 
part of a study.35 All specimens which contained a DCIS component showed the 
measles virus. The research found that a lower histological grade (p=0.011), 
overexpression of the tumour protein p53 (p=0.03) and younger age (p=0.041) were 
significantly associated with the presence of the measles virus. Due to the presence of 
the measles virus antigen in these three subgroups of breast cancer, including DCIS, it 
appeared to be a factor in the development of breast cancer. In turn this provides further 
support for immunization programs in order to reduce the risk of developing breast 
cancer. 
 
However it should be remarked that women without any apparent risk factors can still 
develop DCIS. Therefore further research is required. 
 
 
2.7 Detection 
A number of methods can be used to detect DCIS, but mammography is the most 
widely used. Very uncommonly, DCIS can be palpated either by self-breast or clinical 
examination.   
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2.7.1 Mammography 
Mammography uses low-dose x-rays to create an image of the breast. Most modern 
mammograms are digital, or known as full-field digital mammography, which converts 
the x-ray into electrical signals using solid-state detectors. These can then be viewed on 
a computer. Computer-aided detection is where specialist computer software is able to 
detect abnormalities such as abnormal mass, density or calcification. Mammography 
works by placing the breast into the unit, which is then compressed and held in place 
with a paddle so images can be obtained of only the breast tissue from different angles. 
Radiation is then passed through the tissue in short bursts, allowing the x-ray to be 
captured.36 DCIS is usually identified through routine mammograms by the presence of 
(micro)calcification/s.   
 
Figure 2.3 shows DCIS on a mammogram. During a mammography, lesions detected 
are classified as:36 
1. Benign. 
2. Probably benign. 
3. Indeterminate/equivocal findings. 
4. Suspicious findings of malignancy. 
5. Malignant findings. 
 
Figure 2.3: Ductal carcinoma in situ detected by mammogram 
 
Source: http://www.radiologyassistant.nl/en/p4793bfde0ed53  
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The accuracy of mammography has been well reported in the literature, ranging from 
55.0% to 95.0%.37-41 Large screening programs occur in many countries, and the cost-
benefits of mammography compared to other modalities make it the ideal screening tool 
for breast diseases. 
 
While mammography is an adequate tool in detecting the calcification associated with 
DCIS, mammograms tend to underestimate the actual pathological extent of DCIS.19, 42  
A review of hospital mammograms for diagnosed DCIS cases showed that the extent of 
DCIS on the mammogram was inaccurate by more than 10mm compared to the actual 
pathological extent of DCIS in 43% (89/205) of cases.43 This has been validated by 
other research.44 
 
2.7.2 Ultrasound 
Ultrasound, also known as ultrasound scanning or sonography, uses high-frequency 
sound waves to produce images of the inside of the body. Using a transducer, or small 
probe, and ultrasound gel, the transducer sends soundwaves into the body and receives 
the echoing waves. The transducer is able to detect small changes in the sound’s 
direction and pitch, capturing real-time images on a monitor. A Doppler ultrasound can 
also be used to measure the blood flow, speed and direction through vessels. This is 
useful with breast changes to determine if an abnormal area has any blood flow. The 
advantage of this modality is it does not produce any radiation and the patient can lie 
comfortably on their back whilst undergoing the procedure.45 
 
Whilst invasive breast carcinoma can be seen clearly on ultrasound, DCIS can be 
difficult to distinguish, as shown in Figure 2.4.39 Ultrasound should be used to 
supplement mammography findings.38 
  
20 
Figure 2.4: Ductal carcinoma in situ detected by ultrasound 
  
Source: http://radiopaedia.org/cases/dcis-ultrasound-image-correlation  
 
2.7.3 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) uses magnetic field, radio frequency pulses to 
produce the image of the inside of the body. The traditional MRI unit is a large donut-
shaped tube surrounded by a circular magnet, with a movable bed which passes through 
the centre. Some are cylinder-shaped that the patient moves into, whilst others are open 
MRI units, where the unit is open on the sides and the magnet does not completely 
surround the patient. The unit works by passing an electrical current through wire coils, 
sending and receiving radio waves to produce a signal. A computer program then 
processes these signals into a series of images, which results in thin slices of the area of 
interest.  For a breast MRI the patient is required to lie face down on a platform which 
has been designed to accommodate the breasts and allow them to hang. A contrast, 
gadolinium, which is used to enhance images, is injected intravenously.46 Figure 2.5 
shows the contrast in the duct system during a MRI. 
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Figure 2.5: Ductal carcinoma in situ detected by magnetic resonance imaging 
 
Source: http://www.radiologyinfo.org/en/info.cfm?pg=breastmr 
 
Current data indicates that MRI has a high sensitivity in detecting DCIS, in particular 
high grade DCIS, and dynamic contrast-enhanced MRI is considered to have the highest 
sensitivity.41 The reported accuracy of MRI in detecting DCIS ranges from 77%-96%.39, 
41, 47 However, there is a need for larger sample size studies to support use of MRI. 
Currently, it is recommended to use MRI to supplement mammography in the staging of 
breast disease, particularly those who are at high risk.47 Indeed, a combination of 
mammography, clinical examination and MRI greatly increases the sensitivity of DCIS 
diagnosis, with 100% accuracy reported.39 
 
2.7.4 Breath analysis 
Recently researchers in WA have been testing a novel device to identify women who 
are unlikely to have malignant breast cancer, through the analysis of volatile organic 
compounds in a woman’s breath. Volatile organic compounds are known markers of the 
oxidative stress associated with breast cancer, which leads to lipid peroxidation in cell 
membranes. This generates a number of alkanes which can then be detected by 
analysing the breath. Pilot data has identified a negative predictive value of 99.93% but 
also revealed that co-morbidities such as infectious or inflammatory conditions could 
also cause the oxidative stress.48 Subsequent studies found the sensitivity of the test to 
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be 78.5% and specificity 88.3%.49 Further research with larger sample sizes are required 
and should include DCIS only cases to establish the accuracy of this technology in this 
subgroup. 
 
2.7.5 Other detection techniques 
There are other new techniques under investigation, such as magnetic resonance 
elastography, ultrasound elastography, ductoscopy and ductal lavage, and optical 
imaging.38, 44, 47 
 
 
2.8 Diagnosis 
Diagnosis can only be confirmed through a biopsy (removal of a small sample of tissue 
to be microscopically examined by a pathologist to determine the cytological processes 
of the tissue). Usually a biopsy is performed for diagnosis before the surgeon considers 
removing the lesion. A biopsy can be collected through a number of methods. Typically 
a fine or core needle biopsy is used to remove the sample for pathological examination. 
 
2.8.1 Fine needle biopsy/aspiration 
A fine needle biopsy or aspiration (FNB or FNA or FNAB) is where the surgeon uses a 
very thin needle, which is attached to a syringe, to aspirate a small sample of tissue 
from the area of interest. The needle is finer than those used to withdraw blood for 
testing.50 
 
If the area can be palpated, the surgeon may be able to guide the needle directly into the 
site. But with DCIS the site usually cannot be felt and the surgeon will need to be 
guided. This can occur through two methods. In ultrasound-guided FNB the surgeon 
uses ultrasound to guide them to the DCIS. Alternatively stereotactic FNB uses 
mammogram images from two different angles to guide the surgeon to the DCIS.50 
Figure 2.6 shows a fine needle biopsy of the breast. 
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Figure 2.6: Fine needle biopsy of the breast 
 
Source: http://www.beliefnet.com/healthandhealing/getcontent.aspx?cid=14777 
 
There is minimal pain incurred by such a thin needle. The limitation of this technique is 
only the sample being removed is tested. There is a risk that the DCIS is missed or 
when the full lesion is removed, pathology may identify a different result to the biopsy. 
Fortunately using this technique minimises the risk of such occurrences.  
 
2.8.2 Core needle biopsy/aspiration 
A core needle biopsy or aspiration (CNB or CNA) is the same as a FNB but the needle 
used is larger and hollow. It then removes small cores of the tissue of interest (i.e. 
usually a number of cores are removed for examination), as shown in Figure 2.7. As the 
needle is larger and more samples are taken the results are likely to be more accurate, 
but it can induce some pain and bruising to the breast. Like a FNB, ultrasound-guided or 
stereotactic methods can be used to guide the surgeon.50 
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Figure 2.7: Core needle biopsy of the breast 
 
Source: http://www.mayoclinic.com/health/medical/IM00066 
 
A Mammotome® or Automated Tissue Excision and Collection® system is a vacuum or 
suction assisted CNB. The probe is guided using the technique described above, but 
then, using a vacuum or suction, a cylinder of tissue is drawn into the probe and a 
rotating knife cuts the tissue from the breast. Multiple samples can be removed using 
this technique, allowing a greater quantity for pathological testing.50 
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2.8.3 Advanced breast biopsy instrument 
An advanced breast biopsy instrument (ABBI) is a device used for diagnostic biopsy of 
breast lesions. During an ABBI procedure the patient is lying face down, with the breast 
under investigation brought through an aperture on the table and pressure is applied to 
the breast similar to a mammogram. Stereotactic views are taken for localisation. Once 
the patient has been transferred to the stereotactic table, the ABBI is applied, extending 
a guide needle to position a T-bar for targeting. Further stereotactic views are taken to 
ensure correct placement. An oscillating blade (part of the ABBI) is then inserted 
beyond the target and the specimen is excised using an electrocautery-powered snare.51 
Figure 2.8 shows the positioning of the patient and probe during an ABBI procedure. 
 
Figure 2.8: Advanced breast biopsy instrument 
 
Source: http://www.mayoclinic.com/health/medical/IM04058 
 
A minimally invasive breast biopsy (MIBB) is the same procedure as the ABBI, except 
it is a suction-assisted instrument and is designed similar to the mammotome.  
 
2.8.4 Other techniques 
Other techniques include an open (surgical) biopsy, either incisional or excisional, or a 
wire localisation.  
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2.9 Treatment 
The primary treatment for DCIS is surgical excision, but other treatments are described 
below. The risk of not treating DCIS has been discussed above in section 2.4.3. The ten 
year survival rate is reported as 95-99%, depending on the extent of the treatment 
received.8, 52-54 
 
2.9.1 Surgery 
Once a patient has been diagnosed with DCIS, the surgeon will decide whether to 
recommend surgical excision and what type of surgery is most suitable for the patient, 
based on size, focality and extent of DCIS foci, presence of invasion and family history. 
 
The National Breast Cancer Centre (NBCC) states that complete surgical excision with 
the best cosmetic results should be the aim for surgical treatment of DCIS.19 Therefore 
the decision between a wide local excision (WLE), a quandrantectomy or a mastectomy 
is an important one.  Breast conserving therapy (BCT), through either a WLE or 
lumpectomy, is where a wide area around the lesion is removed. A quadrantectomy is 
where a quadrant or quarter of the breast tissue is removed. And a mastectomy is where 
the whole breast is removed, either simple, radical or sparing (nipple and/or skin). For 
most DCIS patients primary surgical treatment will be BCT rather than a mastectomy, 
but the size of the DCIS, location, grade and surgeon/patient preference will determine 
the method used.19 
 
The role of the pathologist is to ensure all the DCIS has been removed.  They will 
measure the distance between the edge of the DCIS and the edge of the specimen to 
determine the extent of health tissue, or clearance of the margins. The recommended 
width varies by country but most require a 5-10mm distance between the DCIS and the 
margins of the specimen to ascertain whether there is clearance of the margins. Where 
the width is smaller, the surgeon must determine whether to excise more breast tissue in 
case any DCIS remains in the breast.  
 
The literature has indicated that 14 – 39% of women with a diagnosis of DCIS who 
were treated by biopsy alone, without any further surgical intervention, developed 
invasive breast cancer (follow-up 4.4 – 21 years).19, 55 The standardised incidence ratio 
for subsequent invasion after completely excised DCIS varies between 4.5 to 11.7 
(RR=1.13-1.84) and the majority of invasions occurred in the ipsilateral (same) breast.56 
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The NBCC reported 84% of patients were free from disease after being treated by 
surgery alone after 4 years, as compared to 91% for BCT and radiation therapy and 98% 
by mastectomy.56 The survival for women treated for DCIS with BCT alone after 15 
years was 94%. 
 
There is some concern that DCIS cases may be over-treated.8, 52 For primary surgical 
method, it has been reported as many as 58.7% of cases are treated by mastectomy, 
largely due to high grade DCIS.54, 57-60 The subsequent BCE rate following BCT has 
been reported as 3.9-10.5% compared to 0.35-2% following mastectomy.52, 54, 61, 62 
 
2.9.2 Radiation therapy 
There is still much debate as to whether to use radiation therapy following surgery for 
DCIS.  
 
The National Surgical Adjuvant Breast and Bowel Project (NSABP) B-17 study 
evaluated the use of radiation therapy following breast conserving therapy in 790 
patients (recruited from 1985 to the late 1990s in the United States) diagnosed with 
DCIS.63, 64 Patients were randomised to either no further treatment (follow-up only) or 
to receive 50 Gy radiation therapy at 2Gy per week with no boost. Randomisation was 
stratified by age, method of detection, histological subtype and axillary dissection, with 
an even balance between the control and study group. The inclusion of radiation therapy 
in the management of invasive ductal cancer and DCIS resulted in a 1.8-fold reduction 
in risk of a subsequent BCE in both groups (45%; RR=0.56). There was a similar 
distribution between primary surgical methods of BCT and mastectomy. 63, 64 However, 
the study found no reduction or impact on breast cancer mortality (RR=1.12).  
 
The European Organization for Research and Treatment of Cancer (EORTC) conducted 
a randomised phase III trial of radiation therapy following breast conserving therapy.64 
This study found a 55% (RR=0.46) reduction in risk of a BCE but similar to the NSABP 
B-17 study, there was no impact on mortality (RR=0.33). 
 
The Australian & New Zealand Breast Cancer Trial Group (ANZBCTG) collaborated 
with the CRC Breast Cancer Trials Group (United Kingdom DCIS Trial) and the 
Scottish Cancer Trials Breast Group in a large randomised trial between May 1990 and 
August 1998.65 A total of 1030 women were randomised to receive or not to receive 
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radiation therapy. The study found radiation therapy reduced the rate of subsequent 
BCEs by 61%.  
 
Although all of the above studies found statistically significant reductions in risk of 
recurrence, these typically only represented less than 10% of women diagnosed. Other 
research has demonstrated that any treatment of DCIS reduces the BCE rate by 10%.66-
68 
 
Another study examining the impact of radiation therapy on recurrence included margin 
width as a correlating factor.69 With a sample size of 469 cases, the study concluded that 
radiation therapy did not lower the rate of recurrence where the margins were 10mm or 
more. There was also no statistically significant benefit of radiation therapy where 
margins were 1mm-10mm. Statistically significant benefits for post-operative radiation 
therapy was only observed in patients who have a margin width of 1 mm or less. This 
finding was supported by the NSABP, the EORTC and other studies.15, 70-72 
 
2.9.3 Tamoxifen 
The NSABP B-24 study examined the use of tamoxifen (10mg twice daily) for five 
years following BCT and radiation therapy.11 Tamoxifen is an oestrogen antagonistic 
drug used to treat breast cancer following primary treatment (for example, surgery, 
chemotherapy and/or radiotherapy).11 Local recurrence was 8% in the tamoxifen group 
after seven years compared to 11% in the control group (p=0.02). This was not 
significant in DCIS recurrence but was for invasion. There was an increase in 
prevalence in endometrial cancer (0.8% versus 0.3%) in the study group compared to 
the control group, and thromboembolic events (2% versus 1%), but no benefit was seen 
in women over 50 years of age, cases with complete excision or where histology 
showed no necrosis. The study found no effect on breast cancer mortality. Analysis of 
ER positive cases that benefit from tamoxifen was limited to this subgroup.11 
 
In the ANZBCTG study, 1,576 patients participated in the tamoxifen arm of the study, 
to either receive tamoxifen or not receive tamoxifen (control). Patients received BCT 
and no radiation therapy. Results showed an 18% reduction in BCE in the tamoxifen 
group, but was not statistically significant (p=0.13). Although tamoxifen did not affect 
invasive events, there was a 33% reduction in local recurrence (p=0.02).65 
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It appears that the greatest reduction of risk occurs in women aged under 50 years who 
were ER positive. The benefits of using tamoxifen in this group must be weighed 
against the increased risk of incidental events (endometrial cancer, thromboembolic 
events) for the management of DCIS. 
 
2.9.4 Van Nuys prognostic index 
The original Van Nuys prognostic index (VNPI) categorises DCIS cases based on 
nuclear grade, size and margin clearance. Low grade nuclei (1) is where nuclei diameter 
is 1-1.5 times that of red blood cells with diffuse chromatin and inapparent nucleoli, no 
necrosis. Intermediate grade nuclei (2) is where nuclei diameter is 1-2 times that of red 
blood cells with coarse chromatin and infrequent nucleoli, necrosis present. High grade 
nuclei (3) is where nuclei diameter is greater than two red blood cells with vesicular 
chromatin and one or more nucleoli, with or without necrosis.12, 58 Size is grouped as 
less than 15mm (1), 16-40mm (2) and greater than 40mm (3). Clearance of the margins 
is grouped as greater than 10mm (1), 1-9mm (2) and less than 1mm margin (3). The 
sum of the three scores is the VNPI, from 3 to 9. Based on this score, the recommended 
treatment can be identified: 3-4 = BCT, 5-7 = BCT and radiation therapy and 8-9 = 
mastectomy. In 2003 a fourth prognostic factor of age was introduced to the modified 
VNPI: greater than 60 years (1), 40-60 years (2) and less than 40 years (3).58 This 
resulted in a score from 4-12 with recommended treatment as: 4-6 = BCT, 7 – 9 = BCT 
and radiation therapy and 10-12 = mastectomy.58 73 
 
A retrospective study reviewed 104 patients applying the modified VNPI to determine if 
they would have received a different management plan and the impact of the VNPI on 
BCEs.58 Applying the VNPI, the study found that 58.6% of patients had been 
undertreated, with 35.3% experiencing a BCE. Only 7.7% of patients were over-treated, 
with 1.3% of cases experiencing a BCE. Overall, there was an 11.5% rate of BCEs, with 
more than half involving invasion (58%). The study supported the VNPI to ensure 
patients were not over-treated, that high-risk patients received adequate treatment and 
radiation therapy was only used appropriately.  
 
A British study applied the VNPI (not modified since age had no effect on recurrence in 
the study population) retrospectively to 215 DCIS cases treated with BCT alone (except 
nine patients who received radiation therapy). This allowed the analysis of recurrence 
rates in each VNPI category. Those who scored a VNPI of 3-4 had a low recurrence rate 
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(0%, p=0.002). An intermediate score of 5-7 had a 21.5% recurrence rate (p=0.002) and 
a high score of 8-9 had a 32.1% recurrence rate (p=0.002). The report supported the 
VNPI as an accurate predictor of recurrence and the need for increased treatment of 
high risk patients.74  
 
2.10 Treatment guidelines 
In Australia, a set of evidence-based clinical practice guidelines, The Clinical 
Management of DCIS, Lobular Carcinoma In Situ and Atypical Hyperplasia of the 
Breast, was published by the NBCC.19 Table 2.2 is the summary of recommendations 
taken directly from the guidelines. Breast Surgeons of Australia and New Zealand Inc. 
conducted a National Breast Cancer Audit (NBCA) to ascertain adherence to the 
guidelines, in which participation is mandatory for all surgeons wishing to maintain full 
membership status with the Royal Australasian College of Surgeons (RACS) Breast 
Section.75 An analysis of the audit data entered between 1998 and 2004 showed close 
adherence to the guidelines in Australia.  
 
Table 2.2: Summary of the recommendations from “The Clinical Management of 
DCIS, Lobular Carcinoma In Situ and Atypical Hyperplasia of the Breast”. 19 
SUMMARY OF RECOMMENDATIONS 
DIAGNOSIS OF DCIS 
Image-guided core biopsy is the recommended diagnostic method for DCIS. 
PSYCHOSOCIAL SUPPORT 
Women should be offered appropriate support and information about their diagnosis and treatment to 
enhance their emotional wellbeing and physical recovery. 
SURGERY 
It is essential to ensure that clear margins are obtained when DCIS is excised. If the margins are 
involved, further excision is required. Axillary dissection should not be performed in the management of 
DCIS unless invasion is suspected. 
ADJUVANT RADIOTHERAPY 
The addition of radiotherapy after complete local excision reduces the risk of subsequent invasive breast 
cancer and recurrence of DCIS for all pathological subgroups of patients. For women with good 
prognostic features, the overall clinical benefit of adjuvant radiotherapy may be small. In these 
circumstances, the woman may choose to omit radiotherapy. Women with high-grade DCIS with 
necrosis, close margins and larger lesions have a relatively high risk of recurrence with conservative 
surgery alone, and adjuvant radiotherapy is therefore recommended. 
RISK OF RECURRENCE 
The risk of recurrence of DCIS or subsequent invasive breast cancer following complete local excision, 
with or without radiotherapy, will vary depending on identified predictive factors, such as nuclear grade, 
size, presence or absence of necrosis, margin width and other prognostic factors. All these factors should 
be considered when discussing the risk of recurrence and management options with the woman. 
Source: taken directly from page 7 of the NBCC publication [19] 
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2.11 Recurrence and invasion 
An Australian study found the five year probability of invasion following a diagnosis of 
DCIS was 4.36% and ten year probability was 8.27%.20 It is estimated half of 
subsequent BCEs are invasive disease, usually at the original excision site.10 The 
literature identified the following predictors for future recurrence or invasion:7, 10, 76-78 
 Primary surgical method (BCT versus mastectomy); 
 Involved or close margins; 
 Less than 40 years of age; 
 Large lesion size; 
 Poorly differentiated DCIS; 
 High nuclear grade; 
 Architectural growth pattern; 
 Presence of necrosis; 
 Symptomatic detection. 
 
Margin status emerged as the most important predictor of a BCE, followed by age and 
size.71, 79-82 
 
 
2.12 Margins 
It has been generally agreed that BCE often occur at the previous excision site and that 
this could be due to inadequate margins at initial excision.10,16,70,83 A study that 
identified that 96% of recurrences following complete resection of DCIS were at or near 
the initial surgical site concluded that there was inadequate resection of the primary 
DCIS.84 The study recruited patients in which pathology indicated clear margins, to 
undergo further excision within days of the initial surgery to increase the margin of 
safety. In these re-excised tissue samples, 48% had residual DCIS. The study concluded 
that inadequate initial excision of the DCIS was the leading cause of recurrence and 
invasion.84 
 
Therefore, complete excision is vital in the treatment of DCIS. Yet there is no 
universally agreed margin width for complete clearance. Research has demonstrated 
that a margin less than 1mm increases the risk of a BCE.10,72,83,85-87 Most surgeons 
define adequate clearance as a margin width of 2mm (with radiation therapy) to 10mm 
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or more, with many reported surgeons and countries requiring at least a 5mm margin 
and preference for a 10mm margin.10,73,82,85,86,88, 89 
 
Inadequate margin width can result in a patient requiring a second operation, also 
referred to as re-excision. The second operation rate can vary between and within 
countries, from 5-72%, with most reporting a 20-25% re-excision rate.19,54,85 A local 
Royal Perth Hospital review identified there was a higher rate of second operations in 
patients with high-grade DCIS or aged less than 50 years following an initial WLE.  In 
both of these groups, over 50% of patients required a second operation.43 
 
Surgeons rely on mammographic images when determining the extent of tissue to 
remove during surgery. It is very difficult to accurately identify from mammography 
how much should be excised to ensure clearance of the margins.7, 10 The size of DCIS 
on mammography is underestimated, though this can be variable by the architecture of 
the DCIS. It has been reported 80-85% of cases underestimation is by less than 20mm.10 
Another study found more than 40% of cases were underestimated by mammography 
by more than 10mm.85 
 
There have been a number of intraoperative methods for the assessment of surgical 
margins developed, and these will be reviewed in Chapter 3. 
 
2.13 Conclusion 
Although DCIS is a pre-invasive carcinoma, it has a strong association with invasive 
ductal carcinoma. Even where there is a complete excision of DCIS as determined by 
pathology, there is still a risk of a subsequent BCE, lending researchers to question if 
complete excision has been truly achieved. Mammography remains the gold standard 
for detecting DCIS, but advances in other technologies have seen an increase in the use 
of MRI in high risk cases. BCT is the recommended treatment method for DCIS as it is 
minimal treatment for a pre-invasive condition. However mastectomy is still widely 
used, particularly for high grade DCIS. Radiotherapy has shown to decrease the risk of 
BCEs when used in high grade cases. It is important to ensure patients are free of DCIS 
whilst minimising the number of procedures and achieving satisfactory cosmetic 
appearance of the breast. Therefore an effective method is required to identify that 
margins are free of disease during the initial operation.   
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CHAPTER 3 LITERATURE REVIEW: INTRAOPERATIVE ASSESSMENT OF 
SURGICAL MARGINS FOR BREAST CANCER 
 
 
3.1 Introduction 
There is a strong association between ductal carcinoma in situ (DCIS) and invasive 
ductal carcinoma. Ensuring clear margins during the resection of DCIS is part of the 
recommendations made by the National Breast Cancer Centre’s (NBCC) evidence-
based clinical practice guidelines.1 Research has reported that 20-25% of patients 
treated for DCIS using breast conserving therapy (BCT) will require a second operation 
to obtain clear margins, with second operation rates as high as 72% being reported.1-3 
Optimal surgical margin distance varies between and within countries, with most 
reporting between 2mm and 10mm as the optimal minimal margin width.3-5 BCT is the 
preferred surgical method for patients who are not at high risk, therefore surgeons need 
to accurately assess the extent of disease and margin status during surgery to reduce the 
need for a second operation. A method that is able to provide the surgeon with accurate 
information intraoperatively about margin status would potentially reduce the need for a 
second operation.  An intraoperative margin assessment (IMA) method is defined for 
the purpose of this chapter as a non-invasive method applied to the excised tissue or 
within the surgical cavity to produce results about margin status during surgery to 
enable further tissue shavings to be taken. The gold standard assessment will be defined 
as pathology (histology or cytology), performed postoperatively, and hereby referred to 
as the standard assessment. Results from this review will be useful to compare against 
the positron emission tomography (PET) probe results in Chapter 7. 
 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines have been used to structure the format and reporting of this systematic 
literature review.6 Articles were selected and analysed to identify reported IMA methods 
in BCT. Since there are only a few reports on IMA in surgery for DCIS of the breast, 
this review included all breast cancer articles. The objectives of this review were: (1) 
identify published academic literature, using a systematic method, that reports the use of 
an IMA method to determine margin status in breast conserving therapy (BCT); (2) 
identify the level of concordance in margin assessment between reported IMA methods 
and standard assessment; and (3) determine the accuracy of such methods.  
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3.2 Abbreviations 
Below is a list of abbreviations used in this chapter: 
BCT breast conserving therapy 
cm centimetres 
DCIS ductal carcinoma in situ 
IDC invasive ductal carcinoma 
IDSM intraoperative digital specimen mammography 
ILC invasive lobular carcinoma 
IMA intraoperative margin assessment 
LCIS lobular carcinoma in situ 
mm millimetre 
NBCC National Breast Cancer Centre 
No. number 
NPV negative predictive value 
NR not reported 
OCT optical coherence tomography 
PPV positive predictive value 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analyses 
QAS quality assessment score 
QAT quality assessment tool 
RFS radiofrequency spectroscopy probe 
SD standard deviation 
SR specimen radiography 
SSM standard specimen mammography 
STROBE Strengthening the Reporting of Observational Studies in 
Epidemiology 
USA United States of America 
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3.3 Methods 
The methods and format used for this systematic review follow the PRISMA format.6 
 
3.3.1 Eligibility criteria 
The inclusion criteria for articles were those which: 
1. examined breast cancer,  
2. undertook an intraoperative assessment of the surgical margins with the intention 
of immediate feedback on the status (with or without further excision),  
3. human studies only,  
4. available in English,  
5. scholarly journal articles with full text available, and 
6. published between January 2000 and May 2013. 
 
Articles were excluded from consideration if they: 
1. examined phantom (laboratory) or animal data, 
2. used an additional shavings method to increase surgical margins, 
3. examined lesion size, lesion localisation or guidance or specimen orientation 
without margin assessment, 
4. examined various cancers outside of the breast, 
5. examined the predictors of successful margin clearance. 
 
3.3.2 Information sources 
The databases Proquest, Medline, PubMed and Science Direct were searched from 
January 2000 to May 2013. The reference lists of selected journal articles were not 
reviewed in line with the PRISMA approach adopted. 
 
3.3.3 Search strategy 
A search was undertaken on 3 June 2013 using the following strategy: 
 
Keywords = ‘breast’ AND ‘surgery’ AND ‘intraoperative’. 
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3.3.4 Study selection 
The process for study selection is presented in Figure 3.1. 
 
Figure 3.1: Flow diagram of article selection strategy. 
  n, No., number. 
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In the first stage articles were selected using the search strategy outlined in section 3.3.3 
on the databases listed in section 3.3.2. Article titles were reviewed by order of 
publication date (newest to oldest), blinding for author, journal, institution and country 
where the research was conducted, starting with all Proquest results, followed by 
Medline, PubMed and lastly Science Direct. Articles were discarded if the title indicated 
the study was not an intraoperative assessment of margin status for breast cancer in 
BCT. Potential titles were then compared to already selected articles for duplication and 
discarded if appropriate. Next, the abstracts of selected papers were assessed against the 
eligibility criteria listed in section 3.3.1.  
 
Finally, full text articles were then assessed against the eligibility criteria listed in 
section 3.3.1, blinding for author, journal, institution and country where the research 
was conducted. Reason for rejection was documented and later tallied. 
 
Included papers were tabulated and assessed for quality, as described in section 3.3.5.  
 
3.3.5 Assessment of article quality 
A quality assessment tool (QAT) (Appendix A) to assess the strength of each article 
was developed based on the Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) checklist for cohort, case-control and cross-sectional studies 
(combined).7 Weighting was applied for each area based on the level of importance to 
give an overall quality assessment score (QAS) out of 20. The tool was tested by three 
reviewers on the first ten articles. Each reviewer had a minimum five years clinical 
experience. All reviewers discussed the tool before each reviewer completed their 
review individually. The tool was then reviewed by the reviewers to discuss the findings 
for the first ten articles. The tool was then applied to all articles by the investigator. 
 
3.3.6 Data collection process 
Each article was reviewed in its entirety by one reviewer and data items were 
highlighted, because this is a systematic review and not a meta-analysis with 
quantitative synthesis. No further data was obtained or confirmed from 
authors/investigators. These data were then extracted into the tables displayed in 
Section 3.4. 
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3.3.7 Data items 
The following issues were itemised: 
 Method – the method used for intraoperative assessment, 
 Whether the IMA method was used in the surgical cavity, on the excised 
specimen or both, 
 Study method – retrospective review (chart review), prospective observational 
(where the IMA method was used but no further shavings were taken based on 
results) or prospective experimental (where further shavings were taken based 
on the IMA results), 
 Cases recruited, number used in data analysis and number of lesions examined, 
 Recruitment period, 
 Country, 
 Number of hospital sites and surgeons used – to determine the level of potential 
variability within the results, 
 Age of subjects – to determine if all studies were using similar age populations, 
 Histological type, histological grade and tumour size - to determine if all studies 
were using similar pathological populations, 
 The optimal margin size the study used – what margin size the study considered 
to be positive or close and what was classified as negative. This would impact 
on accuracy interpretation, 
 Final intraoperative margin status – the percentage of cases determined to be 
positive by the IMA method, 
 Final pathology margin status - the percentage of cases determined to be positive 
by standard assessment (pathology). This was not always compared to the above 
as further shavings may have been taken after IMA (need to take the study 
methodology into account), 
 Procedure classified success – by the author of the article, with level of 
significance between IMA method and pathology where available, 
 Second operation required – the percentage of patients who required a second 
operation. This does not include additional shavings in the first operation, 
 Average difference in operation time for study method, 
 Statistical measures: sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy percentages. 
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3.3.8 Risk of bias in individual studies 
The risk of bias was assessed as part of the article quality assessment and reflected in 
the QAS and not separately. 
 
3.3.9 Summary measures 
The principal summary measures to meet the objectives of this review were: 
 IMA methods, 
 Level of significance between the IMA methods and standard assessment, 
 Accuracy of the IMA method, or if unavailable the sensitivity and specificity, 
and  
 Second operation rates, taking optimal margin size and study methodology into 
account. 
 
3.3.10 Data analysis 
The data were analysed to determine the accuracy, sensitivity, specificity, PPV and 
NPV, taking the study design, study method, sample size into account. Where the 
accuracy, sensitivity and specificity were not provided, the number of positive and 
negative cases by IMA and pathology was reported. As studies varied by optimal 
margin size and a complete dataset was not provided in a number of studies, a meta-
analysis was not performed and risk of bias across studies was not calculated. 
 
 
3.4 Results 
 
3.4.1 Study selection 
The study selection process is outlined in Figure 3.1. There were 27 studies included in 
this review. 
 
3.4.2 Quality assessment scores 
The QAT was applied to the first ten articles by three independent reviewers to test the 
tool, and results for each article were compared between reviewers. Overall scores 
varied by on average 0.1/20 (range of differences 0-1.25) with an intraclass correlation 
coefficient of 0.998. It was concluded the tool could adequately assess the quality of 
each article and the investigator was consistent with applying the QAT. Consequently, 
the remaining 17 articles were assessed by the investigator only. 
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The results from the article quality assessment are shown in Table 3.1.  
 
Table 3.1: Article quality assessment 
Article 
No. 
First Author Year QAS 
1 Kim 8 2013 14 
2 Ramos 9 2012 14.5 
3 Rivera 10 2012 7 
4 Jorns 11 2012 10 
5 Sabel 12 2012 11 
6 Thill 13 2011 5.75 
7 Olsha 14 2011 16.5 
8 Martin 15 2011 6.25 
9 Doyle 16 2011 11.5 
10 Sumiyoshi 17 2010 12 
11 Nguyen 18 2009 11 
12 James 19 2009 15.5 
13 Dener 20 2009 13.25 
14 Weber 21 2008 17.75 
15 Allweis 22 2008 14 
16 Paredes 23 2008 11 
17 Duarte 24 2007 9 
18 Karni 25 2007 14 
19 Olson 26 2007 16.5 
20 Cabioglu 27 2007 17.25 
21 Kaufman 28 2007 12 
22 Fleming 29 2004 12.75 
23 McCormick 30 2004 10.25 
24 Chagpar 31 2003 10.75 
25 Rahusen 32 2002 10.5 
26 Creager 33 2002 11.75 
27 Moore 34 2001 13.5 
  No., number; QAS, quality assessment score 
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The mean score was 12.19 (standard deviation [SD] 3.13, range 5.75-17.75). A plot of 
the variation between QAS is shown in Figure 3.2. The x-axis is in reverse 
chronological order and the plot indicates the quality of articles has decreased since 
2009. The average QAS for articles published before 2009 averaged 12.93 compared to 
since 2009 averaging 11.40.  
 
Figure 3.2: Plot of quality assessment scores (QAS) from article quality 
assessment. 
 
 
Most studies varied greatly on how they presented their results and this impacted on the 
overall QAS reported above. Studies were rated higher where they clearly identified the 
methodology used, including how subjects were recruited and randomised (where 
applicable), the study method, how results were documented, whether further excision 
would be undertaken based on IMA results in the first operation, the final pathology 
result (preferably compared to IMA results in a matrix), statistical measures, the rate of 
second operations required and the additional operating time required to undertake the 
IMA.  
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3.4.3 Study characteristics 
Most studies used the IMA on the excised specimen (74.1%; 20/27), with 5 (18.5%) 
studies examining the excised specimen and within the surgical cavity and only two 
(7.4%) studies examining in the surgical cavity but not the excised specimen.  
Table 3.2 summarises and defines the IMA methods reported and the number of articles 
which assessed this method. 
 
Table 3.2: Intraoperative margin assessment methods reported by studies 
IMA Method No. studies 
Principle 
Ultrasound 6 Uses soundwaves and receives the echoing waves 
Frozen section 5 The excised tissue is frozen rapidly and then sliced for staining and microscopic examination 
Radiofrequency spectroscopy 
probe (RFS)  4 
Uses radiofrequency to measure the energy in molecules 
Imprint or touch smear 
cytology 3 
Where the margin or edge of the excised tissue is applied 
directly onto the slide for examination 
Gamma camera & probe 2 Using low emitting energy isotopes to measure gamma emissions 
Gross tissue inspection & 
specimen radiography 2 
The excised tissue is examined by the eye and under a x-ray 
Intraoperative digital specimen 
mammography (IDSM) 2 
Using radiofrequency pulses directly on the excised issue 
intraoperatively 
2-view standard specimen 
mammography (SSM) 1 
Different to the above as typically captured in a 
radiography department and on film 
Macroscopic margin 
assessment 1 
Where the excised tissue is examined by the eye 
Optical coherence tomography 
(OCT) 1 
Uses near-infrared light 
IMA, intraoperative margin; No., number. 
 
The main characteristics of the studies are presented in Table 3.3. A third (9/27) of the 
studies recruited subjects prospectively but did not act on results from IMA (prospective 
observational). Eleven (40.7%) studies recruited prospectively and acted on IMA results 
(prospective experimental) whereas the remaining 7 (25.9%) studies were retrospective 
chart reviews. Optimal margin width ranged from ≥0mm to ≥5mm (not reported in four 
studies), with five studies using >0mm, seven studies using >1mm, seven using >2mm 
and four using >5mm.   
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Table 3.3: Study characteristics 
Article 
No. 
IMA method 
(cavity or specimen) 
Study method Optimal 
margins 
Cases 
recruited 
Final sample size No. Lesions Recruitment 
period 
Country No. of 
hospital 
sites 
No. of 
surgeons 
Age mean or 
median in years 
(SD) 
1 Intraoperative digital 
specimen mammography 
(specimen) 
Retrospective 
review 
>1mm 214 201 total: 
96 study;105 control 
(specimen radiography 
[SR]) 
201 Dec 07 – Mar 11 Canada 1 2 Study 59.5 (9.6) 
Control 59.6 
(10.1) 
2 Ultrasound 
(cavity & specimen) 
Prospective 
observational 
>2mm 223 223 total 
(no controls) 
225 Jan 07 – Dec 11 Spain 1 Not reported 59.5 (11.1) 
3 Radiofrequency 
spectroscopy probe  
(specimen) 
Prospective 
experimental 
>1mm 664 596 total: 
298 study; 298 control 
(SR) 
Not reported Not reported USA 21 Not reported Not reported 
4 Frozen section 
(specimen) 
Prospective 
experimental 
DCIS 
>3mm 
IDC 
>2mm 
369 369 total: 
181 study; 188 control 
(SR) 
369 Aug 08 – July 10 USA 1 Not reported Study 58.1 
(11.6) 
Control 57.6 
(12.2) 
5 Frozen section 
(specimen) 
Retrospective 
review 
>2mm 549 549 total: 
278 study; 271 control 
(SR) 
Not reported Jan 09 – Apr 10 USA 1 Not reported Study 56.8 
Control 58.0 
6 Radiofrequency 
spectroscopy probe  
(cavity) 
Prospective 
observational 
>5mm 27 22 total 
(no controls) 
Not reported Sept 09 – May 10 Germany 3 Not reported Not reported 
7 Ultrasound 
(specimen) 
Prospective 
experimental 
>2mm 53 45 total 
(no controls) 
48 Jun 08 – Feb 10 Israel 1 1 Not reported 
8 Imprint cytology 
(specimen) 
Prospective 
observational 
>0mm 47 29 total 
(no controls) 
29 Not reported USA 1 Not reported Not reported 
9 Ultrasound 
(cavity & specimen) 
Prospective 
observational 
Not 
reported 
17 17 total 
(no controls) 
31 Not reported USA 1 1 Not reported 
10 Touch smear cytology 
(specimen) 
Prospective 
experimental 
>0mm 160 160 total 
(no controls) 
160 2005 – 2008 Japan 1 Not reported 58.1 
11 Optical coherence 
tomography 
(specimen) 
Prospective 
observational 
>2mm 37 33 total: 
18 study; 15 control 
(SR) 
33 Not reported USA 1 Not reported Study 66 
Control 62 
12 Ultrasound 
(specimen) 
Prospective 
observational 
>1mm 155 155 total: 
96 study; 59 control 
(mammographic 
needle localisation) 
Not reported 2003 - 2007 USA 1 Not reported Study 59 
Control 56 
13 Frozen section 
(specimen) 
Prospective 
observational 
>2mm 186 186 total 
(no controls) 
190 1997 - 2007 Turkey 1 4 49 
14 Frozen section 
(specimen) 
Retrospective 
review 
>1mm 111 111 total: 
78 study; 33 control 
(SR) 
115 Jan 90 – Dec 04 Switzerland 1 Not reported Study 59.6 
Control 57.5 
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15 Radiofrequency 
spectroscopy probe  
(specimen) 
Prospective 
experimental 
>1mm 300 293 total: 
143 study; 150 control 
(SR or pathology) 
Not reported Nov 06 – Nov 07 Israel 11 Not reported Study 59 
Control 60 
16 Gamma camera & probe 
(cavity & specimen) 
Prospective 
observational 
>5mm 42 42 total 
(no controls) 
Not reported Not reported Spain 1 Not reported 59 (7.8) 
17 Gamma probe 
(cavity) 
Prospective 
experimental 
>0mm 23 23 total 
(no controls) 
23 Jan 05 – Dec 05 Brazil 1 Not reported 51.3 (11.7) 
18 Radiofrequency 
spectroscopy probe 
(specimen) 
Prospective 
observational 
>1mm 68 57 total 
(no controls) 
Not reported Feb 2005 – Dec 
2005 
Israel 2 Not reported Not reported 
19 Frozen section 
(specimen) 
Retrospective 
review 
Not 
reported 
290 290 total 
(no controls) 
292 1993 – May 2005 USA 1 Not reported 56 
20 Gross tissue inspection 
& specimen radiography 
(specimen) 
Retrospective 
review 
>2mm 264 251 total 
(no controls) 
251 Jan 94 – Dec 96 USA 1 Not reported IDC 60 
DCIS 58 
21 Intraoperative digital 
specimen mammography 
(specimen) 
Prospective 
experimental 
Not 
reported 
79 79 total: 
Study group was own 
control (standard 
specimen 
mammography) 
85 Apr 04 – May 05 USA 1 Not reported Not reported 
22 Macroscopic margin 
assessment 
(specimen) 
Prospective 
experimental 
>5mm 220 220 total 
(no controls) 
220 Not reported Ireland 1 Not reported 59 
23 2-view standard 
specimen mammography 
(specimen) 
Prospective 
experimental 
Not 
reported 
97 93 total 
(no controls) 
93 2000 – 2001 USA 1 Not reported Not reported 
24 Gross tissue inspection 
& specimen radiography 
(specimen) 
Retrospective 
review 
>5mm 109 109 total 
(no controls) 
109 Jul 99 – Jul 02 USA 1 Not reported 55 (10) 
25 Ultrasound 
(cavity & specimen) 
Prospective 
experimental 
>1mm 49 49 total: 
27 study; 22 control 
(wire-guided excision) 
Not reported Jun 98 – Jul 01 Netherlands 2 Not reported Not reported 
26 Imprint cytology 
(specimen) 
Retrospective 
review 
>0mm 137 137 total 141 May 97 – May 01 USA 1 Not reported 58 
27 Ultrasound 
(specimen) 
Prospective 
experimental 
>0mm 51 51 total: 
27 study; 24 control 
(SR) 
Not reported Dec 98 – Oct 00 USA Not 
reported 
Not reported Not reported 
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; IMA, intraoperative margin assessment; mm, millimetre; No., number; SD, standard deviation; SR, specimen radiography; USA, United States of America  
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Half (14/27) of the studies were undertaken in the United States of America (USA) and 
the majority of studies (21/27) were undertaken at only one site. Few studies (3/27) 
reported the number of surgeons or users of the IMA method, which does not allow 
comment on the risk of inter-operator variability.  
 
The mean age of participants, where reported, were similar among studies, ranging from 
55 to 60 years. The histological factors of type, grade and tumour size were extracted to 
assess whether study populations were comparable. Tables 3.4, 3.5 and 3.6 summarise 
these results. The type of breast cancer was reported in 22 studies, with the majority 
studies including cases of invasive ductal carcinoma (IDC). Three studies recruited only 
DCIS cases. More than 50% of cases reported by Doyle and colleagues16 were 
‘benign/other’ cases, but their study reported DCIS/invasive cases separately. This study 
also had a very small sample size. 
 
All studies reported the majority of cases as grade II, while there were some variations 
in distribution of grade I and grade III. Sumiyoshi17 (article 10) was the exception, 
reporting 43.75% of cases as grade 1. This study had a good sample size and a majority 
(78.75%) of cases were invasive ductal carcinoma. The greatest variation in study 
characteristics was found in tumour size, as reported in fifteen studies. The majority of 
these studies (12/15) reported a mean tumour size between 1 to 2cm.  
 
  
53 
Table 3.4: Number (and percentage) of each histological type in reported studies 
Article 
No. 
Study 
Group 
DCIS 
No. (%) 
LCIS 
No. (%) 
IDC 
No. (%) 
[with DCIS No. (%)] 
ILC 
No. (%) 
Mixed ID/LC 
No. (%) 
Benign/other 
No. (%) 
1 Study 16 (17.6) 0 64 (70.3) 
[46 (50.6)] 
0 0 11 (12.1) 
Control 30 (27.3) 0 63 (57.3) 
[45 (40.9)] 
0 0 17 (15.5) 
2 Study 0 0 191 (84.9) 25 (11.1) 0 9 (4.0) 
3 Study & 
Control 
NR NR NR NR NR NR 
4 Study 50 (27.6) 0 101 (55.8) 14 (7.7) 11 (6.1) 5 (2.8) 
Control 39 (20.7) 0 115 (61.2) 23 (12.2) 6 (3.2) 5 (2.7) 
5 Study 67 (24.1) 0 140 (50.4) 
[4 (1.4)] 
26 (9.4) 29 (10.4) 16 (5.8) 
Control 56 (20.7) 0 140 (51.7) 
[5 (1.8)] 
30 (11.1) 22 (8.1) 23 (8.5) 
6 Study 22 (100) 0 0 0 0 0 
7 Study 0 0 38 (84.4) 
[22(48.9)] 
5 (11.1) 1 (2.2) 1 (2.2) 
8 Study 9 (31.0) 0 18 (62.1) 2 (6.9) 0 0 
9 Study 5 (16.1) 2 (6.5) 5  (16.1) 
[3 (9.7)] 
1 (3.2) 0 18 (58.1) 
10 Study 7 (4.4) 0 126 (78.8) 0 0 27 (16.9) 
11 Study & 
Control 
15 (48.4) 1 (3.2) 11 (35.5) 0 0 4 (12.9) 
12 Study 96 (100) 0 0 0 0 0 
Control 59 (100) 0 0 0 0 0 
13 Study 0 0 170 (89.5) 16 (8.4) 4 (2.1) 0 
14 Study 12 (11.8) 12 (11.8) 68 (66.7) 
[37 (36.3)] 
0 0 10 (9.8) 
Control 21 (48.8) 1 (2.3) 14 (32.6) 
[9 (20.9)] 
0 0 7 (16.3) 
15 Study (12) 0 (37) (5) (46) 0 
Control (8) 0 (38) (6) (48) 0 
16 Study 4 (9.5) 1 (2.4) 29 (69.1) 3 (7.1) 1 (2.4) 4 (9.5) 
17 Study 0 0 23 (100) 0 0 0 
18 Study NR NR NR NR NR NR 
19 Study 33 (11.3) 0 214 (73.3) 17 (5.8) 1 (0.3) 27 (9.3) 
20 Study 64 (24.2) 0 166 (62.9) 14 (5.3) 0 20 (7.6) 
21 Study 29 (34.1) 0 47 (55.3) 
[4 (4.7)] 
2 (2.4) 0 7 (8.2) 
22 Study 0 0 156 (70.9) 29 (13.2) 12 (5.5) 23 (10.5) 
23 Study  NR NR NR NR NR NR 
24 Study 109 (100) 0 0 0 0 0 
25 Study & 
Control 
NR NR NR NR NR NR 
26 Study 23 (16.3) 0 106 (75.2) 6 (4.3) 6 (4.3) 0 
27 Study & 
Control 
NR NR NR NR NR NR 
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; 
NR, not reported.. 
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Table 3.5: Number (and percentage) of each histological grade in reported studies 
Article 
No. 
Study Group Grade I (low) 
No. (%) 
Grade II 
(intermediate) 
No. (%) 
Grade III (high) 
No. (%) 
1 Study 28 (35.4) 34 (43.0) 17 (21.5) 
Control 33 (35.1) 43 (45.7) 18 (19.2) 
2 Study 81 (36.0) 98 (43.6) 46 (20.4) 
3 Study & Control NR NR NR 
4 Study 30 (22.9) 55 (42.0) 46 (35.1) 
Control 44 (29.5) 69 (46.3) 36 (24.2) 
5 Study 66 (25.8) 107 (41.8) 83 (32.4) 
Control 70 (27.0) 109 (42.1) 80 (30.9) 
6 Study NR NR NR 
7 Study NR NR NR 
8 Study NR NR NR 
9 Study NR NR NR 
10 Study 70 (43.8) 50 (31.3) 40 (25.0) 
11 Study NR NR NR 
12 Study 9 (9.4) 53 (55.2) 34 (35.4) 
Control 5 (8.5) 33 (55.9) 21 (35.6) 
13 Study 26 (13.7) 123 (64.7) 41 (21.6) 
14 Study & Control NR NR NR 
15 Study (18.0) (48.0) (34.0) 
Control (15.0) (44.0) (41.0) 
16 Study NR NR NR 
17 Study NR NR NR 
18 Study NR NR NR 
19 Study NR NR NR 
20 Study 75 (26.4) 173 (60.9) 36 (12.7) 
21 Study NR NR NR 
22 Study NR NR NR 
23 Study NR NR NR 
24 Study 10 (9.2) 55 (50.5) 44 (40.4) 
25 Study & Control NR NR NR 
26 Study NR NR NR 
27 Study & Control NR NR NR 
No., Number; NR, not reported. 
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Table 3.6: Tumour size characteristics in reported studies 
Article 
No. 
Study Group Mean size (cm) SD (cm) Range (cm)  
1 Study & Control NR NR NR 
2 Study 1.21 0.57 NR 
3 Study & Control NR NR NR 
4 Study 1.16 0.99 NR 
Control 1.11 1.10 NR 
5 Study Invasive = 1.76 
DCIS = 1.06 
NR Invasive 0.2 – 9.0 
DCIS = 0.1 – 6.5 
Control Invasive = 1.84 
DCIS = 1.14 
NR Invasive 0.2 – 10.5 
DCIS = 0.1 – 6 
6 Study NR NR NR 
7 Study 1.9 NR 0.5 – 4.8 
8 Study NR NR NR 
9 Study NR NR 1 - 5 
10 Study 2.48 0.7 NR 
11 Study  NR NR NR 
12 Study 1.07 NR 0.0 – 10.2 
Control 1.23 NR 0.05 - 10 
13 Study 2.2 NR 0.4 - 5 
14 Study & Control NR NR NR 
15 Study 1.87 NR NR 
Control 1.71 NR NR 
16 Study NR NR NR 
17 Study 4.05 1.05 2 – 6.1 
18 Study NR NR NR 
19 Study 1.5 NR NR 
20 Study Invasive = 1.4 
DCIS = 0.6 
NR Invasive 0.1 – 3.9 
DCIS = 0.1 – 3.0 
21 Study NR NR NR 
22 Study 1.5 NR NR 
23 Study NR NR NR 
24 Study 1.2 NR 0.2 – 8.0 
25 Study 1.34 NR 0.5 – 2.5 
Control 1.36 NR 0.4 – 2.3 
26 Study 1.7 NR 0.2 – 5.3 
27 Study & Control NR NR NR 
cm, centimetres; DCIS, ductal carcinoma in situ; No., Number; NR, not reported; SD, standard deviation. 
 
 
3.5 Summary measure results and discussion 
The studies were classified and then analysed based on their methodology (retrospective 
review, prospective observational or prospective experimental).  
 
Table 3.7 and 3.8 displays the summary measures for the eleven prospective 
experimental studies. Based on the reported level of concordance, where the IMA 
method was compared to the standard assessment status, the radiofrequency 
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spectroscopy (RFS) probe performed well (p<0.0001 Rivera10 [article 3]; p=0.044 
Allweis22 [article 15]). The 2-view standard specimen mammography (SSM) and the 
macroscopic margin assessment technique, which had the largest optimal margin 
distance of >5mm, reported the lowest second operation rates of 5% and 7.3%, 
respectively. The reporting of additional operation time was not reliable as some studies 
compared against a standard procedure whereas others reported against another study 
method. According to the reported times, the intraoperative digital specimen 
mammography (IDSM) (Kaufman28 [article 21]) reduced operation times by on average 
19 minutes when compared to SSM, but this is not a standard procedure in many 
countries. The 2-view SSM (McCormick30 [article 23]) reported an average 15 minute 
increase in operation time when compared to the standard procedure. This time could be 
added to the findings of Kaufman28 (article 21). Ultrasound was also reported to reduce 
operation times (Moore34 [article 27]: 15 minutes; Rahusen32 [article 25]: 1 minute). 
Frozen section increased operation times on average by 27 minutes. The introduction of 
any additional intraoperative methods will increase operation times and needs to be 
weighed against the reduction in the second operation rate. On this basis, ultrasound 
(Moore34 [article 27]) performed best with a second operation rate of 13.7%, a decrease 
of an average 15 minutes in operation time and statistically significant level of 
concordance (p<0.05). However, ultrasound has its own limitations, with a decreased 
accuracy in assessing multifocal disease and calcifications. 
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Table 3.7: Summary measures margin status, success, second operation rate and time for prospective experimental studies 
Article 
No. 
IMA method Optimal 
margins 
Intraoperative margin 
status(a) 
Pathological margin 
status(b) 
Procedure classified 
success 
Second operation 
required 
Average difference in operation time 
for study method 
3 Radiofrequency 
spectroscopy probe  
>1mm NR NR Yes 
p<0.00 
Study 14.1% 
Control 29.9% 
NR 
4 Frozen section DCIS >3mm 
IDC >2mm 
Study 59.3% positive NR Yes Study 19.3% 
Control 55.3% 
(p=0.096) 
+ 27 minutes 
7 Ultrasound >2mm 15.5% positive 24.4% positive Yes 4.4% NR 
10 Touch smear cytology >0mm 11.25% positive 12.5% positive Yes NR NR 
15 Radiofrequency 
spectroscopy probe  
>1mm NR Study 40% positive 
Control 59% positive 
Yes 
p=0.04 
Study 12.6% 
Control 18.6% 
(p=0.098) 
NR 
17 Gamma probe >0mm NR 21.1% positive No 
p=0.23 
NR NR 
21 Intraoperative digital 
specimen 
mammography 
(IDSM) 
NR IDSM = 29% positive 
SSM = 23% positive 
28.2% positive Yes - no significant 
difference between 
IDSM & SSM 
NR - 19 minutes when compared to SSM 
22 Macroscopic margin 
assessment 
>5mm 36.81% positive 9.1% positive Yes 7.3% NR 
23 2-view standard 
specimen 
mammography (SSM) 
NR 17.2% positive 11.8% positive Yes 5% +15 minutes 
25 Ultrasound >1mm NR Study 11% positive 
Control 45% positive 
Yes 
p=0.01 
NR -1 minute 
27 Ultrasound >0mm NR Study 3.5% positive 
Control 29% positive 
Yes 
p<0.05 
13.7% -15 minutes  
(a) – margin status classified by the IMA method and includes close, defined as less than the optimal margin distance 
(b) Margin status classified by pathology and includes close, defined as less than the optimal margin distance 
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; IDSM, intraoperative digital specimen mammography; IMA, intraoperative margin assessment; No., number; NR, not reported; SSM, standard specimen 
mammography. 
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Table 3.8: Summary measures of sensitivity, specificity, positive predictive value, 
negative predictive value and accuracy for prospective experimental studies 
Article 
No. 
IMA method Optimal 
margins 
Sensitivity Specificity PPV NPV Accuracy 
3 Radiofrequency 
spectroscopy 
probe  
>1mm NR NR NR NR NR 
4 Frozen section DCIS >3mm 
IDC >2mm 
91.1% 100% 100% 97.9% 98.3% 
7 Ultrasound >2mm 25% 95% 27% 95% NR 
10 Touch smear 
cytology 
>0mm 70% 97.1% 77.78% 95.8% 93.8% 
15 Radiofrequency 
spectroscopy 
probe  
>1mm NR NR NR NR NR 
17 Gamma probe >0mm NR NR NR NR NR 
21 Intraoperative 
digital specimen 
mammography 
NR IDSM = 
36% 
SSM = 
31% 
IDSM = 
71% 
SSM = 
74% 
IDSM = 
50% 
SSM = 
38% 
IDSM = 
84% 
SSM = 
90% 
NR 
22 Macroscopic 
margin 
assessment 
>5mm 73% 88% NR NR NR 
23 2-view standard 
specimen 
mammography 
NR 54.6% 87.8% 37.5% 93.5% NR 
25 Ultrasound >1mm NR NR NR NR NR 
27 Ultrasound >0mm NR NR NR NR NR 
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; IMA, intraoperative margin assessment; No., number; NPV, 
negative predictive value; NR, not reported; PPV, positive predictive value. 
 
The overall accuracy of IMA in prospective experimental studies was only reported in 
two studies: frozen section (Jorns11 [article 4]) reported a 98.3% accuracy and touch 
smear cytology (Sumiyoshi17 [article 10]) reported a 93.8% accuracy. Sensitivity and 
specificity rates were reported in half of the prospective experimental studies, with 
frozen section (Jorns11 [article 4]) reporting the highest sensitivity (91.1%) and 
specificity (100%). This study had an adequate sample size (369 patients) and was 
conducted recently (concluding in July 2010), but reported an additional average 
operation time of 27 minutes. Interestingly the other two studies which reported good 
sensitivity and specificity rates were also intraoperative pathological assessments. 
Touch smear cytology (Sumiyoshi17 [article 10]) reported a 70% sensitivity and 97.1% 
specificity rate with a sample size of 160 patients. Touch smear cytology only assesses 
the direct (or outside) margins of the specimen and will not identify any residual disease 
within 5mm of the surface of the margin. Macroscopic margin assessment (Fleming29 
[article 22]) reported a sensitivity and specificity of 73% and 88% respectively, with a 
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sample size of 220 patients. This study also used a larger optimal margin width of 
>5mm. It is hypothesised that if the optimal margin width was reduced for comparison 
against the other studies with an optimal margin width of >1mm and >2mm, the 
sensitivity and specificity would be improved. 
 
Tables 3.9 and 3.10 provide the summary measures for the 16 prospective observational 
studies and retrospective chart reviews. Based on the reported level of concordance, a 
number of IMA methods performed well. Ultrasound showed no significant difference 
to standard assessment in two studies (Doyle16 [article 9] and James19 [article 12], both 
p<0.05), which supported the findings of the two prospective experimental studies 
(Rahusen32 [article 25]: p=0.0007; Moore34 [article 27]: p<0.05). IDSM reported a 
statistically significant level of concordance (p=0.012 ) in a retrospective review (Kim8 
[article 1]), that also supported the findings of the prospective experimental study 
(Kaufman28 [article 21]) which found no difference between IDSM and SSM. All three 
IMA pathological methods reported a statistically significant level of concordance: the 
combined use of gross tissue inspection and specimen radiology (SR) (p<0.001) 
(method not used in any prospective experimental studies), imprint cytology (p<0.001) 
(touch smear cytology in the prospective experimental study designs did not report the 
level of concordance) and frozen section (p=0.002) (frozen section in the prospective 
experimental study designs did not report the level of concordance).  
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Table 3.9: Summary measures of margin status, success, second operation rate and time for prospective observational and retrospective 
studies 
Article 
No. 
IMA method Optimal margins Intraoperative margin 
status (a) 
Pathological margin 
status(b) 
Procedure classified 
success 
Second operation required Average difference in operation 
time for study method(c) 
1 Intraoperative digital 
specimen mammography 
>1mm Study 38.0% positive 
Control 63.8% positive 
Study 21.8% positive 
Control 47.6% positive 
Yes 
p=0.01 
Study 14.6%; Control 
17.1% (p=0.64) 
-2 minutes 
2 Ultrasound >2mm Study 45.7% positive Study 13.3% positive Yes Study 4% NR 
5 Frozen section >2mm NR Study 6% positive 
Control 10% positive 
Yes Study 11%; Control 25% 
(p<0.001) 
+30 minutes 
6 Radiofrequency 
spectroscopy probe  
>5mm NR NR Yes Study 18% 
Historical 38.8% 
NR 
8 Imprint cytology >0mm NR NR Yes 
p<0.001 
NR +20-25 minutes 
(min 10 minutes) 
9 Ultrasound NR NR NR Yes 
Ductal carcinoma 
peak density p<0.05 
NR NR 
11 Optical coherence 
tomography 
>2mm 55% positive 45% positive Yes NR NR 
12 Ultrasound >1mm NR Study 33.3% positive 
Control 39.0% positive 
Yes Study 20.8%; Control 
30.5% (p=0.184) 
NR 
13 Frozen section >2mm NR 16% positive Yes 16%  +25 minutes 
14 Frozen section >1mm Study 46.3% positive 
Control 51.4% positive 
Study 12.5% positive 
Control 20.0% positive 
Yes 
p=0.002 
Study 12.5%; Control 
37.1% (p=0.002) 
NR 
16 Gamma camera & probe >5mm NR Centred 39% positive 
Non-centred 57.9% 
positive 
NR NR +5 minutes 
18 Radiofrequency 
spectroscopy probe 
>1mm 33.3% positive 38.6% positive Yes NR +7.37 minutes 
19 Frozen section NR 24% positive 11.3% positive Yes 11.4% NR 
20 Gross tissue inspection & 
specimen radiography 
>2mm Invasive = 35.5% 
positive 
DCIS = 18.75% positive 
Invasive = 17% positive 
DCIS = 28.1% positive 
Yes 8.7% NR 
24 Gross tissue inspection & 
SR 
>5mm 54.1% positive 24% positive Yes 
p=0.00005 
22% (p=0.029) NR 
26 Imprint cytology >0mm 21.9% positive 10.9% positive Yes NR + 20 minutes 
(a) Margin status as determined by IMA method, including close margins, defined as less than the optimal margin distance 
(b) Margin status as determined by pathology, including close margins, defined as less than the optimal margin distance 
(c) Compared to standard assessment unless specified otherwise 
IMA, intraoperative margin assessment; No., number; NR, not reported; SR, specimen radiography.  
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Table 3.10: Summary measures of sensitivity, specificity, positive predictive value, 
negative predictive value and accuracy for prospective observational and 
retrospective studies 
Article 
No. 
IMA method Optimal 
margins 
Sensitivity Specificity PPV NPV Accuracy 
1 Intraoperative 
digital specimen 
mammography 
>1mm NR NR NR NR NR 
2 Ultrasound >2mm 80% 86.6% 23.3% 95.1% 99.6% 
5 Frozen section >2mm NR NR NR NR 94% 
6 Radiofrequency 
spectroscopy 
probe  
>5mm NR NR NR NR 73% 
(2mm 
86%) 
8 Imprint cytology >0mm 85% 
(71.4% in 
DCIS) 
100% NR NR 89.7%  
(77.8% in 
DCIS) 
9 Ultrasound Not reported 100% 74% NR NR NR 
11 Optical coherence 
tomography 
>2mm 100% 82% 82% 100% 90% 
12 Ultrasound >1mm NR NR NR NR NR 
13 Frozen section >2mm NR NR NR NR NR 
14 Frozen section >1mm 80% 87.5% 86.5% 81.4% 83.8% 
16 Gamma camera & 
probe 
>5mm NR  NR NR NR 60% 
18 Radiofrequency 
spectroscopy 
probe 
>1mm 71% 68% NR NR NR 
19 Frozen section Not reported 73.1% 99.6% 91.9% 98.3% 98.0% 
20 Gross tissue 
inspection & 
specimen 
radiography 
>2mm 91.7% 77.8% NR NR 87.4% 
24 Gross tissue 
inspection & 
specimen 
radiography 
>5mm NR NR NR NR NR 
26 Imprint cytology >0mm 80% 85% 40% 97% 85% 
IMA, intraoperative assessment; No., number; NPV, negative predictive value; NR, not reported; PPV, positive predictive value. 
 
When examining second operation rates, frozen section reported the largest difference 
between study and control rates (Sabel12 [article 5]: p<0.001; Weber21 [article 14]: 
p=0.002). Gross tissue inspection with SR (Chagpar31 [article 24]) also reported a 
significant difference (p=0.029). There was no significant difference in second 
operation rate reported for IDSM (Kim8 [article 1]) or ultrasound (James19 [article 12]). 
Comparing second operation percentages to the prospective experimental studies, 
ultrasound (Ramos9 [article 2]) was the only study that reported comparable results to 
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the prospective experimental studies, thus confirming the value of excising more tissue 
during the first operation based on IMA findings. 
 
Only six studies reported the variations in operation times when an IMA method was 
introduced. IDSM (Kim8 [article 1]), as with the prospective experimental studies, 
reported a decrease in operation time by 2 minutes. Similar to the prospective 
experimental study, this was compared to SSM, although it is not the standard protocol 
in many countries. The gamma camera and probe increased operation times on average 
by 5 minutes. Studies using frozen section reported an increase in operating time 
ranging from 20 to 30 minutes, supporting the finding of the prospective experimental 
study reported in Jorns11 [article 4] that this method considerably extends operation 
times.  
 
Accounting for level of concordance, second operation rates and operation time, where 
all data measures were reported, IDSM (Kim8 [article 1]) performed the best with a 
second operation rate of 14.6% (no significant difference), a decrease of an average 2 
minutes (plus approximately 15 minutes against SSM) in operation time and a 
statistically significant level of concordance (p=0.012). Ultrasound (James19 [article 
12]) also performed well, with a second operation rate of 20.8% (no significant 
difference), and no significant difference against standard assessment (average 
operation times not reported). 
 
Overall, accuracy of IMA in prospective observational studies and retrospective chart 
reviews was well reported. Ultrasound (Ramos9 [article 2]) reported the highest level of 
accuracy (99.6%), followed by frozen section (Olson26 [article 19]: 98.02%; Sabel12 
[article 5]: 94%) and optical coherence tomography (Nguyen18 [article 11]: 90%). 
Imprint cytology (Martin15 [article 8]) reported a sensitivity of 85% (71.4% in DCIS) 
and specificity of 100%. The study only had 29 patients, added 20 to 25 minutes to 
operation time and similar to touch smear. It could only assess the direct margins but 
not any residual disease within 5mm of the surface. The other imprint cytology study 
reported a sensitivity and specificity of 80% and 85% respectively. Optical coherence 
tomography (OCT) (Nguyen18 [article 11]) reported a sensitivity of 100% and 
specificity of 82%, but again the study only involved a small sample size (33 patients) 
and did not report average operation times. Ultrasound (Doyle16 [article 9]) reported a 
sensitivity and specificity of 100% and 74%, with a second study (Ramos9 [article 2]) 
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reporting 80% and 86.6% respectively. Whilst the first study (Doyle16 [article 9]) only 
had a small sample size (17 patients) the second (Ramos9 [article 2]) had a sample size 
of 223 patients. Neither reported the additional surgical time taken to apply the 
ultrasound to the specimen and in the cavity.  
 
Only four studies reported follow-up data, so this information was not analysed. 
 
Where accuracy was reported, it was compared against the optimal margin width, 
average operation time and QAS. The second operation rate was not included in this 
comparison as it varied depending on whether additional shavings were taken during the 
first operation based on the IMA findings. The results are collated and presented in 
Table 3.11.  
 
Table 3.11: Comparison of optimal margin width, accuracy, average difference in 
operation time, sample size and quality assessment score (QAS) 
Article 
No. 
IMA method Optimal margins Accuracy Average difference 
in operation time for 
study method 
Sample 
size 
QAS 
2 Ultrasound >2mm 99.6% Not reported 223 14.5 
4 Frozen section DCIS >3mm 
IDC >2mm 
98.3% + 27 minutes 369 10 
19 Frozen section Not reported 98.02% Not reported 290 16.5 
5 Frozen section >2mm 94% +30 minutes 549 11 
10 Touch smear 
cytology 
>0mm 93.8% Not reported 160 12 
11 Optical coherence 
tomography 
>2mm 90% Not reported 33 11 
8 Imprint cytology >0mm 89.7%  
(77.8% in DCIS) 
+20-25 minutes 
(min 10 minutes) 
29 6.25 
20 Gross tissue 
inspection & 
specimen 
radiography 
>2mm 87.4% Not reported 251 17.25 
26 Imprint cytology >0mm 85% + 20 minutes 137 11.75 
14 Frozen section >1mm 83.8% Not reported 111 17.75 
6 Radiofrequency 
spectroscopy 
probe 
>5mm 73% 
(2mm 86%) 
Not reported 22 5.75 
16 Gamma camera & 
probe 
>5mm 60% +5 minutes 42 11 
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; IMA, intraoperative assessment; mm, millimetre; No., number; 
QAS, quality assessment score. 
 
Of the 12 studies that reported accuracy, four of the top five studies were intraoperative 
pathology methods: frozen section and touch smear cytology (93.8 – 98.3% accuracy). 
Ultrasound (Ramos9 [article 2]) reported the highest accuracy (99.6%) for a >2mm 
optimal margin width. Although average operation time was not reported, it is 
hypothesised that ultrasound would be quicker to apply and return results (in the 
operating theatre) than frozen section or touch smear cytology, yet it does not perform 
as well with multifocal cancers or calcifications. Only one RFS probe study (Thill13 
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[article 6]) reported the accuracy (73% at >5mm, 86% at > 2mm), however, the study 
only examined 22 cases and did not score highly in the QAS. Only two studies that 
reported the use of a radiopharmaceutical guided probe (Paredes23 [article 16] and 
Duarte24 [article 17]) but neither scored highly in the QAS, had small sample sizes and 
only one article reported the accuracy of this device (Paredes23 [article 16]: 60%).  
 
 
3.6 Discussion 
Breast cancer was the most commonly diagnosed cancer among females in Australia in 
2012, and the second leading cause of death by cancer.35 During 2006-10 the 5 year 
survival rate for breast cancer in females was 89%.36 It is the sixth leading cause of 
burden of disease for females and expected to contribute more years of life lost (40,800) 
than years of health life lost to disability (20,500).36 Local recurrence following BCT 
for DCIS has been reported as 3.9-10.5% and invasive breast cancer 5-22%, with 
positive or close margins being a risk factor. 2,4,37-41 With approximately 25% of 
women requiring a second operation to ensure clear margins, a method of accurately 
assessing margins intraoperative would potentially reduce the number of second 
operations required as well as the recurrence rate. 
 
In general, intraoperative pathological methods performed well according to the 
systematic review. Accuracy for frozen section were reported between 83.8-98.3%, 
touch smear and imprint cytology between 85%-93.8% and gross tissue inspection 
combined with specimen radiology was 87.4%, all with large sample sizes used.11-
12,15,17,21,26-27,33 The sensitivity rates in the frozen section studies reported here (73.1%-
91.1%) are slightly higher than that reported in other literature (65-80%). The 
specificity rates reported here appear to be consistent with those reported in the 
literature (87.5-100%).21,42,43 Also, the imprint cytology sensitivity rates reported here 
(70-85%) are similar to those reported in the literature (72-100%), while specificity 
appeared to be consistent with those reported in the literature (85-100%).43-45  
 
Although the sensitivity, specificity and accuracy of pathological IMA methods are 
high, these methods add significant time to operation time, often between 20-30 minutes 
on average. This additional time has a number of adverse implications including 
additional costs, the number of cases that can be treated per day, additional time under 
anaesthetic and loss of productivity time for theatre staff whilst waiting for results to be 
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returned. In addition touch smear and imprint cytology methods only assess the direct 
surgical margin and do not identify where there may be residual disease up to 5mm 
under the surface. 
 
Among the other methods, ultrasound was the only IMA that returned notable results. 
At a >2mm optimal margin width, a 99.6% accuracy had been reported using a large 
sample size (223 patients), with only a 4% second operation rate.9 The positive 
concordance between ultrasound and standard procedures was supported by the 
literature analysed.14,16,19,32,34 Ultrasound is often used to guide surgery but there has 
been little report in terms of accuracy, sensitivity and specificity to assess the surgical 
margins. The sensitivity rates reported here ranged from 25 to 100% and specificity 
ranged from 74 to 95%. A study by Jeong had reported a sensitivity of 80% and 
specificity of 90%, which is within the range reported here.46 Ultrasound can be used in 
the operating theatre and, when applied by a trained operator, it can produce results 
immediately, allowing the decision to take further shavings with minimal impact on 
operating times. However it should be noted that one study did report a poor sensitivity 
(25%), with a PPV of 27%, when using ultrasound on the excised specimen.14 Also 
ultrasound is known not to perform well where there is calcifications or multifocal 
disease, limiting its applicability in DCIS surgery greatly. 
 
A RFS probe offers an alternative to ultrasound, by examining the electromagnetic 
signature of the tissue in the operating theatre. Four articles reported the use of a RF 
spectroscopy probe in breast surgery, two with large samples (Rivera10 [article 3]: 596 
patients; Allweis22 [article 15]: 293 patients) from multicentre studies.10,13,22,25 All four 
articles reported a statistically significant level of concordance (p<0.05) but only two 
studies provided statistical measures of performance, both with small sample sizes. 
Thill13 (article 6) reported an accuracy of 86% when the optimal margin width was 
>2mm and Karni25 (article 18) reported a sensitivity and specificity of 71% and 68%, 
respectively. This was lower than the reported sensitivity and specificity in the literature 
ranging from 70 to 100% and 70 to 87% respectively.47 Although these devices do not 
greatly increase operating time and provide immediate feedback, the sensitivity and 
accuracy reported here are lower than pathological IMA methods, and second operation 
rates did not vary significantly from controls in prospective experimental studies. 
Statistical measures of sensitivity, specificity and accuracy for the larger studies should 
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be provided to determine if the above rates were affected by the small sample sizes and 
to ascertain whether the device has an important role in IMA in breast surgery.  
 
Three studies reported the use of intraoperative mammography technology.8,28,30 Two 
studies applied IDSM,8, 28 compared to standard SR or mammography, whilst the third 
used 2-view SSM.30 Whilst all three studies reported concordance with standard 
procedures (Kim8 [article 1]: p=0.012), only one study reported a small second 
operation rate (McCormick30 [article 23]: 5%). There was no significant difference in 
second operation rates in article 1 (Kim8), however it was a retrospective chart review. 
Both Kaufman28 [article 21] and McCormick30 [article 23] reported poor sensitivity 
rates (36% and 54.55% respectively), while no accuracy rates were provided for either 
study. Use of this device took approximately the same time, or slightly longer, as a hand 
held ultrasound or RFS probe, yet it reduced the second operation rate in only one study 
with a poor sensitivity, which could result in the excision of more tissue than necessary. 
Further research with larger sample sizes is required and confirmed against standard 
procedures to identify the actual additional operation time required. 
 
Lastly, for OCT, only one study examined the use of such interferometry technology.18 
The study reported 90% accuracy, with sensitivity, specificity, PPV and NPV of 100%, 
82%, 82% and 100% respectively. Additional operation time and the second operation 
rate were not reported. Whilst a number of publications48-49 have emerged examining 
the potential use of this technology in surgery, specifically breast surgery, data on 
accuracy, sensitivity or specificity rates in breast surgery to compare were lacking. 
Further research reporting on these statistical measures is required before making any 
recommendations.  
 
The limitation of this systematic review is it does not include a meta-analysis of pooled 
data. Articles were reviewed in reverse chronological order and therefore there was a 
learning effect. Articles were analysed and presented individually and this approach did 
not impact on findings. 
 
3.7 Positron Emission Tomography probe 
An IMA method that did not appear in this review is the positron emission tomography 
(PET) probe. There is little research dedicated to examining the use of this technology is 
breast cancer, with most papers either animal models or report the use of the probe in 
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surgery for many different cancers. PET works by injecting a radionuclide that targets 
specific tissue characteristics. 18F-fluorodeoxyglucose (FDG) is a positron-emitting 
analog of glucose, which is seen to have higher metabolism in tumour cells. As gamma 
rays can travel several centimetres into tissue, whereas positrons only travel millimetres, 
a handheld dual PET probe capable of detecting positron rays can identify tissue with 
greater accuracy during surgery following injection of FDG.50, 51 The PET probe works 
as a combined gamma and beta probe. The central scintillator detects both positron 
(beta) and gamma rays whilst the surrounding scintillator detects just gamma rays, 
allowing the unit to subtract one count from the other to obtain generate only the 
positron count.50, 51 The main limitation for PET probes is the uptake of FDG by the 
heart, liver, bladder and brain. The heart is the main concern in breast cancer surgery 
due to its close proximity to the breast tissue potentially returning false positive count 
rates. 
 
Raylman and colleagues52 examined the use of a PET probe in rats implanted with 
mammary tumours. They found uptake of FDG in this model to only be in the bladder, 
liver and brain. Bladder uptake can be reduced in humans by encouraging the patient to 
void before surgery. The study reported good uptake of FDG by mammary tumour 
tissue and recommended the use of a smaller probe when applying to smaller tumours. 
The probe was able to differentiate between normal and tumour tissue and results 
between the probe results and pathology correlated well, with a good sensitivity 
(percentage not reported). The findings in this study are supported by another animal 
study, using a mouse model.53 They found the PET probe was able to detect positron 
rays at a close range to the site of interest and concluded the PET probe may have a 
higher sensitivity compared to the gamma probe. Both studies recommended further 
research using the PET probe in breast surgery, including the timing from FDG 
injection and using the probe intraoperatively.  
 
The ability of the PET probe to detect small tumours was supported by Essner and 
colleagues.50, 54 However their studies did not include breast cancer cases. Two other 
studies applied the probe in breast surgery cases, but it was only applied to the lymph 
nodes.55, 56 Molina and colleagues57 used the PET probe on three patients with a past 
history of breast cancer. All patients were intravenously injected with 10-12 mCi of 
FDG 3-4 hours prior to the procedure. The probe was able to accurately identify the 
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recurrent breast lesions in all three cases, but the study only used the probe for lesion 
localisation and not margin assessment.  
 
The only study to examine primary breast tumours was undertaken by Piert and 
colleagues.58 The study included one case of invasive ductal breast cancer. The patient 
was intravenously injected with 41.1 MBq of FDG and the probe was used 105 minutes 
after injection. The site of interest was identified by the PET probe, however the probe 
was only used for tumour localisation and not margin assessment. The study also 
concluded the performance of the probe depended on the uptake and metabolism of the 
injected radionuclide, the technical performance of the probe, the time between 
injection and using the probe and the size of the probe. They also concluded that the 
radiation burden to theatre staff is less that that associated with high-energy gamma 
probes.  
 
A literature search did not identify any studies where the PET probe was used to assess 
surgical margins in breast cancer cases. The potential application of the PET probe in 
this context was identified as necessary for future research in three other articles not 
mentioned above.59-61 Utilisation of a PET probe may allow more accurate delineation 
of normal from abnormal tissue and may accurately assess surgical margins, particularly 
in DCIS BCT. Further research is required on the suitability of FDG for DCIS, timing 
between injection and using the probe and suitable injection quantities. 
 
 
3.8 Conclusion 
This review systematically selected and analysed published literature on IMA methods 
in BCT for breast cancer. Different pathological IMA methods, specifically frozen 
section and touch smear or imprint cytology, reported high accuracy but they can add 20 
to 30 minutes on operation time and thus are less appealing. Whilst the two studies 
reporting the use of ultrasound showed high accuracy, a third performed poorly. Whilst 
ultrasound can return results in a short time period compared to pathological assessment 
methods, it does not perform well where there is associated calcification or multifocal 
cancers. Further research, particularly using large samples, is required for the 
application of mammography, radiofrequency spectroscopy, and optical coherence 
tomography in IMA during BCT. The impact on intraoperative assessment methods in 
multifocal cancers also needs to be further explored. The PET probe is a novel device 
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with no research published in this area. Further research is required to determine its 
application in breast surgery. 
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CHAPTER 4 EPIDEMIOLOGY OF DUCTAL CARCINOMA IN SITU IN 
WESTERN AUSTRALIA 1996 - 2005 
 
4.1 Introduction 
Before attempting to implement an intraoperative margin assessment (IMA) technology 
to improve the clinical outcomes for women diagnosed with ductal carcinoma in situ 
(DCIS), it is essential to identify the current status of DCIS in Western Australia (WA).  
In March 2010 the Australian Institute of Health and Welfare (AIHW) published a 
report examining the characteristics of Australian women diagnosed with DCIS 
between 1995 and 2005, including data from BreastScreen Australia for 1996 to 2005.1 
The purpose of this chapter was to compare the WA data against the national results, 
and to supplement with information available in WA that was not reported in the 
national report. The objectives of this epidemiological study were to: (1) identify the 
characteristics of women who have been diagnosed with DCIS in WA between January 
1996 and December 2005; (2) determine the rate of second operations and breast cancer 
events (BCE) (recurrence or invasion) in the study population; and (3) identify risk 
factors for a breast cancer event in the study population. 
 
 
4.2 Abbreviations 
Below is a list of abbreviations used in this chapter: 
AIHW Australian Institute of Health and Welfare 
ASR age-standardised incidence rate 
BCE breast cancer event 
BCT breast conserving therapy 
CI confidence interval 
CIS carcinoma in situ 
DCIS ductal carcinoma in situ 
ICD-10-AM International Statistical Classification of Diseases and Related 
Health Problems, Tenth Revision, Australian Modification 
IMA intraoperative margin assessment 
Int. intermediate 
No. number 
NOS not otherwise specified 
OR odds ratio 
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RR relative risk 
SD standard deviation 
SPSS Statistical Package for the Social Sciences 
WA Western Australia 
 
 
4.3 Methods 
Ethical approval from the Human Research Ethics Committee, Curtin University 
(Appendix B) was sought before the Confidentiality of Health Information Committee 
for the Department of Health, WA, approved the release of the data for this 
epidemiological study. De-identified data were extracted from the Cancer Registry of 
WA and the Hospital Morbidity Database for WA, and provided in two separate 
Microsoft Excel spreadsheets linked by a cancer registry number.  Cases where the first 
diagnosis in WA between 1 January 1996 and 31 December 2005 with International 
Statistical Classification of Diseases and Related Health Problems, Tenth Revision, 
Australian Modification (ICD-10-AM) classification codes “C50.x” or “D50.x” (breast) 
and morphology code with a tumour behaviour “/2” were selected.  The Cancer Registry 
of WA did not have complete cases for DCIS until after 1995, which is why the start 
date is 1996, and examines a ten year period. Data was selected until 2005 to match the 
national dataset and to allow data collection for a minimum 5 year follow-up (status as 
of 31 December 2010). Cases were then selected based on the reported morphology. All 
cancer registries in Australia use a ‘four month rule’ whereby any record with a 
diagnosis of DCIS that had a subsequent diagnosis of invasive breast cancer within four 
months was discarded.1  
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4.3.1 Extracted variables 
Extracted variables included: 
 Initial diagnosis and subsequent (related) diagnoses, 
 Age at time of diagnosis, 
 Indigenous status, 
 Date and basis of diagnosis, 
 Site, morphology, behaviour and grade, 
 Surgical method/procedures during admission/s, 
 Surgical length of stay,  
 Second operation to obtain adequate margins for primary DCIS, 
 Breast cancer events (BCE), specifically  recurrence and invasion, including 
date, site, morphology, behaviour, grade and treatment, 
 Other treatment data, specifically chemotherapy and radiotherapy, 
 Date and cause of death. 
 
4.3.2 Data analysis 
The data was cleaned and cross-matched to create one spreadsheet containing the data 
from the two different databases.  This data was then analysed using Statistical Package 
for the Social Sciences (SPSS) version 21. Incidence means, distribution and frequency 
were estimated. The probability of developing invasive breast cancer following DCIS 
was calculated by the Kaplan-Meier method. Odds ratios of a BCE, and specifically 
invasion, were calculated using a multivariate logistic regression analysis, including 
variables of age group, grade, first operation type, if a second operation (re-excision) 
occurred and type, and radiotherapy use. 
 
 
4.4 Epidemiology of ductal carcinoma in situ in Western Australia 
 
4.4.1 Incidence 
Between January 1996 and December 2005 there were 1,356 new DCIS cases 
diagnosed in WA.  The peak increase in incidence rate occurred in 2003 but the largest 
percentage increase from the previous year was seen in 2000, as shown in Table 4.1 and 
Figure 4.1. There was an incidence increase on average of 9.6% per year. 
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Table 4.1: Incidence by year of primary ductal carcinoma in situ, Western 
Australia 1996 – 2005 
Year Incidence Percentage of total 
cohort 
Percentage increase 
from previous year 
1996 81 6.0%  
1997 84 6.2% 3.70% 
1998 108 8.0% 28.57% 
1999 107 7.9% -0.93% 
2000 153 11.3% 42.99% 
2001 163 12.0% 6.54% 
2002 174 12.8% 6.75% 
2003 180 13.3% 3.45% 
2004 141 10.4% -21.67% 
2005 165 12.2% 17.02% 
 
 
Figure 4.1: Incidence by year of primary ductal carcinoma in situ, Western 
Australia 1996 – 2005 
 
4.4.2 Age and age-standardised incidence rate 
The average age at time of diagnosis for primary DCIS was 58.13 years (95% 
confidence interval [CI] 57.55, 58.72, standard deviation [SD] 10.93). The range was 
20.0 to 95.7 years with a normal distribution (Shapiro-Wilk p=0.000). Figure 4.2 shows 
the distribution of age in the study population. 
  
 79 
Figure 4.2: Distribution of age of primary ductal carcinoma in situ, Western 
Australia 1996 – 2005 
 
 
The incidence varied noticeably by age. When examined by age group, the highest 
number of cases were reported in the 50-59 years, followed by 60-69 years, in every 
year except 2001 (Table 4.2). These two age groups accounted for more than half of 
cases each year, with 71.08% (118/166 cases) of cases diagnosed in 2005 aged between 
50-69 years.   
 
Table 4.2: Crude incidence by age group of primary ductal carcinoma in situ, 
Western Australia 1996 – 2005 
  1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 Total 
<40 8 5 5 3 4 2 6 8 2 6 49 
40 - 49 19 19 18 30 24 34 30 24 25 26 249 
50 - 59 23 30 40 40 65 52 57 68 57 66 498 
60 - 69 21 21 28 21 40 53 54 59 34 52 383 
70 - 79 8 9 10 7 15 18 24 18 15 9 133 
≥80 2 0 6 6 5 3 3 4 8 7 44 
Total 81 84 107 107 153 162 174 181 141 166 1356 
 
In 2005 the age-standardised incidence rate (ASR) was 15.4 cases per 100,000 females, 
as shown in Table 4.3. Between 1996 and 2005 the ASR increased on average by 5.4%, 
but in the age groups 50-59 years and 60-69 years the ASR increased by 26.2% and 
21.3%, respectively. Figure 4.3 graphically represents the age-standardised rate by year 
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and age group, showing the increase in incidence in the 50-59 years, followed by 60-69 
years age group. 
 
Table 4.3: Age-standardised incidence rate of ductal carcinoma in situ, Western 
Australia 1996 – 2005.  
Age (years) 
<40 40 - 49 50 - 59 60 - 69 70 - 79 ≥80 ASR(a) 
1996 8.2 21.0 30.3 23.5 9.2 2.4 10.0 
1997 5.1 20.6 36.9 23.2 10.0 0.0 10.1 
1998 5.1 19.1 46.6 30.3 10.7 6.9 12.5 
1999 2.0 31.2 44.2 22.1 8.3 6.7 12.1 
2000 4.0 24.4 68.3 41.1 15.3 5.3 16.7 
2001 2.0 34.0 52.0 53.0 18.0 3.0 17.1 
2002 6.0 29.5 54.6 52.1 23.8 2.9 17.8 
2003 8.0 23.2 62.4 54.2 17.6 3.7 17.8 
2004 2.0 23.9 50.6 30.5 14.5 7.2 13.6 
2005 5.9 24.6 56.5 44.8 8.6 6.1 15.4 
(a) Age-standardised incidence rate (ASR). Rates are age-standardised to the Western Australian population at 30 June 2001 and 
expressed per 100,000 women per year.  
 
Figure 4.3: Age-standardised incidence rate (ASR) by year, age group of primary 
ductal carcinoma in situ, Western Australia 1996 – 2005 
 
 
4.4.3 Patient characteristics 
Table 4.4 summarises the patient characteristics of DCIS in WA. Only 18/1356 (1.3%) 
of cases reported they were Aboriginal or Torres Strait Islander. The majority 
(1298/1356; 95.72%) of cases were diagnosed by histology, with 50/1356 (3.69%) 
diagnosed by cytology. Whilst more than a third of cases (37.02%) did not specify the 
site of DCIS, 380/1356 (28.02%) were located in the upper-outer quadrant of the breast. 
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This percentage was larger than the percentages for the other areas of the breast, albeit 
statistically non-significant. 
 
With respect to the lateral site of the tumour the side of the breast was approximately 
evenly distributed between left and right: 50.66% left compared to 45.98% right, 0.15% 
bilateral and 3.24% not reported. Data was not available for the grade of the DCIS for 
nearly half the cases (46.09%), but 411/1356 (30.31%) of cases were classified high 
grade (poorly differentiated), and 208/1356 (15.34%) of cases were classified 
intermediate grade (moderately differentiated). The majority of cases (94.40%) were 
classified as intraductal carcinoma noninfiltrating [morphology code 8500]. 
 
Table 4.4: Patient characteristics of primary ductal carcinoma in situ, Western 
Australia 1996 – 2005 
  Total % 
Race Indigenous Australian 18 1.3 
Non-Indigenous 1338 98.7 
Basis for diagnosis Histopathology 1298 95.72 
Cytology 50 3.69 
Not reported 8 0.59 
Site of DCIS Central portion of breast [C501] 62 4.57 
Upper-inner quadrant [C502] 104 7.67 
Lower-inner quadrant [C503] 76 5.60 
Upper-outer quadrant [C504] 380 28.02 
Lower-outer quadrant [C505] 78 5.75 
Other [C500 or C506] 31 2.28 
Overlapping lesion [C508] 123 9.07 
Unspecified [C509] 502 37.02 
Lateral Left breast 687 50.66 
Right breast 623 45.98 
Bilateral 2 0.15 
Not reported 44 3.24 
Grade 1 - Low / Well differentiated 109 8.04 
2 - Int. / Moderately differentiated 208 15.34 
3 - High / Poorly differentiated 411 30.31 
4 - Anaplastic / Undifferentiated' 3 0.22 
9 - Not determined / not stated 625 46.09 
Morphology 
(Behaviour = 2 [in 
situ]) 
CIS NOS [8010] 4 0.29 
Cribriform CIS [8201] 10 0.74 
DCIS, solid type [8230] 21 1.55 
Intraductal carcinoma, noninfiltrating NOS [8500] 1280 94.40 
Comedocarcinoma, noninfiltrating [8501] 31 2.29 
Noninfiltrating intraductal papillary adenocarcinoma 
[8503] 
9 0.66 
Noninfiltrating intracystic carcinoma [8504] 1 0.07 
%, percentage; CIS, Carcinoma in situ; DCIS, ductal carcinoma in situ; Int., intermediate; NOS, not otherwise 
specified. 
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Surgical length of stay data was available for 282 patients, ranging from same day to 9 
days, with a mean 2.11 days (95% CI: 1.81, 2.41; SD 2.54) including same day cases, 
and a mean 3.20 days (95% CI: 2.67, 3.74; SD 3.22) excluding same day cases. Nearly 
half (140/282) of the cases were same day procedures for treatment of a primary DCIS 
diagnosis. 
 
4.4.4 Primary operation type and other treatment 
Operation type for the surgical treatment of primary DCIS was available for 287 
patients, with the remaining cases not reported in the data provided. Breast conserving 
therapy (BCT) was the most common procedure used for surgical treatment of primary 
DCIS, with 206/287 (71.8%) of patients treated by this method. Table 4.5 shows the 
frequency and percentage of surgical methods. A quarter of patients (70/287; 24.4%) 
elected to undergo mastectomy. Of these, where the nuclear grade was available (43 
patients), 31/43 (72.09%) were high grade DCIS, with 11/43 (25.58%) intermediate 
grade and 1/43 (2.32%) low grade.  
 
A third of patients (469/1356; 34.59%) underwent radiotherapy following surgery. Of 
these, where the nuclear grade was reported (286 patients), 205/286 (71.68%) of cases 
were high grade DCIS, 64/286 (22.38%) of cases were classified intermediate grade and 
17/286 (5.94%) of cases were low grade. There was only one reported case of 
chemotherapy following surgery for primary DCIS. This patient underwent BCT and 
radiotherapy, but the grade was not specified. 
 
Table 4.5: Surgery method for treatment, with histological grade, of primary 
ductal carcinoma in situ, Western Australia 1996 – 2005 
Surgery type Frequency Grade Number Overall Percentage 
Biopsy 11 1 6 3.8% 
2 1 
3 1 
NS 3 
Breast Conserving Therapy 206 1 22 71.8% 
2 35 
3 70 
NS 79 
Mastectomy 70 1 1 24.4% 
2 11 
3 31 
NS 27 
      NS, not specified. 
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4.4.5 Second operation 
Following surgery for primary DCIS, 245/1356 (18.07%) of patients required a second 
operation within six weeks of the initial surgery to obtain adequate margins. Of these, 
where the nuclear grade was reported (188 patients), 173/188 (92.02%) were high grade 
(poorly differentiated) DCIS, 13/188 (6.91%) of cases were classified intermediate 
grade (moderately differentiated) and 2/188 (1.06%) of cases were low or well 
differentiated. Without the full dataset for primary surgery type it is difficult to obtain 
statistics of the frequency of second operations following BCT.  
 
4.4.6 Breast cancer events 
There were 235/1356 (17.30%) cases reporting a recurrence of DCIS and/or invasion 
(defined as a BCE) by the 31 December 2010. Of the BCEs 86/1356 (6.34%) of all 
cases reported a recurrence of DCIS, and 159/1356 (11.72%) of all cases reported 
invasion, including ten cases that reported invasion following recurrence. The mean 
follow-up time was 9.44 years (95% CI 9.30-9.59; SD 2.80) and median time was 9.18 
years. 
 
BCEs after DCIS diagnosis occurred between 5 months and 14 years and 4 months, 
with a mean BCE time of 5 years and 3 months (5.23) (95% CI: 4.79-5.67; SD 3.42). 
The average time since diagnosis of DCIS for recurrence was 4.64 (95% CI 3.92-5.35; 
SD 3.32) and invasion was 5.36 (95% CI 4.82-5.90; SD 3.45).  
 
The probability of a woman in WA following the diagnosis of DCIS having a BCE is 
4.36% (95% CI 4.26-4.46) within 5 years and 8.27% (95% CI 8.08-8.46) within 10 
years. The probability of a woman in WA following the diagnosis of DCIS having a 
diagnosis of invasive breast cancer is 4.55% (95% CI 4.46-4.64) within 5 years and 
8.78% (95% CI 8.60-8.96) within 10 years. Figures 4.4 and 4.5 show the increase in 
probability of a BCE (Figure 4.4) or invasion (Figure 4.5) following a diagnosis of 
DCIS. Data for patients between 5 to 10 years following diagnosis was only available 
for 532 (39.23%) patients in the cohort, which may explain the lag observed in Figures 
4.4 and 4.5 
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Figure 4.4: Probability of having a breast cancer event (recurrence or invasion) 
following diagnosis of ductal carcinoma in situ, Western Australia, 1996 – 2005. 
 
 
Figure 4.5: Probability of having invasive breast cancer following diagnosis of 
ductal carcinoma in situ, Western Australia, 1996 – 2005. 
 
 
4.4.7 Risk factors for a breast cancer event 
Known risk factors of age, histological grade, type of primary surgery, whether a second 
operation was performed to ensure adequate margins, type of second operation 
performed and the use of radiotherapy were analysed to identify if they were risk factors 
for a BCE in this study population. There was an increased risk in women under 40 
years of age having a subsequent BCE, and specifically invasion, with an adjusted odds 
ratio (OR) for a BCE of 8.86 (p<0.001; 95% CI 4.85-16.19), and an adjusted OR for 
invasion of 5.45 (p<0.001; 95% CI 2.99-9.93). There was also an increased risk in 
women with grade 3 DCIS having a subsequent BCE, and specifically invasion, with an 
adjusted OR for a BCE of 1.34 (p=0.058; 95% CI 1.00-1.81), and 1.42 (p=0.049; 95% 
CI 1.00-2.01) for invasion. 
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There was a statistically significant adjusted OR of 16.28 (p<0.001; 95% CI 4.26-62.14) 
of a BCE where biopsy alone was used instead of excision on the primary DCIS. This 
was not statistically significant for invasion, with the adjusted OR 2.05 (p=0.363; 95% 
CI 0.44-9.62), largely due to the small number of cases which underwent biopsy alone. 
When the data was examined for the difference in risk for excision compared to 
mastectomy, the difference was not significant (p=0.090). 
 
There was a 9.85-fold (p<0.001; 95% CI 4.94-19.63) increased risk for a BCE in 
patients who did not have a second operation to excise the primary DCIS, and 7.08-fold 
(p<0.001; 95% CI 3.47-14.47) increased risk for invasion. The risk of a BCE was 
decreased for those who had an excision alone for their second operation, however the 
small sample size must be acknowledged and the increased frequency of high grade 
DCIS in those who underwent mastectomy compared to low or intermediate grade for 
those who only had re-excision. There is an increased risk for those who did not 
undergo postoperative radiotherapy for a BCE (p=0.049) and specifically invasion 
(p=0.043). Tables 4.6 and 4.7 displays the crude and adjusted ORs for BCEs and 
specifically invasion.  
 
Table 4.6: Odds ratio for breast cancer event for risk factors in women diagnosed 
primary ductal carcinoma in situ, Western Australia 1996 – 2005 
Risk factor BCE No. (%) 
No BCE 
No. (%) 
Crude OR (95% 
CI) Adjusted OR (95% CI) p
* 
Age 
(years) 
(No.=1356) 
< 40 31 (13.2) 18 (1.6) 9.35 (5.13 – 17.03) 8.86 (4.85 – 16.19) <0.001 
≥ 40 204 (86.8) 1103 
(98.4) 
1.00 1.00 
Grade 
(No.=729) 
3 73 (55.3) 339 (56.8) 1.46 (1.09 – 1.95) 1.34 (1.00 – 1.81) 0.058 
1 or 2 59 (44.7) 258 (43.2) 1.00 1.00 
Primary surgical 
type (No.=287) 
Biopsy alone 8 (16.7) 3 (1.3) 15.73 (4.00 – 
61.83) 
16.28 (4.26 – 62.14) <0.001 
Excision or
mastectomy 
40 (83.3) 236 (98.7) 1.00 1.00 
Second 
operation 
(No.=1356) 
No second operation 219 (93.2) 892 (79.6) 3.51 (2.07 – 5.96) 9.85 (4.94 – 19.63) <0.001 
Second operation 16 (6.8) 229 (20.4) 1.00 1.00 
Second 
operation type 
(No.=244) 
Re-excision 11 (68.8) 167 (73.2) 0.28 (0.15 – 0.53) 0.86 (0.04 – 0.20) <0.001 
Mastectomy 5 (31.3) 61 (26.8) 1.00 1.00 
Radiotherapy 
(No.=1356) 
No radiotherapy 167 (71.1) 720 (64.2) 1.37 (1.01 – 1.86) 1.38 (1.00 – 1.90) 0.049 
Radiotherapy 68 (28.9) 401 (35.8) 1.00 1.00 
* Adjusted for age and grade   
BCE, breast cancer event; CI, confidence interval; No., number; OR, odds ratio. 
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Table 4.7: Odds ratio for invasive breast cancer following for risk factors in 
women diagnosed primary ductal carcinoma in situ, Western Australia 1996 – 
2005 
Risk factor Invasion No. (%) 
No 
Invasion 
No. (%) 
Crude OR (95% 
CI) 
Adjusted OR (95% 
CI) p
* 
Age 
(years) 
(No.=1356) 
< 40 20 (12.6) 29 (2.4) 5.79 (3.19 – 
10.52) 
5.45 (2.99 – 9.93) <0.001 
≥ 40 139 (87.4) 1168 (97.6) 1.00 1.00 
Grade 
(No.=729) 
3 50 (58.8) 362 (56.2) 1.53 (1.09 – 2.15) 1.42 (1.00 – 2.01) 0.049 
1 or 2 35 (41.2) 282 (43.8) 1.00 1.00 
Primary surgical 
type (No.=287) 
Biopsy alone 2 (6.7) 9 (3.5) 1.68 (0.36 – 7.85) 2.05 (0.44 – 9.62) 0.363 
Excision or 
mastectomy 
28 (93.3) 248 (96.5) 1.00 1.00 
Second 
operation 
(No.=1356) 
No second operation 149 (93.7) 962 (80.4) 3.64 (1.89 – 7.01) 7.08 (3.47 – 14.47) <0.001 
Second operation 10 (6.3) 235 (19.6) 1.00 1.00 
Second 
operation type 
(No.=244) 
Re-excision 7 (70.0) 171 (73.1) 0.28 (0.13 – 0.60) 0.14 (0.06 – 0.31) <0.001 
Mastectomy 3 (30.0) 63 (26.9) 1.00 1.00 
Radiotherapy 
(No.=1356) 
No radiotherapy 115 (72.3) 772 (64.5) 1.44 (1.00 – 2.08) 1.48 (1.01 – 2.17) 0.043 
Radiotherapy 44 (27.7) 425 (35.5) 1.00 1.00 
* Adjusted for age and grade   
CI, confidence interval; No., number; OR, odds ratio. 
 
4.4.8 Mortality 
There were 76 patients reported as deceased by 31 December 2010, with cause of death 
outlined in Table 4.8. Of these ten recorded the cause of death as breast cancer. 
Therefore there was a 0.74% mortality rate in this study group. Of the ten deceased 
patient, nine developed invasive ductal breast cancer in the ipsilateral (same) breast as 
the primary DCIS. The tenth patient developed invasive lobular breast cancer in the 
ipsilateral (same) breast. Of the other 66 patients who died of other causes, only one 
case had a reported recurrence (with a cause of death as colorectal cancer), and one had 
invasive breast cancer (with a cause of death as ovarian cancer). 
 
The time between diagnosis of DCIS and death due to breast cancer was documented 
for six of the ten patients, ranging from 4.2 years to 5 years, with a mean of 4.48 (SD 
0.37) years. 
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Table 4.8: Cause of death in women diagnosed with primary ductal carcinoma in 
situ, Western Australia 1996 – 2005 
Cause of death Frequency Proportion (%) 
Malignant neoplasms of breast 10 13.16 
Cardiovascular disorders 20 26.32 
Malignant neoplasms of digestive organs 8 10.53 
Malignant neoplasms of female genital organs 5 6.58 
Malignant cancer other 4 5.26 
Lung 3 3.95 
Non-Hodgkin lymphoma 3 3.95 
Malignant neoplasms of urinary tract 2 2.63 
Malignant neoplasms of brain 2 2.63 
Malignant myeloma 2 2.63 
Digestive disorders (not malignant) 2 2.63 
Genitourinary disorders 2 2.63 
Pneumonia 1 1.32 
Not reported 12 15.79 
Total 76 100 
 
 
4.5 Comparison with national data 
The purpose of this section was to compare characteristics of DCIS in the WA context 
against those reported by the AIHW.1 The national data examined an eleven year 
period, but Cancer Registry WA data was incomplete for DCIS until after 1995 so only 
1995 to 2005 data, which matches the national BreastScreen data timeframe, was 
examined. The AIHW reported that complete national data for DCIS was not available 
until 1997, which may explain some differences between the WA and national data for 
the first two years of our cohort.2 The WA cohort represented 10.49% of the total 
national incidence rate during 1996 to 2005. The variations in incidence between years 
were not the same between WA and nationally, as shows in Table 4.9. The variations by 
year could not be explained by differences in breast screening, by year, as shown by 
Table 4.10, however it is acknowledged this is data for BreastScreen WA only and there 
may have been an increase in mammography use in private services. There was only a 
5.67% increase in breast screening through BreastScreen WA during the study period, 
following the national implementation of the screening program in 1991. Whilst the 
WA cohort demonstrated an increase in incidence by an average of 9.60% per year, the 
national cohort only had an incidence increase by average of 7.51% per year.  
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Table 4.9: Comparison of difference in percentage increase of ductal carcinoma in 
situ between Western Australia and national data, 1996 - 2005 
Year Percentage increase from previous year 
 Western Australia National2 
1997 3.70% 25.24% 
1998 28.57% 13.15% 
1999 -0.93% 1.78% 
2000 42.99% 9.08% 
2001 6.54% 10.54% 
2002 6.75% -3.94% 
2003 3.45% 3.31% 
2004 -21.67% 6.69% 
2005 17.02% 1.70% 
 
Table 4.10: Number of women aged 50-69 participating in BreastScreen (Western 
Australia), 1996-1997 to 2005-2006 (adapted from BreastScreen Australia3) 
Year Participantsa Populationb Percentage 
participating 
Percentage 
increase from 
previous year
1996 – 1997 845,143 1,645,331 51.37 
1997 – 1998 927,735 1,700,951 54.54 9.77
1998 – 1999 976,182 1,754,254 55.65 5.22
1999 – 2000 1,012,184 1,809,735 55.93 3.69
2000 – 2001 1,064,246 1,868,832 56.95 5.14
2001 – 2002 1,102,642 1,928,878 57.16 3.61
2002 - 2003 1,118,823 1,989,802 56.23 1.47
2003 – 2004 1,144,008 2,051,480 55.77 2.25
2004 – 2005 1,188,955 2,114,036 56.24 3.93
2005 - 2006 1,242,210 2,177,660 57.04 4.48
(a) Participants are the number of women screened through BreastScreen Australia in each 2-year reporting period. The screening 
periods cover 1 January of the initial year to 31 December of the latter year indicated. 
(b) Population is the average of the ABS estimated resident population for women aged 50-69 for the two reporting years 
 
The WA cohort also varied from the national reporting by age. Both cohorts reported 
low incidence in women under 40 years of age and over 80 years. The national study 
found the highest incidence in the age group 60-69 years, whereas the WA cohort has 
the highest incidence in the age group 50-59 years, followed by 60-69 years. The ASR 
was similar between cohorts except between 2000-2003 when it was higher in WA, as 
shown in Table 4.11. This is in line with the increase in incidence seen in WA in 2000 
but again cannot be explained by breast screening in WA.  
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Table 4.11: Age-standardised incidence rate of ductal carcinoma in situ in females, 
Western Australia 1996 – 2005 
Year Age-standardised rate(a) 
Western Australia National2 
1996 10.0 10.4 
1997 10.1 11.7 
1998 12.5 12.8 
1999 12.1 12.8 
2000 16.7 13.6 
2001 17.1 14.7 
2002 17.8 13.8 
2003 17.8 13.9 
2004 13.6 14.5 
2005 15.4 14.4 
a) Rates are age-standardised to the Western Australian population at 30 June 2001 and expressed per 100,000 women 
 
The probability of having a BCE (recurrence or invasion) following DCIS was not 
reported in the national data, but the probability of invasion was reported. The WA 
cohort was only slightly lower than the national cohort, with the five year probability of 
4.36% versus 5.30% and ten year probability of 8.27% versus 10.90% in the WA and 
national cohort, respectively. Whilst cases in WA were tracked and matched by the 
Cancer Registry as patients move between local health providers, some cases were lost 
to follow-up if they moved interstate, a limitation not applicable to the national data. 
The WA cohort also had a smaller sample size which may also explain the difference. 
 
As population data for invasive breast cancer was not available, the overall relative risk 
(RR) of a woman diagnosed with DCIS developing invasive breast cancer could not be 
calculated. As with the national study, there was a significant (p<0.001) increase in risk 
of a BCE, and specifically invasion, for women under 40 years. The national study did 
not examine other risk factors.  
 
 
4.6 Discussion 
A number of countries have published data on the incidence of DCIS. A study in the 
Netherlands examined newly diagnosed DCIS cases reported between January 1989 and 
December 2003.4 In a population of 800 women, they reported 77% of cases underwent 
BCT for initial surgery, compared to 23% mastectomy. Over half (54%) of the cases 
were grade 3. Of patients treated with BCT, 40% also received radiotherapy. A study in 
Canada examined all cases between 1991 to 2000 newly diagnosed through the Ontario 
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Breast Screening Program.5 The study examined 727 patients, where 26.3% were 
treated by mastectomy compared to 73.7% treated with BCT. 23.1% of patients had 
grade 3 DCIS. Nearly half (49.43%) of the patients treated with BCT also received 
radiotherapy. An Australian study of all new DCIS cases in 1995 reported 55% of the 
415 women were grade 3.6 Two-thirds (62%) of patients underwent BCT compared to 
23% mastectomy. The study surveyed surgeons on reasons for DCIS management 
decisions and reported 40% of surgeons did not consider radiotherapy as they did not 
use radiotherapy for DCIS. Only 22% of patients were referred for radiotherapy 
consultation.  
 
There was an increase in incidence seen in WA in 2000. Literature identifying any 
difference in pathology reporting could not be identified. This increase may be 
explained by an improvement in the detection and interpretation by mammography of 
DCIS given it is within a decade of introduction in WA, an unreported change in 
pathology reporting or methods for DCIS biopsy, and the smaller increase in 
mammography use and DCIS incidence in the year prior. An increase in incidence was 
reported in New South Wales from 1995 to 2000 which was attributed to the 
introduction of mammography, as was the increase experienced in the Netherlands.7, 8 
An Australian study reported that only half of all DCIS tumours diagnosed in Australia 
in 1995 were detected through the BreastScreen program so there may have been an 
increase in mammography use through other providers.6 The WA cohort also reported 
an increase in DCIS diagnosis in women 50-69 years during 2000, so an alternative 
hypothesis is an increase in promotion of mammography to this population prior to 
2000 led to an increase in women seeking mammography screening. 
 
Age and grade has been positively associated widely in the literature with a BCE 
following the diagnosis of DCIS.9-11 Our study identified there was an 8-fold increased 
risk for women under 40 years, relative to those over 40 years, to have a subsequent 
BCE, and 5-fold increased risk where the DCIS was grade 3, relative to grade 1 and 
grade 2 DCIS.  
 
Given the reported association between DCIS site and site of subsequent BCEs, the 
need to ensure adequate margins is essential.12-18 This study identified an increased risk 
of a subsequent BCE (p<0.001), and specifically invasion (p<0.001), where a second 
operation was not performed. Although the WA cohort reported 18.07% of cases 
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underwent a second operation, which is lower than that reported in the literature, the 
significant finding suggests under the WA protocol sufficient margins may not be taken 
during the primary surgery and residual DCIS is remaining in the breast.  
 
The debate around the use of mastectomy for non-invasive breast cancer continues to be 
reported in the literature. Whilst a lower BCE rate is seen in those who undergo 
mastectomy, it is viewed by some as overtreatment.12,19-23 Although in the WA cohort 
there was a statistically significant increase in risk of a BCE (p<0.000) following biopsy 
alone, the risk was not significant for invasion (p=0.363) nor for excision versus 
mastectomy (p=0.090). Only 11 patients in the cohort underwent biopsy alone. 
 
The findings in the WA cohort matched that reported in the literature with regards to the 
use of radiotherapy following surgery. The risk of a BCE was 1.38-fold for those who 
did not have postoperative radiotherapy, and 1.48-fold for invasion. The use of 
radiotherapy between 1996 to 2005 in the WA cohort doubled. Half (50%) of the cases 
that underwent BCT also received radiotherapy in the WA cohort. 
 
As of 1st June 2001 there were 66,069 Indigenous Australians living in WA, 
representing 3.47% of the WA population.24 Our cohort reported only 1.3% of cases 
were identified as Indigenous Australians but none had a BCE. Despite the apparent 
underutilisation of health services among Indigenous populations, breast services were 
the most used cancer services by Indigenous Australians, likely due to the increased 
awareness of the disease and availability of information.25 Although no literature on 
DCIS could be found, a lower incidence and mortality rate for invasive breast cancer is 
seen in Indigenous versus non-Indigenous populations in Australia.26, 27 Interestingly 
whilst most literature supports lower incidence rates in Indigenous populations, a higher 
mortality rate has been reported in this population. Research has also identified an 
association between Indigenous status and more aggressive tumours.28-30 Further 
research on DCIS in Indigeonous Australians is required. 
 
 
4.7 Conclusion 
A higher age-standardised incidence rate of DCIS has been reported since 2000 in WA. 
Whilst a lower incidence rate is seen in the under 40 years of age group both at a state 
and national level, the highest incidence rate is seen in the 50-59 year group in WA, 
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compared to 60-69 years nationally. The five and ten year probability of a BCE, and 
specifically invasion, is lower in WA compared to nationally. Risk factors of age, grade, 
second operation (re-excision) and radiotherapy use were statistically significant 
associated with a subsequent BCE, and specifically invasion, in WA. The statistical 
analysis of DCIS in WA supports the need for ensuring adequate margins are excised 
during the first operation to reduce the number of second operations and the risk of a 
subsequent BCE. An in-depth study of the effect of screening promotion and disease 
progression among Indigenous Australians is also recommended. 
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CHAPTER 5 COMPARISON OF RADIOPHARMACEUTICALS IN THE 
DETECTION OF DUCTAL CARCINOMA IN SITU WITH POSITRON 
EMISSION TOMOGRAPHY 
 
5.1 Introduction 
A diagnostic method not discussed in Chapter 2 is positron emission tomography (PET). 
PET works by giving the patient an intravenous injection of a radiopharmaceutical 
labelled with a positron-emitting radionuclide that targets specific tissue characteristics 
and scanning the patient using a PET scanner (camera). The camera is able to detect the 
high energy gamma emissions from the radiopharmaceutical caused by annihilation of 
the positrons in the tissues and generate a three-dimensional image of the region 
scanned. Areas which take up the radiopharmaceutical will show as a ‘hot spot’ on the 
image that can be measured to determine the tumour to background (TTB) ratio. 
Approximately 90% of clinical studies use 18F-fluorodeoxyglucose (FDG), a positron-
emitting analog of glucose, because a higher metabolism of glucose is noted in tumour 
cells.1 The reported sensitivity of FDG PET in breast cancer (including in situ cancers) 
varies in the literature, from 25% to 96% and is higher for positron emission 
tomography – computer tomography (PET-CT).2-4 Most studies report a poor sensitivity 
of PET for in situ and small size tumours.2-4 Given this poor sensitivity, it is important 
to test FDG against another radiopharmaceutical to determine which is the best to use 
with ductal carcinoma in situ (DCIS). A number of radiopharmaceuticals that target 
other tissue characteristics have been studied in breast cancer and PET, again showing 
poor sensitivity and accuracy for in-situ and small size tumours.1, 5 One 
radiopharmaceutical that is available in Perth, Western Australia (WA) and has not been 
reported in the literature for DCIS, is 18F-fluoromethylcholine (FCH). Choline is a 
constituent of phosphatidylcholine. This is a major component of the phospholipid cell 
membrane (the fatty covering of cells). Malignant tumours have an increased 
intracellular choline pool and increased production and turn-over of cell membranes.1 
 
The objectives of this study were to (1) determine if both FD) PET and FCH PET can 
detect newly diagnosed DCIS; (2) identify the TTB ratio for each radiopharmaceutical 
in DCIS; and (3) determine the best radiopharmaceutical to use with the PET probe.  
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5.2 Abbreviations 
Below is a list of abbreviations used in this chapter: 
BAC Breast Assessment Centre 
BMI body mass index 
CI confidence interval 
DCIS ductal carcinoma in situ 
FCH 18F-fluoromethylcholine 
FDG 18F-fluorodeoxyglucose 
MBq megabecquerel 
mm millimetre 
mmol/l millimoles per litre 
mSv millisievert 
PET positron emission tomography 
PET-CT positron emission tomography – computer tomography 
ROI region of interest 
RPH Royal Perth Hospital 
SD standard deviation 
SUV standardised uptake value 
TTB tumour to background 
WA Western Australia 
WLE wide local excision 
 
 
5.3 Methods 
Patients with newly diagnosed DCIS at Royal Perth Hospital (RPH), Perth Western 
Australia, who met the inclusion criteria, were invited to participate in the study.  
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5.3.1 Eligibility criteria 
The eligibility criteria for the subjects were: 
 
Inclusion Criteria: 
1. Patient with newly diagnosed DCIS of the breast that is >10mm on mammogram 
(as previous research showed PET has a poor sensitivity on tumours <10mm2-4), 
2. Planned to undergo surgical excision of DCIS, 
3. Female, between 50 and 69 years of age. A high incidence rate was reported for 
this age group in Chapter 4. Exclusion of women under 50 years and over 69 
years excludes the at risk age group and reduces the risk of co-morbidities seen 
in the older population, and 
4. Able to provide informed consent. 
 
Exclusion Criteria: 
1. Planned neoadjuvant therapy for DCIS; 
2. Concurrent invasive carcinoma of the ipsilateral breast; 
3. Previously diagnosed DCIS of the ipsilateral or contralateral breast, or primary 
malignancy of the breast; 
4. Previous history of another primary malignancy; 
5. Uncontrolled diabetes mellitus; 
6. Pregnant at the time of PET scan; 
7. Other indications not allowable by PET, such as pacemaker or weight in excess 
of 135kgs. 
 
5.3.2 Sample size 
These eligibility criteria were necessary for participants to undergo a PET scan and to 
reduce the risk of confounders. It was anticipated that this eligibility criteria, coupled 
with the radiation risk and time limitation to undergo two PET scans prior to surgery, 
would greatly impact on the number of patients eligible for and willing to consent for 
this study.  Therefore, the sample size for this pilot study was ten participants.  
 
5.3.3 Study procedure 
Following ethical approval from Curtin University (Appendix B) and Royal Perth 
Hospital (Appendix C) and approval from the Radiological Council of Western 
Australia (Appendix D), the investigator attended the Breast Assessment Centre (BAC) 
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at RPH twice a week to assess all cases for eligibility in the study. When a patient was 
identified as meeting the eligibility criteria, the study information was attached to the 
front of the medical record with instructions to the attending surgeon to discuss the 
study with the patient when they attended for their appointment (Appendix E). At this 
time, if the patient expressed an interest in the study the information sheet and consent 
form was provided for them to take home to read and discuss with family and friends 
and the Surgeon would notify the investigator. Two business days after their 
appointment, the patient was contacted by telephone by the investigator to enquire if 
they had read the information and if they had any questions. If the patient agreed to 
participate in the study the investigator made an appointment to meet with the patient 
and then booked the two PET scans, at the Department of Nuclear Medicine, Sir 
Charles Gairdner Hospital, Perth Western Australia. At the appointment, informed 
consent was obtained and appointment details for the two PET scans was provided. The 
investigator also ensured the patient had already undergone mammography, ultrasound 
and biopsy prior to the PET scans. Where these had not been performed, the 
investigator liaised with the surgeon to organise these prior to the first PET scan. Figure 
5.1 is a flowchart of the above process. 
 
At the conclusion of each PET scan, regions of interest (ROI) were drawn and the 
activity and standard deviation was obtained for the DCIS, in the contralateral breast 
and in the mediastinal blood pool. From this the tumour to background (TTB) ratio was 
calculated. This is the measure of the radiopharmaceutical activity in the DCIS 
compared to that in the contralateral breast. The standardised uptake value (SUV) was 
not used as a measure of comparison as SUVs in FCH PET had not previously been 
validated at the time of the study. A PET clinician reported the PET scan findings, but 
results were not released to the surgeon prior to surgery, unless there were exceptional 
circumstances.   
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The reason for blinding the surgeon to the PET results was because PET in the 
diagnosis of DCIS had yet to be validated.  Exceptional circumstances included:  
 PET identified a tumour in the ipsilateral breast or regional lymph nodes, which 
could potentially alter the planned course of management. 
 PET identified an incidental finding, such as a second primary tumour elsewhere 
in the body. If found to be benign and patient were to receive surgery for DCIS 
within the next month following the PET scan, the patient would remain in the 
study. 
 
Should invasive breast cancer be found in the contralateral breast, the findings would be 
reported to the surgeon immediately, but the patient would not be withdrawn from the 
study. 
 
The surgeon then removed the DCIS as planned. The pathologist documented the 
dimensions of the DCIS and other routine data was gathered (for example: grade, 
clearance of the margins, necrosis). 
 
Following surgery, a multidisciplinary study meeting (separate to the multidisciplinary 
breast cancer meeting) was held to review the data.  There was no data sharing between 
PET and the other disciplines prior to this meeting outside of exceptional circumstances.  
For each patient, data was presented in the following order: 
1. Radiology specifies mammogram and ultrasound findings, including location 
and dimensions of DCIS. 
2. Surgeon specifies type of surgery and location of surgery. 
3. Pathologist specifies dimensions of DCIS, the margins and if there was presence 
of any residual disease. 
4. Surgeon specifies if re-excision was needed and type of surgery and location of 
surgery if re-excision was required. 
5. Pathologist specifies dimensions of DCIS, the margins and if there was presence 
of any residual disease. 
6. PET specifies findings including location and tumour to background ratio for 
each tracer. 
 
Presenting the data with the PET results at the end of the presentation assisted with 
blinding to the PET results. This provided a background to the patient’s management 
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before revealing if the PET results were concordant with pathology and mammography. 
Five year follow-up information was obtained from medical records. Figure 5.2 is a 
flowchart of the study procedure. 
 
Figure 5.1: Participant recruitment flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FCH, 18F-fluoromethylcholine, FDG, 18F-fluorodeoxyglucose; PET, positron emission tomography.  
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Patient underwent FDG 
PET scan. A minimum 
24 hours later patient 
underwent FCH PET
Team determined if PET was 
concordant with pathology and/or 
mammography & performance of FDG 
versus FCH
PET physician did not inform 
surgeon if no significant findings 
other than DCIS are identified
Surgeon removed 
DCIS
Pathologist documented 
dimensions, grade, margins, 
necrosis and other 
significant findings
PET physician reviewed 
both PET scans and 
documented ROIs, TTB 
ratio and findings
PET physician informed surgeon 
if any significant findings that 
can alter planned management 
are identified
Patient withdrawn if ipsilateral 
invasive breast cancer or positive 
nodes identified, or if malignant 
disease identified elsewhere
Multidisciplinary meeting:
Radiology findings
Surgery information
Pathology findings
Re-excision information (if 
applicable)
Re-excision pathology (if 
applicable)
PET findings
Figure 5.2: Study procedure flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DCIS, ductal carcinoma in situ; FCH, 18F-fluoromethylcholine, FDG, 18F-fluorodeoxyglucose; PET, positron emission 
tomography; ROIs, regions of interest, TTB, tumour to background 
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5.3.4 Radiation dose 
Patients underwent both a FDG and a FCH PET scan.  The effective dose of radiation 
for a whole body FDG PET scan in women is 5.7 millisievert (mSv).  The effective 
dose of radiation for a whole body FCH PET scan in women is 7.3 mSv.  This gives a 
13 mSv effective dose of radiation.  The amount of extra radiation exposure from these 
two PET scans is equal to about 8½ years of natural background radiation.  This has a 
probability for the induction of cancer of 6.5 x 10-4 or one in 1500.  The risk of this 
occurring is about one half of the risk of being killed on WA roads in the next 10 years. 
These figures were provided by the Radiological Council of Western Australia at the 
time of radiological approval. 
 
5.3.5 PET imaging procedures 
The imaging protocol for FDG PET was: 
1. Patients fasted overnight or for 6 hours prior to the PET study. This is because 
foods containing glucose can affect the uptake of FDG. Patients were requested 
to drink liberal amounts of water to optimise hydration and promote urinary 
excretion of FDG. 
2. An intravenous cannula was inserted into a peripheral vein. 
3. Patient’s height, weight and blood glucose levels were recorded and body mass 
index (BMI) calculated. 
4. No generally accepted recommendations were available if the serum glucose 
level is elevated.  Consequently, if the blood glucose level was greater than 
10mmol/l (millimoles per litre), the investigator may have opted to continue 
with the scan, withdraw the patient from the study, administer insulin to 
normalize serum glucose and proceed as long as more than 4 hours can elapse 
between the last dose of short-acting insulin and FDG administration, or 
reschedule the study for a time when serum glucose was better controlled. 
5. Approximately 370MBq (megabecquerel) FDG was administered intravenously.  
The injected dose of FDG was adjusted for patient BMI. 
6. Patients remained in a relaxed position for a minimum of 45 minutes during the 
FDG uptake period.  In selected cases, sedation may have been required to 
minimise muscle activity during the uptake period. 
7. Patients who have not been catheterised were asked to void prior to 
commencement of the PET scan. In the case of patients who had been 
catheterised, the urinary catheter bag was drained prior to scanning. 
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8. At approximately 1 hour following FDG administration, PET emission and 
transmission data was acquired from the base of skull to below inguinal nodes. 
9. ROIs for the DCIS site, contralateral breast and mediastinal blood pool were 
generated and activity and standard deviations (SD) in the ROI calculated, with 
a minimum of five recordings each. TTB ratios were then calculated. 
 
The imaging protocol for FCH PET was: 
1. Patients were not required to fast prior to the FCH PET study. This is because 
food consumption prior to an FCH injection will not affect FCH uptake. Patients 
were requested to drink liberal amounts of water to optimise hydration and 
promote urinary excretion of FCH. 
2. An intravenous cannula was inserted into a peripheral vein. 
3. Patient’s height and weight were recorded and BMI calculated. 
4. Patients were asked to void prior to commencement of the PET scan. 
5. Approximately 200MBq of FCH was administered intravenously.  The injected 
dose was adjusted for BMI. 
6. Patients were imaged immediately after injection for 10-15 minutes using 
dynamic imaging of the breast only, and then PET emission and transmission 
data were acquired from the base of skull to below the inguinal nodes  for the 
next 45 minutes. 
7. ROIs for the DCIS site, contralateral breast and mediastinal blood pool were 
generated and activity and standard deviations (SD) in the ROI calculated, with 
a minimum of five recordings each. TTB ratios were then calculated. 
 
5.3.6 PET image interpretation 
The PET scans were read by two specialists credentialed for PET interpretation by the 
Joint Nuclear Medicine Credentialing and Accreditation Committee of the Royal 
Australasian College of Physicians and the Royal Australian and New Zealand College 
of Radiologists. They were not blinded to the results of the other scan data and had 
access to full clinical history, using attenuation corrected emission PET images. The 
ROIs and calculations were generated by the attending specialist and the investigator. 
 
5.3.7 Data collection 
Data collected included patient demographic data (age, age group), significant clinical 
history, pathological data (histological grade, necrosis, focality and extent of disease, 
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the margins, and presence of residual disease or invasion), surgical notes, imaging 
findings, management plan before surgery, postoperative clinical management and any 
adverse events.  All data was entered onto a database at Curtin University.   
5.4 Results 
 
5.4.1 Patient recruitment. 
Between September 2005 and December 2006,the medical records of 192 female 
patients attending the BAC at RPH were reviewed for consideration of inclusion in the 
study.  All 192 patients were reported on mammography to have DCIS with no 
invasion.  One patient was excluded as they were outside the age range suitable for the 
study, 29/192 (15.10%) were found to have an invasive component on biopsy and 
68/192 (35.42%) were reported as having DCIS smaller than 10mm measured by 
mammography. Furthermore, 27/192 (14.06%) of patients had a past history of DCIS or 
invasive breast cancer and 59/192 (30.73%) had already undergone surgery or the 
planned surgery date would not allow time for the PET scans. Once the eligibility 
criteria were applied, only 8 patients (4.17%) were eligible and invited to participate in 
the study. Screening information is presented in Table 5.1. 
 
Table 5.1: Screening information 
Patients reviewed 192 
Age of screening population Range 31-73 
54.65 years Mean 
 
DCIS size on mammography of screening 
population 
Range 
Mean 
2 – 90mm 
26.44mm 
Reason for exclusion:  
Patients age <50 years or > 70 years 1 (0.52%) 
Patients with invasion detected by biopsy 29 (15.10%) 
Patients with DCIS size on mammography <10mm 68 (35.42%) 
Patients with past history of DCIS or invasion 27 (14.06%) 
Patients already undergone surgery for DCIS or insufficient time before surgery 
for PET scans 
59 (30.73%) 
Patients remaining eligible for study 8 (4.17%) 
DCIS, ductal carcinoma in situ; PET, positron emission tomography. 
 
Of these eight eligible patients, four declined to participate in the study due to the 
radiation risks. Another patient declined due to family reasons and another did not 
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provide a reason for declining. Two patients agreed to participate in the study. The 
study team ceased recruitment at 16 months due to the difficulties in recruitment, and 
the study was examined as a case study with these two patients. 
 
5.4.2 Patient 1 
Patient 1, aged 63 years, was referred to the RPH BAC by her general practitioner 
following a mammogram identifying a localised cluster of calcification in the right 
breast. This patient was asymptomatic with no breast discharge, lump or pain. The 
patient reported no past history of breast or ovarian cancer and no known family history. 
Patient 1 had undergone a core biopsy approximately ten years prior for a benign lesion 
of the breast, site not recorded. Other clinical history included arthritis, recent right 
shoulder pain, uterine prolapsed and a stapedectomy many years prior. The patient 
commenced menarche at 13-14 years of age and had a past history of six pregnancies, 
with five resulting in a live birth, all breast fed, with the first pregnancy at eighteen 
years of age. There was no prior use of the contraceptive pill or hormone replacement 
therapy and the patient underwent menopause in her late 40s. 
 
5.4.2.1 Patient 1: mammography and biopsy 
Clinically, both breasts and axillae were normal. Mammographically, the lesion 
measured as 25mm in the lower outer quadrant of the right breast. A stereotactic core 
biopsy of the mammographic abnormality showed high grade DCIS.  Immediately 
following the core biopsy, the patient was seen in the RPH BAC and provided with the 
information about the study.  
 
5.4.2.2 Patient 1: positron emission tomography imaging 
The patient was booked to undergo the FDG PET scan two weeks after the core biopsy. 
This was to allow sufficient time for any inflammatory response in the biopsy site to 
subside and was also booked before the FCH PET scan as the effect of FCH on a FDG 
PET scan was unknown and not reported in the literature at the time. The FCH PET 
scan was booked 24 hours after the FDG PET to allow time for decay and elimination 
of the FDG. 
 
The patient was not a diabetic and had a BMI of 29.9. Her blood sugar level was 
measured as 6.0 mmol/l. The patient was injected with 386MBq of FDG and rested 
supine for 43 minutes in a dimly lit stall. The DCIS was visualised on the PET image. 
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No other incidental findings were reported. The tumour activity ranged from 1095 
(standard deviation ±332) to 1139 (±462) in the tumour, 705 (±233) to 794 (±128) in the 
contralateral breast and 3038 (±312) to 3179 (±339), giving a TTB ratio of 1.494 
(±0.084; 95% CI 0.740-2.248). 
 
The following day, Patient 1 returned for the FCH PET scan. The patient reported no 
adverse effects from the PET scan the previous day. The patient was injected with 
207MBq of FCH and imaged immediately. Whilst the DCIS could be visualised on the 
PET image, it was not as ‘hot’ as with the FDG scan. No other incidental findings were 
reported by either PET clinician. The tumour activity ranged from 424 to 2590 in the 
tumour, 203 to 1150 in the contralateral breast and 968 to 2610 , giving a TTB ratio of 
1.486 (±0.695; 95% CI 0.241-3.212). The FDG PET and FCH PET images for Patient 1 
are shown in Figure 5.3 
 
Figure 5.3: Patient 1 FDG PET (top) and FCH PET (bottom) images for DCIS 
 
 
 
DCIS, ductal carcinoma in situ; FCH, 18F-fluoromethylcholine, FDG, 18F-fluorodeoxyglucose; PET, positron emission 
tomography. 
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5.4.2.3 Patient 1: surgery and histology 
Patient 1 underwent a wide local excision (WLE) six days post FCH PET scan. A 
modified Koplan’s hookwire was inserted in the lateral aspect of the right breast on the 
lateral medial compression on the morning of surgery. During the WLE a mass 
weighing 121g and measuring 85mm superior to inferior, 90mm medial to lateral and 
20mm deep to superficial was excised. The hookwire was in situ. A shaving from the 
superior margin was also excised, measuring 75x50x15mm. The cavity surface 
appeared focally haemorrhagic. Of the excised tissue the deep margin was inked black 
and the remainder of the specimen inked blue. 19 serial slices from medial to lateral 
were taken. No definite lesion was identified and pins were put in place in slices 9 and 
12. 
 
Histology reported calcifications were present in the DCIS and benign breast changes 
with pseudoangiomatous hyperplasia recorded in the shaving.  No invasive component 
was found. Cell type was classified as comedo/solid with comedo necrosis present. It 
was unifocal with a high nuclear grade. Microscopic dimensions of the tumour 
measured 15mm. The margin was 6mm from the superficial margin and greater than 
10mm from all other margins. Normal parenchyma was seen between the DCIS and 
margins. Tubal score was 3 and Nottingham category B. Table 5.2 provides a summary 
of the above and in comparison to Patient 2. 
 
5.4.2.4 Patient 1: post-surgery and follow-up 
The case was reviewed at a multidisciplinary breast cancer meeting where it was 
determined that no further excisions would be undertaken and that surgery was 
complete. As the peripheral margins were clear, mastectomy was not recommended. 
The meeting recommended radiotherapy to the breast and chest wall only, and not the 
axillary nodes. Chemotherapy was not recommended. A follow-up mammography was 
recommended in one year’s time. 
 
Six weeks post WLE the scar still showed some puckering and swelling, with no 
erythema. There was good arm movement. The patient received postoperative 
radiotherapy to the right breast using tangents. Towards the end of radiotherapy a breast 
abscess formed and was treated with oral antibiotics (flucoxcallin).  
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Six months post WLE Patient 1 was reviewed in the BAC. No changes in the breast 
were noted, including no masses palpable in either breast or axilla. The patient reported 
a number of viral infections. Bilateral parenchyma was noted. A mammogram was 
booked for six months time.  The patient requested an appointment with the BAC nine 
months post WLE, reporting chest wall pain.  On examination, tenderness was reported 
in the costochondral junction and the patient was recommended non-steriodial 
treatment. Clinically, no masses were noted. 
 
The bilateral mammogram was brought forward to ten months post WLE.  The scan 
showed postsurgical scarring only. Architectural distortion and skin thickening 
inferiorly in the right breast was consistent with surgery. No contralateral stellate was 
noted. Bilateral calcifications appear mammographically benign, with no residual 
calcifications and no new suspicious microcalcifications. No axillary lymphadenopathy 
was noted.  
 
The next mammogram was undertaken two years following the above mammogram.  
Less than 25% of parenchymal density was demonstrated in the breasts in unchanged 
distribution. No new masses, stronal distortion or pleomorphic microcalcifications were 
seen. A repeat mammogram performed 15 months later reported the same, with a small 
amount of residual parenchyma noted bilaterally, occupying now 25% of the breast 
volume.  The last reported mammogram taken six years and nine months post WLE 
showed the residual fibrograndular tissue now occupied 25-50% of the breast tissue. 
There were persistent nodular densities throughout both breasts which are stable when 
compared to previous scans. No new lesion, distortion or masses were detected and no 
axillary lymphadenopathy.  
 
The only other clinically relevant event post PET for Patient 1 was that she was referred 
to King Edward Memorial Hospital 5½ year post WLE for vaginal prolapsed surgical 
care. Permission was obtained from the Breast Surgeon at the RPH BAC to prescribe 
vaginal oestrogen therapy (Vagifem). Permission was granted with the recommendation 
of using Ovestin as it was less likely to have systematic oestrogenic effects. A review at 
the RPH Breast Clinic six years and nine months post WLE shows no signs of 
recurrence clinically or on mammography and the patient was still waiting to undergo 
the vaginal prolapsed repair and had not started on Ovestin. A five year follow-up with 
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the GP confirmed no recurrence or new masses had been detected and the patient was 
clinically stable. 
 
5.4.3 Patient 2 
Patient 2, aged 56 years, was referred to the RPH BAC by Breast Screen WA following 
her third screening mammography identifying calcification in the lower outer quadrant 
of the left breast. The patient was asymptomatic with no previous history or family 
history of breast or ovarian cancer. The patient reported four pregnancies which resulted 
in three live births, with the first pregnancy at 23 years of age. She did not breastfeed 
and reported using the contraceptive pill in the past for approximately three years. The 
patient was postmenopausal (at 47 years of age) and had never taken hormone 
replacement therapy. Significant past clinical history included removal of a left renal 
calculi.  
 
5.4.3.1 Patient 2: mammography and biopsy 
Clinically, both breasts and axillae were normal. Mammographically, the lesion was 
measured as 30mm in the lower outer quadrant of the left breast. A stereotactic core 
biopsy identified high grade DCIS with no invasive component in the biopsied sample. 
Because of the 30mm size of the tumour, it was classified as borderline for breast 
conservation therapy and the patient was provided with information about both a WLE 
with radiotherapy or mastectomy, in order to consider her options. The patient elected to 
undergo a WLE with radiotherapy. At this same appointment at the RPH BAC the 
patient was provided with the information about the study.  
 
5.4.3.2 Patient 2: positron emission tomography imaging 
The patient was booked to undergo the FDG PET scan four weeks after the core biopsy, 
with the FCH PET scan 24 hour later and the WLE two days following this. The patient 
was not a diabetic and had a BMI of 30.4. Her blood sugar level was measured as 
5.3mmol/l. The patient was injected with 361MBq of FDG and rested supine for 42 
minutes in a dimly lit stall. The DCIS could be visualised on the PET image and no 
other incidental findings were reported by either PET clinician. The tumour activity 
ranged from 1004 (±316) to 1182 (±473) in the tumour, 725 (±306) to 759 (±379) in the 
contralateral breast and 3439 (±802) to 3695 (±838), giving a TTB ratio of 1.471 
(±0.122; 95% CI 0.375-2.567). 
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The following day, Patient 2 returned for the FCH PET scan. The patient reported no 
adverse effects from the PET scan the previous day. The patient was injected with 
202MBq of FCH and imaged immediately. Whilst the DCIS could be visualised on the 
PET image, it was not as ‘hot’ as with the FDG PET scan. No other incidental findings 
were reported by either PET clinician. The tumour activity ranged from 517 (±208) to 
589 (±209) in the tumour, 412 (±200) to 512 (±208) in the contralateral breast and 2107 
(±173) to 2195 (±238), giving a TTB ratio of 1.203 (±0.074; 95% CI 0.539-1.866). 
 
The FDG PET and FCH PET images for Patient 2 are shown in Figure 5.4. 
 
Figure 5.4: Patient 2 FDG PET (top) and FCH PET (bottom) images for DCIS 
 
 
 
DCIS, ductal carcinoma in situ; FCH, 18F-fluoromethylcholine, FDG, 18F-fluorodeoxyglucose; PET, positron 
emission tomography. 
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5.4.3.3 Patient 2: surgery and histology 
Patient 2 underwent a WLE two days post FCH PET scan. A modified Koplan’s 9cm 
hookwire was inserted from the lateromedial approach of the left breast on the morning 
of the day case. During the WLE a mass weighing 21g and measuring 45mm superior to 
inferior, 55mm medial to lateral and 15mm deep to superficial was excised. The 
hookwire was in situ. Of the excised tissue the deep margin was inked black and the 
remainder of the specimen inked blue. 12 serial slices from medial to lateral at 5mm 
intervals were taken. No definite lesion was identified and pins were put in place in 
slices 4 and 8. 
 
Histology reported secretory calcifications were present in the DCIS and some benign 
breast changes (microcysts, apocrine metaplasia).  No invasive component was found. 
Cell type was classified as comedo/solid, cribriform, with comedo necrosis present. It 
was unifocal with an intermediate nuclear grade. Microscopic dimensions of the tumour 
measured 35x7x5mm. The margin was 1mm from the deep margin, 1mm from the 
inferior margin and 6mm from the superficial margin. All other margins were greater 
than 10mm. Normal parenchyma was seen between the DCIS and margins. Tubal score 
was 4 and Nottingham category A.  
 
5.4.3.4 Patient 2: post-surgery & follow-up 
The case was reviewed at a multidisciplinary breast cancer meeting where it was 
determined that no further excisions would be undertaken and surgery was complete. 
Mastectomy was not recommended. The meeting recommended radiotherapy to the 
breast and chest wall only and not the axillary nodes, and chemotherapy was not 
recommended. A follow-up mammography was recommended in one year’s time. 
 
Six weeks post WLE the patient received postoperative radiotherapy to the left breast. 
One week later the patient developed renal calculi. The patient completed radiotherapy 
after three months with no adverse effects other than a mild skin reaction. The patient 
was reviewed in the BAC six months post WLE. Although there was still some breast 
sensitivity, clinically there were no signs of recurrence in the scar and the remaining 
breast tissue was normal. The patient was referred to be followed by the radiation 
oncology department with bilateral mammogram booked for six months’ time. 
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The patient was reviewed in Radiation Oncology ten months post WLE. The patient 
reported mild intermittent pain in the left breast but otherwise well. A clinical exam did 
not identify any masses in either breast and no axillary lymphadenopathy. There was 
some mild altered sensation in the left breast over the radiation therapy area and some 
mild discolouration. The mammogram report was not available for review but noted by 
the oncologist that no new suspicious microcalcifications were seen. Follow up 
appointment was made for six months’ time. 
 
The patient was again reviewed 16 months post WLE in Radiation Oncology with no 
change to the previous clinical findings. The patient was prescribed antibiotics for 
possible mastitis. No further mammogram data was available for this patient. A five 
year follow-up with the Radiation Oncologist and general practitioner confirmed no 
recurrence or new masses had been detected and the patient was clinically stable. 
 
  
 113 
Table 5.2: Age, clinical, mammography, pathology and PET findings 
Characteristics Patient 1 Patient 2 
Age 63.6 56.3 
Significant past history Benign breast lesion, site 
unspecified 
Nil 
Breast Lower outer quadrant of right Lower outer quadrant of left 
Surgery type WLE WLE 
Margin identification Inking Inking 
Histological type Comedo/solid, pseudoangiomatous 
change 
Comedo/solid, cribriform, 
with comedo necrosis 
present 
Grade/Focality High/ Unifocal Intermediate/ Unifocal 
Size mammography 25mm 30mm 
Size 
excised 
specimen 
Superior to 
inferior 
85mm 45mm 
Medial to 
lateral 
90mm 55mm 
Deep to 
superficial 
20mm 15mm 
Weight 121g 21g 
Microscopic dimensions of 
tumour 
15mm 35mm x 7mm x 5mm 
Volume ~3375mm3 1225mm3 
Invasive components No No 
Tubular score 3 4 
Nottingham category B A 
Margins 
– 
distance 
from 
DCIS to 
margin 
Superficial 6mm 6mm 
Medial >10mm >10mm 
Deep >10mm 1mm 
Lateral >10mm >10mm 
Inferior >10mm 1mm 
Superior >10mm >10mm 
Shaving Superior margin 75x50x15mm. 
Benign changes 
Not applicable 
TTB ratio FDG (± standard 
deviation) 
1.49 (±0.08) 1.47 (±0.12) 
TTB ratio FCH (± standard 
deviation) 
1.49 (±0.70) 1.20 (±0.07) 
DCIS, ductal carcinoma in situ; mm, millimetre; FCH, 18F-fluoromethylcholine; FDG, 18F-fluorodeoxyglucose; g, gram; TTB, 
tumour to background; WLE, wide local excision 
 
 
5.5 Discussion 
The poor sensitivity of FDG PET in detecting DCIS has been well reported in the 
literature. Avril and colleagues reported a 50% sensitivity and accuracy for detecting 
DCIS larger than 20mm (3/6 cases) and 0% in tumours under 20mm in size (0/6 cases), 
with an overall 25% sensitivity (41.7% when sensitive image reading was used).3 The 
same sensitivity was also reported by Heinisch, but the study only included two cases of 
DCIS.6 This low sensitivity is presumed to be due to the low spatial resolution of PET 
and because DCIS has a decreased glycolytic activity and vascularity.6 Tumour size, 
histological type and grade, hormone receptor status and other immunohistochemical 
factors can all impact on the uptake of FDG in breast cancer.1 This conclusion was 
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supported by a study that reported a statistically significant difference (p<0.05) in 
sensitivity of PET between invasive ductal carcinoma (IDC) and DCIS (98% versus 
60%), with higher uptake in IDC cases (p=0.07).7 However there was better uptake of 
FDG in ductal carcinoma than lobular or other histological types of breast cancer.1  
 
Abbey8 performed FDG PET imaging on mice with a similar cancerous growth to 
DCIS. They were able to follow the development of disease in one mouse over a 
considerable period of time using PET.  Although only a case study providing limited 
findings, it demonstrated that FDG PET was able to visualise the extent of DCIS and 
monitor its changes over time. 
 
While there have been a small number of studies examining FCH in prostate and 
hepatocellular carcinoma, any published accounts of the use of FCH PET in diagnosis 
of breast cancer in women could not be found, which is supported by Peñuelas and 
colleagues.1 There was a reported case of an incidental finding in a male during the 
examination of prostate cancer using FCH PET.9 Uptake was good and pathology 
confirmed invasive ductal breast cancer. FCH PET was reported in a female with a past 
history of invasive breast cancer who had undergone a mastectomy three years prior. 10 
The FCH PET was able to accurately identify metastatic disease with SUVs ranging 
from 5.0 to 9.5.  
 
In this study, the DCIS for both patients was detected by both FDG and FCH PET. Both 
patients had tumours greater than 10mm (patient 1=15mm, patient 2=35mm) thus 
overcoming one of the limitations reported for PET in DCIS. The nuclear grade was 
intermediate and high, respectively, for each patient, and histological type was 
comedo/solid, which has also been reported as having a better outcome for PET.1  
 
The TTB ratio for FDG PET was higher in both patients compared to the TTB ratio for 
FCH PET in both patients. This indicates that there was a better uptake of FDG by 
DCIS. A previous study reported the mean SUV in DCIS for a FDG PET is lower than 
in IDC, with a mean SUV of 3.1 (±2.1).11 A separate study reported a wider range of 
SUV in DCIS for a FDG PET, with a mean SUV of 2.3 (SD 7.2) in 5 cases.7 
 
FDG is the recommended radiopharmaceutical for DCIS imaging and hand-held PET 
technology given FDG PET performed better than FCH PET and is clinically available 
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more widely than FCH. A smaller FDG dose may be used when using hand-held PET 
technology directly on the disease area due to the high uptake of FDG by DCIS. 
 
The limitation of this study is the low recruitment of participants. In retrospect, using a 
matched case sampling method, requiring participants to only undergo one PET scan, 
not two, and recruiting from a number of hospitals, may have increased the sample size 
of the study. 
 
 
5.6 Conclusion 
Both FDG and FCH PET were able to identify newly diagnosed DCIS. The higher 
uptake and clinical availability of FDG makes this the preferred radiopharmaceutical for 
DCIS imaging and hand-held PET technology. Given the radiation implications of PET 
and limited availability in some rural and remote locations in Australia, mammography 
is still the recommended imaging modality for breast screening. Further research is 
required to evaluate the role of PET and in particular PET-CT and the hand-held PET 
probe technology, in DCIS staging and monitoring for DCIS larger than 10mm and high 
grade cases. 
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CHAPTER 6 POSITRON EMISSION TOMOGRAPHY PROBE LABORATORY 
TESTING AND PHANTOM STUDY 
 
6.1 Introduction 
An intraoperative margin assessment (IMA) method that was not identified by the 
Chapter 3 systematic review is the positron emission tomography (PET) probe. There 
has been little research examining the use of this technology in breast cancer. Existing 
studies have focused on either animal models or use of the probe in surgery for other 
cancers. Unlike gamma rays that can travel several centimetres into tissue, positrons 
only travel millimetres allowing a handheld dual PET probe to identify microscopic 
diseased tissue with greater accuracy during surgery following injection of 18F-
fluorodeoxyglucose (FDG).1,2 The PET probe works as a combined gamma and beta 
probe. The central scintillator detects both positron (beta) and gamma rays whilst the 
surrounding scintillator detects only gamma rays, allowing the unit to subtract one count 
from the other to generate only the positron count.1,2 The main limitation for PET 
probes is the uptake of FDG by the heart, liver, bladder and brain can potentially return 
a false positive result if the site of interest is less than 10mm from one of these organs. 
Whilst the heart is close to the breast tissue, unless the tumour is deep it should not 
return a false positive count rate. 
 
Raylman and colleagues3 examined the use of a PET probe in rats implanted with 
mammary tumours. They found uptake of FDG in this model to only present in the 
bladder, liver and brain. The study reported good uptake of FDG by mammary tumour 
tissue and recommended the use of a smaller probe when applied to smaller tumours. 
The probe was able to differentiate between normal and tumour tissue and results 
between the probe and pathology correlated well, with a good sensitivity (percentage 
not reported). The findings are supported by another animal study, using a mouse 
model.4 They found the PET probe was able to detect positron rays at a close range to 
the site of interest and concluded the PET probe may have a higher sensitivity compared 
to the gamma probe. Both studies recommended further research using the PET probe in 
breast surgery, including the timing from FDG injection and using the probe 
intraoperatively.  
 
The ability of the PET probe to detect small tumours was supported by Essner and 
colleagues, however their studies did not include breast cancer cases.1,5 Two other 
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studies applied the probe in breast surgery cases, but it was only applied to the lymph 
nodes.6,7 Molina and colleagues8 used the PET probe on three patients with a past 
history of breast cancer. All patients were intravenously injected with 370-444 
megabecquerel (MBq) (10-12mCi) of FDG 3-4 hours prior to the procedure. The probe 
was able to accurately identify the recurrent breast lesions in all three cases, but the 
study only used the probe for lesion localisation and not for margin assessment, with 
large doses of FDG injected.  
 
The only study to examine primary breast tumours was undertaken by Piert and 
colleagues.9 The study included one case of invasive ductal breast cancer. The patient 
was intravenously injected with 41.1MBq of FDG and the probe was used 105 minutes 
after injection. The site of interest was identified by the PET probe, however the probe 
was only used for tumour localisation and not for margin assessment. The tumour to 
background ratio was 5.6 and the standardised uptake value (SUV) mean was 2.8. The 
study concluded the performance of the probe could vary due to: the uptake and 
metabolism of the injected radiopharmaceutical; the technical performance of the probe; 
the time between injection and using the probe; and the size of the probe tip. They also 
concluded that the radiation burden to theatre staff is less than that associated with high-
energy gamma probes.  
 
A literature search did not identify any studies where the PET probe was used to assess 
surgical margins in breast cancer cases (in situ or invasive). The potential application of 
the PET probe in this context was considered important for future research in three other 
articles not mentioned above.10-12 Utilisation of a PET probe may allow more accurate 
delineation of normal from abnormal tissue and may accurately assess surgical margins, 
particularly in DCIS breast conserving therapy (BCT). Further research is required on 
the suitability of FDG for DCIS, timing between injection and using the probe and 
suitable injection quantities. 
 
A PET probe laboratory test was conducted to determine how the PET probe worked 
under various conditions. The methods used by Daghighian2, Piert9 and Yamamoto13 
was replicated for benchmarking. A phantom PET study was then conducted to test the 
probe against various FDG doses and SUVs. The objectives for this study were to (1) 
identify the sensitivity and linearity, specific activity, spatial resolution, source detector 
distance and depth response of the PET probe in a laboratory setting, and (2) determine 
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the ideal level of activity correlating the probe response with PET standardised uptake 
value (SUV). 
 
 
6.2 Abbreviations 
Below is a list of abbreviations and symbols used in this chapter: 
@ at 
& and 
BCT breast conserving therapy 
CPS counts per second 
F-18 fluorine-18 
FDG 18F-fluorodeoxyglucose 
FWHM full width at half maximum  
g grams 
I-131 iodine-131 
IMA intraoperative margin assessment 
IMI IntraMedical Imaging  
kBq kilobecquerel 
keV kiloelectronvolt 
LSO lutetium oxyorthosilicate  
MBq megabecquerel 
MeV megaelectron volt 
ml millilitres 
mm millimetre 
NA Not applicable 
PET positron emission tomography 
SUV standardised uptake value 
TTB tumour to background 
μl microliter 
μm micrometre 
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6.3 Methods 
 
6.3.1 Equipment 
The PET probe to be tested is the IntraMedical Imaging (IMI) (Los Angeles) 
NodeSeeker PET probe, designed to detect the positrons emitted by the decay of F18. 
Figure 6.1 shows the PET probe.  
 
Figure 6.1: Intramedical Imaging NodeSeeker PET probe 
 
Source: http://www.gammaprobe.com/products/betaprobe/ (13/04/2008) 
 
The probe consists of two detectors. The central detector is sensitive to positrons while 
remaining insensitive to the high energy gamma photons. This detector is a cerium-
doped lutetium oxyorthosilicate (LSO) plastic scintillator, with an 8mm diameter and 
7mm deep.15 A second peripheral detector surrounds the central detector, and acts as a 
reference detector. This peripheral detector is shielded from positrons by 1mm stainless 
steel, which stops most beta particles with energy below 1.5 MeV.2 Both detectors are 
scintillators connected to photomultiplier tubes by fibre optics. The control unit for the 
probe collects information from both detectors, and performs a weighted subtraction to 
obtain the positron count rate. The need for weighted subtraction is due to the differing 
efficiencies of the two detectors.2 The NodeSeeker Control Unit is shown in Figure 6.2. 
 
Figure 6.2: Laboratory testing setup for PET probe and control unit  
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A room dedicated to laboratory testing the PET probe and all equipment was provided 
by the Department of Medical Technology and Physics at Sir Charles Gairdner 
Hospital, Perth Western Australia. Figure 6.2 shows the PET probe within the surgical 
probe cover and control unit. 
 
6.3.2 Sensitivity and linearity 
The sensitivity and linearity test determines the sensitivity of the probe at set levels of 
FDG and if the probe counts per second (CPS) is linear to dose. To determine the 
sensitivity and linearity of the PET probe, the CPS were recorded over a 24 hour period.  
A 1 micro-litre drop of 459kBq (kilobecquerel) of FDG was placed on a piece of filter 
paper 5mm in diameter. CPS was taken 1mm and 10mm vertical distance from the 
source and with and without a 0.1mm thick latex probe cover. This test was performed 
twice with results averaged.  
 
6.3.3 Specific activity 
The specific activity test determines how the probe responds to sources with the same 
activity but different surface areas. This was achieved by placing a 1 micro-litre drop of 
242kBq of FDG on 10 pieces of filter paper ranging from 3mm to 30mm in diameter.  
The probe was positioned 3mm above each source. The CPS was obtained with the 
probe cover on and recorded three times per source, with results averaged. 
 
6.3.4 Spatial resolution 
Spatial resolution tests how the probe will respond as it moves laterally away from the 
source. The approximate spatial resolution of the PET probe was determined by 
positioning the probe 1mm above a piece of filter paper 5mm in diameter on which a 1 
micro-litre drop of 200kBq of FDG was placed. The source was then moved in 1mm 
steps to both sides of the probe for a maximum of 5mm in distance. The CPS was 
recorded with and without the probe cover and each test was performed three times, 
with results averaged. The full width at half maximum (FWHM) is calculated by 
determining the CPS when the probe is 1mm from the source and then moving away 
from the source until the CPS is half that at 1mm. Therefore the FWHM calculates the 
capacity of the probe at half of its maximum value. 
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6.3.5 Source detector distance 
The source-detector distance determines how the probe will respond as it moves 
horizontally away from the source. As this laboratory test is specifically for clinical 
information, all testing was performed with the probe cover on.  The probe was 
positioned 1mm above a piece of filter paper 5mm in diameter on which a 1 micro-litre 
drop of 185 kBq of FDG was placed. The probe was then moved in 1mm steps upwards 
from the source for a maximum of 10mm in distance and CPS recorded three times for 
each 1mm per test. The test was replicated three times and the results averaged to 
determine the FWHM. Figure 6.3 shows the probe setup for this test. 
 
Figure 6.3: Probe setup for source detector distance test 
 
 
6.3.6 Depth response 
Although the aim is to use this probe on surgical margins, how the probe responds to 
sources when there is a layer of tissue between the probe and the tumour site needed to 
be determined. The depth test identifies how far beneath a tissue margin a tumour can 
be for the probe to accurately detect it.  5mm discs of filter paper containing a 1 micro-
litre drop of 250kBq of FDG were placed into individual agar moulds from the surface 
(0mm) to 10mm in depth, varying by 0.5mm intervals.  This resulted in 21 different 
agar moulds. A 1mm polycarbonate sheet was laid over each mould. The CPS were 
taken with the probe cover on holding the probe 1mm above the surface of each mould, 
recorded three times per source and the results averaged to determine the FWHM.  
There was no background activity in the agar moulds. 
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6.3.7 Laboratory test comparison 
These laboratory tests have been undertaken by a number of different authors on the 
same and different PET probes. This study will compare the results of these 
experiments to the results from the studies reported by Daghighian2, Piert9 and 
Yamamoto13. The comparison of methods used is shown in Table 6.1. 
 
Table 6.1: Published laboratory test methods for PET probe 
Test Method 
This study (F-18 FDG) Daghighian2 (I-131 & 
F-18) 
Piert9 (F-18 FDG) Yamamoto13 (F18) 
Manufacturer Intramedical Imaging Intramedical Imaging Silicon Instruments Kobe City College of 
Technology 
Detector diameter 8mm 8mm 16mm 20mm 
Sensitivity and 
linearity 
 1μl drop 459kBq. 
 Filter paper 5mm in 
diameter. 
 1mm x 20mm 
aluminium covering 
source. 
 Probe 1mm & 10mm 
above. 
 24 hours. 
 With & without 
0.1mm thick latex 
probe cover. 
 Small drop. 
 Tissue paper 5mm 
in diameter fixed 
between 25μm 
thick tape. 
 Probe 0mm above. 
 Time not 
specified. 
 With 0.1mm thick 
latex probe cover. 
 1μl drop 409kBq. 
 Filter paper 5mm 
in diameter. 
 1mm x 20mm 
aluminium 
covering source. 
 Probe 1mm 
above. 
 26.3 hours. 
 With & without 
probe cover. 
Method not described 
Specific activity  1μl drop of 242kBq. 
 10 pieces filter paper 
ranging from 3mm 
to 30mm in 
diameter. 
 Probe 3mm above 
each. 
 With probe cover. 
Not performed Different method used 
based on weight  
Not performed 
Spatial resolution  1μl drop of 200kBq. 
 Filter paper 5mm in 
diameter. 
 Probe 1mm above. 
 Source moved 1mm 
steps to both sides to 
max. 5mm. 
 With & without 
probe cover. 
Not described  1μl drop of 
185kBq. 
 Source not 
specified. 
 Probe 1mm 
above. 
 Source moved 
1mm steps to both 
sides. 
 With & without 
probe cover. 
 1μl drop of 
100kBq. 
 Filter paper 1mm 
in diameter. 
 Probe 5mm, 10mm 
& 15mm above. 
 Source moved 
1mm steps to both 
sides. 
 Without probe 
cover. 
Source detector 
distance 
 1μl drop of 185 kBq. 
 Filter paper 5mm in 
diameter. 
 Probe 1mm above. 
 Probe moved 1mm 
steps upwards to 
max. 10mm. 
 With probe cover. 
Not performed Not performed Not performed 
Depth response  1μl drop of 250kBq. 
 21 x filter paper 
5mm in diameter. 
 Individual agar 
moulds (no 
background activity) 
from 0mm to 10mm 
in depth (by 0.5mm). 
 1mm polycarbonate 
sheet  
 Probe 1mm above. 
 With probe cover  
Not performed Not performed  Activity and 
dimension source 
not specified. 
 Plastic films 
different thickness 
inserted between 
source and probe 
 With & without 
0.2mm thick probe 
cover 
@, at; &, and; cps, counts per second; F-18, fluorine-18; F-18 FDG, 18F-fluorodeoxyglucose; FWHM, full width at half maximum; 
I-131, iodine-131; kBq, kilobecquerel; mm, millimetre; μl, microliter; μm, micrometre. 
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6.3.8 Level of activity 
This test was to determine whether the PET probe could detect a ‘tumour’ which could 
not be visualised by the PET scanner. Five moulds of agar to represent the background 
tissue were made consisting of 100ml of agar and 3ml of 640kBq of FDG set in a 250ml 
semi-spheric Pyrex bowl. The mould weighed approximately 86g when set. Separately, 
five moulds of agar to represent the tumour were made, consisting of 7ml of agar, 3ml 
of varying levels of FDG activity (see Table 6.1) and a drop of blue food colouring, set 
in a 12ml semi-spheric plastic container. Only 4g of this mould when set was used to 
represent the tumour. The smaller moulds were made first followed immediately by the 
larger moulds, to allow the smaller moulds to set first and be inserted into the larger 
mould before it set. The moulds were then let to set for 110 minutes to represent one 
half-life of FDG prior to PET imaging. 
 
After 110 minutes the moulds were transported to the Western Australia PET Service 
through the special elevator to transport radiopharmaceuticals (dumb waiter). Each 
mould was scanned individually on polystyrene trays and blueys to minimise possible 
contamination. The predicted activity at time of scanning is shown in Table 6.2. 
 
Table 6.2: FDG activity for moulds at time of dispensing and scanning 
Mould 
Number 
FDG activity at 
‘dispensing’ (kBq) 
FDG activity at 
scanning (kBq) 
Predicted 
TTB Ratio 
Background 640 320 NA 
1 1280 640 2:1 
2 2560 1280 4:1 
3 3840 1920 6:1 
4 5120 2560 8:1 
5 6400 3200 10:1 
 FDG, 18F-fluorodeoxyglucose; kBq, kilobecquerel; NA, not applicable;  TTB = tumour to background. 
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6.4 Results 
 
6.4.1 Sensitivity and linearity  
The PET probe performed well in sensitivity and linearity testing, with a 21% decrease 
in sensitivity with the probe cover on when measured 1mm from the source. The 
sensitivity of the PET probe for F-18 detection was measured as 250 CPS per kBq at a 
distance of 1mm from a point source without a cover, as shown in Figure 6.4.   
 
Figure 6.4: Sensitivity of PET probe 
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6.4.2 Specific activity  
The results were in accordance to theoretical calculations, indicating that high specific 
activity improves detection. This is demonstrated in Figure 6.5.  
 
Figure 6.5: Specific activity of PET probe 
 
 
6.4.3 Spatial resolution  
The FWHM was 6mm at 1mm distance from point source. At a 10mm distance from 
source the resolution decreased slightly to a FWHM of 8mm. This is shown in Figure 
6.6. 
 
Figure 6.6: Spatial resolution of PET probe 
 
 
 127 
6.4.4 Source detector distance  
It was found that the beta count fell approximately half the FWHM of its 1mm value, at 
about 4mm in distance.  This suggests how close the probe must be to the source in 
order to detect a lesion with a SUV of 2. This is shown in Figure 6.7. 
 
Figure 6.7: Source detector distance of PET probe 
 
6.4.5 Depth response  
Results show the beta count falls about half the FWHM of its 1mm value, at 
approximately 3mm in depth.  This indicates how deep under a margin a source can be 
for the probe to detect a lesion with an SUV of 2. The range of values is shown in 
Figure 6.8. 
 
Figure 6.8: Depth response of PET probe 
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6.4.6 Laboratory test comparison 
The PET probe performed well when compared to other PET probe tests undertaken by 
Daghighian2, Piert9 and Yamamoto13. Table 6.3 shows the comparison of results to 
these experiments. 
 
Table 6.3: Results published laboratory test methods for PET probe 
Test (at 1mm from 
source) 
Results 
This study (FDG) Daghighian2 (F-18) Piert9 (FDG) Yamamoto13 (F-18) 
Sensitivity and linearity 
(1mm without cover) 
250 cps/kBq 108 cps/kBq 250 cps/kBq 2.6 cps/kBq (@5mm) 
Specific activity 
(FWHM) 
5mm Not applicable Results reported 
tumour to background 
ratio 
Not applicable 
Spatial resolution 
(FWHM) 
6mm 10mm 5mm 11mm (@5mm) 
Source detector distance 
(FWHM) 
4mm Not applicable Not applicable Not applicable 
Depth response 
(FWHM) 
3mm Not applicable Not applicable Not reported 
@, at; cps, counts per second; F-18, fluorine-18; F-18 FDG, 18F-fluorodeoxyglucose; FWHM, full width at half maximum; kBq, 
kilobecquerel; mm, millimetre. 
 
6.4.7 Level of activity  
Figure 6.9 shows that the PET probe and PET scanner was able to detect each phantom 
tumour.  At 640kBq and a SUV of 2.2 the CPS were on average 5320, held for 30 
seconds. At 3200kBq and a SUV of 10.2 the CPS were on average 10850, held for 30 
seconds. The experiment was therefore unable to identify a level where the probe could 
detect the phantom tumour and the PET scan could not. From SUV calculations we 
might expect that the 640kBq tumour was at the limit of detection by the PET scan.  
The PET probe has plenty of dynamic range and further investigation is required to test 
this hypothesis. 
 
Figure 6.9: Levels of activity PET images 
 
 
             640kBq              3200kBq 
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6.5 Discussion 
PET imaging was first introduced in Australia in the 1990s. Since 2000 there has been 
interim approval to use FDG for 21 indications.15 With more than 15,000 publications 
demonstrating the use of PET and various radiopharmaceuticals, PET has become part 
of routine clinical management for a number of indications.16 However PET does have 
its limitations, such as false positives where there is the presence of inflammation or 
infection, uptake in normal tissue, such as the heart, liver, kidney and bladder, and poor 
sensitivity for tumours under 10mm in size. The development of a handheld device 
which can be used in surgery to localise tumours or nodes created a number of 
opportunities for radiopharmaceuticals in surgery. Isotopes such as technetium-99m or 
indium-111 have been used for a number of years for radioguidance and nodal 
assessment. However these probes are designed to detect low-energy particles and not 
high-energy photons. With such radiopharmaceuticals there may be waiting periods 
following injection before surgery can be performed and poor TTB ratios that can 
impact on sensitivity. 
 
The administration of FDG allows (requires) surgery to be performed the same day and 
produces high-energy photons which allow for a better TTB uptake. However the use of 
FDG requires the use of a probe designed to detect 511keV (kiloelectronvolt). To date 
several gamma probes have been developed to detect high-energy gammas, but few 
positron probes to detect beta rays. Such probes will allow not only tumour localisation 
and nodal assessment, but also allow tumour margin assessment to identify if there is 
residual disease remaining in the incision site.  
 
The PET probe tested performed well when compared against other reported 
experiments by Daghighian2, Piert9 and Yamamoto13. All four studies examined the 
sensitivity (with or without linearity) of the probe. Whilst the activity of the source was 
not described by Daghighian2 or Yamamoto13, the counts per second per kBq was 
notably smaller than that reported in this study and Piert9. Whilst this could imply the 
sensitivity of this probe is higher than Daghighian2 and Yamamoto13, the probe used in 
this study was manufactured by the same company as Daghighian2 and only the type 
and level of the activity and size of the source could explain the difference. This study 
and Piert9 noted a decrease in sensitivity with the probe cover, with a 21% decrease in 
reported in study and 33% in the Piert9 study. As noted by Piert9, gas sterilisation is not 
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possible and therefore an increased dose is required for intraoperative use to overcome 
this decrease in sensitivity.  
 
The spatial resolution FWHM reported by Yamamoto13 (11mm) is nearly twice of that 
reported by this study (6mm) and Piert9 (5mm). This means the probe designed by 
Yamamoto13 is able to detect a source from a larger lateral distance due to their wider 
detector diameter. Whilst this means the Yamamoto13 probe has a wider field for 
tumour or node localisation, multiple or small tumours/nodes and margin assessment 
may be difficult to localise. 
 
Piert9 recommended that future research should include a depth test that identifies the 
probes’ performance when there is ‘tissue’ of varying thickness between the probe and 
the tumour. This study found the FWHM was approximately 3mm when the probe was 
held 1mm above the tumour. This means the probe should be able to detect a lesion with 
a SUV of 2 up to 3mm beneath the margin, with CPS over 100. This is a significant 
finding when using the probe to assess surgical margins for residual disease. 
Yamamoto13 did not quantify their findings but reported a similar sharp decrease in 
counts with increased thickness. They also reported a 40 - 50% decrease in sensitivity 
with the addition of a probe cover.  
 
Piert9 developed a phantom using small amounts of gel with varying levels of density 
(15, 25, 75, 250 or 1,000mg). These were inserted into a plastic container filled with 
gel. The tumour to background ratio was 10. The probe then measured the counts per 
second for each ‘tumour’, advancing by 1mm up to 10mm from the source, and CPS for 
the background activity. They reported the counting ratio between the ‘tumour’ and 
background, reporting a decrease as the size of the ‘tumour’ reduced. The tumour to 
background ratio for the 1g ‘tumour was 1.4:1 and for the 250g tumour 1.3:1. While 
employing a different method, these results are similar to our specific activity test which 
found a sharp decrease to a FHWM of 5mm, but the CPS were still over 100 for the 
30mm ‘tumour’.  
 
Both this study and Piert9 examined how the PET probe performed against different 
levels of activity compared to a PET scan. Whilst the PET scan was able to detect all of 
our samples, we believe the smallest sample was the limit of detection for the PET scan, 
which returned 5320 CPS with the PET probe. Piert9 and Raylman17 suggested such a 
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limit does exist and small lesions not detected by a PET scan can be identified by an 
intraoperative PET probe.  
 
Essner1 compared the spatial resolution of the gamma probe against the PET probe in 
laboratory tests. They reported the gamma probe was most sensitive at a FWHM 1.7 but 
sensitivity to detect high-energy positrons was minimal. The PET probe, which was the 
same probe used in our laboratory tests, had a FWHM of less than 1cm but it was not 
affected by background radiation and was capable of detecting tumours as small as 
2mm. They concluded that 50 CPS as the minimum counts to positively differentiate 
between tumour and background, with only a 2:1 ratio required.  
 
These laboratory tests and phantom study enabled the investigator to determine that an 
injected dose of approximately 150MBq would be adequate to detect a source less than 
10mm in diameter with the PET probe, cover on. The radiopharmaceutical should be 
injected 30-45 minutes prior to use and can be used up to two hours after injection. 
Counts above 50 counts per second should be used as the minimum limit to determine a 
positive reading. 
 
 
6.6 Conclusion 
The NodeSeeker PET probe performed well in laboratory tests. This probe is able to 
accurately identify tumours smaller than 10mm in diameter with a good sensitivity and 
detect tumours beneath a small margin of tissue. These positive findings support the 
potential use of the PET probe for intraoperative margin assessment. The probe 
performed well when used with FDG but the administrative dose needs to be increased 
for larger sized tumours. The findings from these laboratory tests inform clinical use. A 
much smaller dose compared to clinical imaging doses should be applied to accurately 
localise tumours/nodes and assess margins. 
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CHAPTER 7 INTRAOPERATIVE POSITRON EMISSION TOMOGRAPHY 
(PET) PROBE FOR MARGIN ASSESSMENT OF DUCTAL CARCINOMA IN 
SITU 
 
7.1 Introduction 
Chapter 4 reported that the rate of re-excision in Western Australia to obtain adequate 
surgical margins for ductal carcinoma in situ (DCIS) is 18%. This equates to nearly 1 in 
5 women requiring a second operation for re-excision. This has implications on the 
patients’ quality of life with the required additional time for surgery and recovery, the 
potential additional personal cost and the increased risk of infection or an adverse event. 
It also impacts on the health service with additional theatre time, staffing, resources and 
costs. Even when adequate margins were obtained there is a 17% breast cancer event 
rate in this population. With approximately 96% of breast cancer events occurring at or 
near the original DCIS site. It could be postulated that not all of the DCIS had been 
removed.1, 2 
 
In Chapter 5 18F-fluorodeoxyglucose (FDG) was identified to be the most appropriate 
radiopharmaceutical to use with the positron emission tomography (PET) probe for 
DCIS surgery and Chapter 6 determined the protocol for use of the probe in surgery. 
The objectives for this study were to: (1) determine if the use of a PET probe can 
accurately assess the surgical margins intraoperatively in women undergoing breast 
conserving therapy (BCT) for DCIS; (2) determine if there is an association between 
PET probe findings and histological factors such as DCIS size, nuclear grade or 
necrosis; (3) compare the results of this study with those identified in the systematic 
literature review; and (4) determine the level of radiation exposure for the surgeon 
excising and handling the excised tissue. 
 
 
7.2 Abbreviations 
Below is a list of abbreviations used in this chapter: 
BCT breast conserving therapy 
CPS counts per second 
DCIS ductal carcinoma in situ 
ER oestrogen receptor 
FDG 18F-fluorodeoxyglucose 
 135 
FN false negative 
FP false positive 
FUP follow-up 
HER2 human epidermal growth factor receptor 2 
ID identification number 
MBq megabecquerel 
mm millimetre 
mSv millisievert 
NS not specified 
PET positron emission tomography 
PR progesterone receptor 
RAPID Radiopharmaceutical Production and Development Centre 
SD standard deviation 
SPSS Statistical Package for the Social Sciences 
 
 
7.3 Methods 
All patients with newly diagnosed DCIS and booked to undergo BCT at the Mount 
Hospital, Perth Western Australia, who met the inclusion criteria, were invited to 
participate in the study.  
 
7.3.1 Eligibility criteria 
The eligibility criteria for the study were: 
 
Inclusion Criteria 
1. Newly diagnosed DCIS, 
2. Planned to undergo wide local excision of DCIS, and 
3. Able to provide informed consent. 
 
Exclusion Criteria 
1. Planned mastectomy or neoadjuvant therapy for DCIS; 
2. Invasive component detected by biopsy; 
3. Previous history of invasive breast disease; 
4. Uncontrolled diabetes mellitus; 
5. Pregnant at the time of surgery. 
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7.3.2 Sample size 
The study was undertaken at a private hospital in Perth, Western Australia, which 
treated approximately 25 cases of DCIS per year by two surgeons. The study planned to 
recruit patients for three years and the sample size was calculated at a 50% recruitment 
rate. As a validation study, a sample size of 35 was determined sufficient to detect the 
accuracy of the probe in a small setting.  
 
7.3.3 Study procedure 
This study was approved by the Human Research Ethics Committees for Curtin 
University (Appendix B) and the Mount Hospital (Appendix F) and received approval 
from the Radiological Council of Western Australia (Appendix D). Two surgeons 
recruited patients for the study. Following identification of DCIS by mammography and 
diagnosis by biopsy, patients of each surgeon were invited to participate in the study. 
The surgeon provided the information sheet and consent form to the patient to take 
home and read. The surgeon would send to the study centre a form with the patient’s 
demographic details (Appendix G). Two business days after the patient’s appointment, 
the Investigator would contact the patient by telephone to enquire if she had read the 
information and if she had any questions. If the patient agreed to participate the 
Investigator would contact the RAPID (Radiopharmaceutical Production and 
Development Centre) team in the Department of Medical Technology and Physics at Sir 
Charles Gairdner Hospital, who provided the FDG, with information about the date and 
time of surgery and dose of FDG required. This same information was then sent to the 
nuclear medicine physician and the breast cancer nursing team at the Mount Hospital. 
 
The FDG was transported from Sir Charles Gairdner Hospital to the Nuclear Medicine 
Department at the Mount Hospital by specialist courier on the morning of surgery.  The 
Investigator would visit the patient in the morning to answer any other questions and to 
obtain her written consent (Appendix H). After all other pre-operative procedures have 
taken place, and approximately forty-five minutes prior to theatre, nuclear medicine 
physician would inject intravenously either 100 or 150 megabecquerels (MBq) of FDG, 
through a cannula placed in the arm contralateral to the breast undergoing surgery. The 
dose administered was alternated between each patient recruited (for example patient 
one received 100MBq, patient two received 150MBq and so on). A previous study by 
 137 
Piert3 indicated the lower dose was sufficient yet the laboratory tests and phantom study 
indicated a higher dose was required, hence the two dose levels were tested. 
 
Following the injection a nurse from the breast cancer team would place a notice on the 
patient’s room door to inform staff not to disturb the patient or enter the room unless 
necessary. The patient was then required to lie on her bed until it was time to transport 
to surgery, preferable in a dimly lit room. Approximately fifteen minutes prior to theatre 
an orderly would collect the patient, who was required to void before being transported 
on a gurney to theatre. The patient was then placed in the pre-operative room where the 
theatre nurse and the Investigator would ensure she had voided and answer any final 
questions. The patient would then be transported into theatre approximately 35-40 
minutes post-injection and the DCIS removed surgically approximately 45-50 minutes 
post-injection.  
 
Once the DCIS had been removed, the surgeon applied the PET probe with its cover on 
within the surgical cavity, slowly moving it across the surgical margins. The 
Investigator would monitor the control unit for the counts per second (CPS). If there 
was a count above zero, the Investigator would ask the surgeon to hold the probe in 
place to determine if the count could be replicated and held for 5 seconds. Any held 
CPS greater than 50 was classified as a positive result but all counts were documented. 
Although the control unit was electronically capturing and storing the data the 
Investigator also obtained the exact location (superior, inferior, medial, lateral and deep 
– superficial was not measured in the cavity) of the probe verbally from the surgeon and 
documented on a data collection form (Appendix I), the location, maximum and range 
of CPS captured. The control unit was turned away from the surgeon to blind them of 
the count rate and the audible tone was turned off. Once all the surfaces on the surgical 
cavity had been explored, the excised tissue was orientated and pinned to a Styrofoam 
tray for the Investigator to perform the same procedure on the excised tissue, including 
any shavings. The Investigator documented any findings on the data capture form, 
including CPS and margin (including superficial on the excised tissue and shavings). 
Lastly the Investigator applied the gamma probe over the excised tissue and 
documented the mean and range of the CPS. As this was a validation study no 
additional shavings were taken based on the probe result. However, if the surgeon took 
further shavings based on clinical findings, the PET probe was also applied to the 
shavings and they were recorded separately but analysed as ‘excised tissue’. 
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The excised sample was then taken to pathology. The pathologist documented the 
dimensions of the DCIS and reported other routine data (for example, grade, the 
margins, and necrosis). Clearance was determined as ≥10mm between the surgical 
margin and the tumour. 
 
All investigators met within four weeks after final surgery (taking second operations 
into account) to review the data.  No data sharing was arranged between the Investigator 
and the Mount Hospital prior to this meeting.  For each patient, data was presented in 
the following order: 
1. Surgeon specified mammogram and/or ultrasound findings 
2. Surgeon specified type of surgery, location of surgery and any problems during 
surgery. 
3. Pathologist specified dimensions of tumour, the margins and presence of any 
residual disease, specifically invasion. 
4. Investigator specified probe findings. 
5. Surgeon specified whether a second operation was needed and type of surgery 
and location of surgery if required. 
 
The Investigator then collected from the hospital and the surgeon’s medical records 
information regarding past medical history, diabetes status, adverse events following 
surgery, mammography, other imaging findings, other pathology information such as 
grade, hormonal and human epidermal growth factor 2 (HER2) status, and postoperative 
therapy (radiotherapy, chemotherapy and tamoxifen). These records were again 
reviewed 12 months following the initial surgical date, specifically mammography 
findings, for instances of breast cancer events (defined as recurrence or invasion more 
than four months following initial surgery). Where the patient had not returned to the 
surgeon the general practitioner was contacted for this information. 
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The patient recruitment and study procedures are summarised in Figure 7.1. 
 
Figure 7.1: Participant recruitment flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CPS, counts per second; FDG, 18F-fluorodeoxyglucose; PET, positron emission tomography 
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7.3.4 Radiation dose and dosimetry 
In this study, patients received a pre-surgical FDG injection.  The effective dose of 
radiation for an injected dose of 150MBq of FDG in women is approximately a 4.5 mSv 
maximum effective dose of radiation.  This equals to about eighteen months of natural 
background radiation. 
 
Piert and colleagues reported a radiation dosimetry burden on clinical staff during 
surgery following injection of 41.4 to 47.0MBq of FDG.3  Radiation exposure in 
surgeons was reported as 0.0025 to 0.0086 mSv/h (per hour), and exposure to the 
anaesthetist was 0.0008 mSv/h. In the phantom studies completed in Chapter 6, 
following a stimulated injection of 75MBq, the radiation exposure was 0.003mSv/h 
following a one hour uptake period.   
 
A number of monitoring and precautionary procedures were put in place during the 
study. The surgeon, the nuclear medicine physician and the Investigator wore a 
radiation monitoring badge.  Recordings were analysed monthly and procedures could 
be altered (or the study discontinued) for any abnormal readings, which did not occur.  
All staff handling the excised tissue or any other biological waste (including urine) was 
encouraged to wear two sets of gloves.  Protocols were developed for urine disposal, 
distance from patient and room location requirements and provided to all staff in contact 
with the patient.  All pregnant staff, other than the Investigator, was advised not to work 
closely with the patient until three hours after injection.  The Investigator was required 
to wear a surgical iron gown whilst pregnant and breastfeeding. 
 
7.3.5 Data classification 
Each margin has been classified as: 
 True positive: where the probe identified FDG avid tissue (the control unit 
detected an average CPS of ≥50) and histology reported less than 10mm 
between the margin and the DCIS. 
 False Positive: where the probe identified FDG avid tissue (the control unit 
detected an average CPS of ≥50) but histology reported at least 10mm between 
the margin and the DCIS.  These patients were required to undergo a 
mammography one year post-surgery to identify any recurrence at the suspected 
margin. If there was no future recurrence at the margin suspected, the margin 
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remained a false positive, but if recurrent disease or invasion was identified it 
became a true positive. 
 False Negative: where the probe did not identify any FDG avid tissue (the 
control unit detected an average CPS of <50) but histology reported less than 
10mm between the margin and the DCIS.  This was reassessed based on re-
excision histology results (where undertaken). If no residual disease was 
reported by pathology on re-excision, the margin was then classified as true 
negative. If residual disease was found on re-excision, the margin remained a 
false negative. 
 True Negative: Both the probe did not identify any FDG avid tissue (the control 
unit detected an average CPS of <50) and histology reported at least 10mm 
between the margin and the DCIS. 
 
7.3.6 Data collection 
As mentioned in section 7.3.3 a data collection sheet was developed to capture 
intraoperative information. Data were entered onto a database at Curtin University, both 
electronically from the control unit and manually from data collection sheets.  
Information entered included age, clinical history and family history for breast diseases, 
pathology data (histological grade, necrosis, focality and extent of disease, the margins, 
and presence of residual disease or invasion), surgical notes, imaging findings, 
management plan before surgery, re-excision data, any adverse events and CPS for the 
excised tissue and excision cavities.  Follow-up data were also entered onto the same 
database. 
 
7.3.7 Data analysis 
Accuracy statistics (including sensitivity and specificity) was calculated for the PET 
probe results compared to histology, with sub-analysis using injected FDG dose, 
histological grade and necrosis. T-test and multiple linear regressions were performed to 
detect the statistical differences when compared to pathological results.  Hypothesised 
risk factors such as nuclear grade, tumour size and necrosis were taken into account.  
Pearson’s correlations were used to assess the association between the probe findings 
and histological grade. All statistical analyses were performed using SPSS (Statistical 
Package for the Social Sciences) version 21. 
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7.4 Results 
Between December 2008 and January 2012, 44 patients were recruited to participate in 
the study. Five patients were removed from the study for the following reasons: a pre-
surgical review of the biopsy report showed invasion, the FDG dose was not delivered 
to the Mount Hospital in time for surgery, the fuse on the control unit blew during 
surgery, and on two occasions surgery was cancelled and rescheduled for a time when 
the Investigator was unable to attend.  
 
For the 39 patients included, a total of 49 procedures were performed; 39 wide local 
incisions and ten second operations (re-excision) (BCT or mastectomy). Only the 
margins during the first operation were examined, with 195 margins examined within 
the cavity and 234 margins examined on the excised tissue. The mean age of 
participants was 60.14 years (standard deviation [SD] ±6.37). There were 23 (59.0%) 
cases of high grade DCIS, and the mean tumour size was 16.14mm (±8.96). The mean 
follow-up time was 3.58 years (±0.85). There were eight (20.5%) cases of subsequent 
breast cancer events occurring between 0.44 to 2.83 years. Table 7.1 summarises the 
patient characteristics of the sample. 
 
There were 50/234 (21.37%) close or involved margins, defined as less than 10mm 
between the DCIS and the surgical margin. Table 7.2 summarises the number of 
margins close or involved by margin. 
 
The average dose injected was 110.65MBq (±38.76) of FDG. By the time the PET 
probe was applied in the surgical cavity, accounting for decay, the average dose was 
72.40MBq (±30.37), and applied on the excised tissue was 70.11MBq (±29.45). The 
average time between injection and the start of surgery was 1 hour and 11 minutes, with 
the average time to apply the probe in the surgical cavity 1 hour and 22 minutes and on 
the excised tissue 1 hour and 25 minutes. The additional surgical time to use the probe 
in the surgical cavity was on average 4 minutes and 5 seconds. Table 7.3 provides the 
summary information for dose and time since injection. 
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Table 7.1: Patient characteristics 
Age Range 47.30 – 68.96 years 
 Mean±SD 60.14 years±6.37 
Breast   
Left  22 (56.41%) 
Right  17 (43.59%) 
No. procedures   
WLE  39 
Re-excision  10 (25.64%) 
Positive re-excision 6 (60%) 
Histology   
Grade Low 3 (7.7%) 
 Intermediate 13 (33.3%) 
 High 23 (59.0%) 
Size (diameter) Range 4 – 40mm 
 Mean±SD 16.14mm±8.96 
Necrosis present  19 (48.72%) 
ER positive  12 (30.8%) 
PR positive  8 (20.5%) 
HER2 positive  4 (10.3%) 
Margins   
In cavity  195 
Excised  234 
Involved or close margins (pathology) 
Number 50/234 (21.37%) 
Range 0.1 – 8.8mm 
Mean±SD 3.40mm±2.18 
Positive margins by PET probe  
In cavity 47/195 (24.10%) 
Excised tissue 58/234 (24.79%) 
Gamma recordings Range 21 – 381 CPS 
 Mean±SD 117.69±83.23CPS 
Follow-up Range 1.43 - 4.51 years 
 Mean±SD 3.58 years±0.85 
Breast cancer events  
Number 10 (25.64%) 
Number BCE at site pathology>10mm, PET CPS>0 8 
Time to BCE Range 0.44 – 2.83 years 
 Mean±SD 1.37 years±0.82 
BCE, breast cancer event; CPS, counts per second; ER, oestrogen receptor; HER2, human epidermal growth factor 2; 
mm, millimetre; No., number; PET, positron emission tomography; PR, progesterone receptor; SD, standard deviation; 
WLE, wide local excision. 
 
Table 7.2: Summary of close or involved margin width by margin 
Measurements Superior Inferior Medial Lateral Superficial Deep 
Number 5 5 9 8 13 10 
Range (mm) 2.2 – 3.5 0.5 – 8.0 0.1 – 8.8 1.5 – 7.8 0.7 – 5.0 0.2 – 5.0 
Mean (mm) 
±SD 
3.02±0.49 3.70±2.82 3.43±3.18 5.07±2.39 2.62±1.60 3.08±1.53 
mm, millimetre; SD, standard deviation. 
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Table 7.3: Dose and time since injection summary 
 Range Mean±SD 
Injected dose (MBq) 41.4 – 158.8 110.65±38.76 
Dose at time of using PET probe in cavity (MBq) 26.6 – 117.5 72.40±30.37 
Dose at time of using PET probe on excised tissue (MBq) 26.3 – 113.8 70.11±29.45 
Dose at time of using gamma probe on excised tissue (MBq) 25.8 – 111.7 68.26±28.72 
Time between injection and start surgery (h:mm:ss) 0:20:00 – 2:30:00 1:11:09±0:04:45 
Time between injection and PET probe in cavity(h:mm:ss) 0:30:00 – 2:44:00 1:22:32±0:04:55 
Time between injection and probe on excised tissue (h:mm:ss) 0:35:00 – 2:46:00 1:25:56±0:04:49 
Additional surgical time (minutes) 2 – 7  4.05±1.26 
h:mm:ss, hour:minutes:seconds; MBq, megabecquerel; SD, standard deviation. 
 
There was a high negative association between CPS and margin width within the cavity 
(r=-0.785, p<0.001) and on the excised tissue (r=-0.778, p<0.001). When controlled for 
dose the association remained significant for in cavity (r=-0.781, p<0.001) and the 
excised tissue (r=-0.781, p<0.001). Table 7.4 shows the correlation between CPS and 
margin width when adding the conditions of dose at injection, grade, tumour size and 
necrosis, for both in cavity and the excised tissue. There was a significant negative 
association between CPS and margin width when the conditions were added. 
 
Table 7.4: Correlation between count per second and margin width, in cavity and 
excised tissue, with conditions 
Conditions In cavity * Excised tissue* 
Dose -0.781 -0.781  
Grade -0.786  -0.776  
Size -0.781  -0.779  
Necrosis -0.785  -0.776  
Dose + Grade -0.782  -0.779  
Dose + Size -0.778  -0.781  
Dose + Necrosis -0.779  -0.778  
Grade + Size -0.781  -0.777  
Grade + Necrosis -0.781  -0.776  
Size + Necrosis -0.779  -0.776  
Dose + Grade + Size -0.779  -0.780  
Dose + Grade + Necrosis -0.782  -0.778  
Dose + Size + Necrosis -0.775  -0.778  
Grade + Size + Necrosis -0.782  -0.776  
Dose + Grade + Size + Necrosis -0.778  -0.778  
* all values p≤0.001 
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Table 7.5 indicates that the accuracy of the PET probe in the cavity compared to a 
margin width less than 10mm was 89.7% (p<0.001) as opposed to 94.5% (p<0.001) on 
the excised tissue. As the literature has reported variable margin width, Table 7.5 
provides the accuracy, sensitivity and specificity for 1mm, 2mm, 5mm and 10mm 
margin widths. At the 10mm margin width any counts recorded on the control unit 
above zero had a good sensitivity and specificity, with in the cavity sensitivity 83.8% 
and specificity 89.9%, and on the excised tissue sensitivity 92.0% and specificity 
93.5%.  
 
Table 7.5: Accuracy statistics PET probe 
 Margin 
width ≤ 
(mm) 
n Summary statistics (%) 
Accuracy* 95% CI Sensitivity Specificity 
In cavity 
 
10 195 89.7 82.3 – 97.1 83.8 89.9 
5 195 89.4 81.3 – 97.5 85.7 86.2 
2 195 92.5 81.6 - 100 90.9 79.9 
1 195 98.2 95.6 – 100 100 77.9 
Excised tissue 
 
10 234 94.5 89.9 – 99.1 92.0 93.5 
5 234 92.0 86.3 – 97.7 90.2 89.1 
2 234 96.5 95.6 – 99.3 93.3 90.1 
1 234 97.2 82.9 – 100 97.5 87.4 
* all values p≤0.001 
%, percentage; CI, confidence interval; mm, millimetre; n, number. 
 
The accuracy of the PET probe on an individual margin basis demonstrated the best 
results in the lateral and deep margins (Tables 7.6 and 7.7), however with only 39 cases 
the conclusion is only tentative. 
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Table 7.6: Accuracy statistics by margin for in cavity 
Margin Accuracy (%)* 95% CI 
Superior 92.9 77.4 - 100 
Inferior 86.1 59.0 - 100 
Medial 86.3 67.2 - 100 
Lateral 100 100 - 100 
Deep 97.2 92.7 - 100 
* all values p≤0.001 
      %, percent; CI, confidence interval; n, number. 
 
Table 7.7: Accuracy statistics by margin for excised tissue 
Margin Accuracy (%)* 95% CI 
Superior 96.4 90.9 – 100 
Inferior 100 100 – 100 
Medial 93.5 81.1 – 100 
Lateral 100 100 – 100 
Superficial 93.3 83.0 – 100 
Deep 100 100 - 100 
* all values p≤0.001 
      %, percent; CI, confidence interval; n, number. 
 
The accuracy of the PET probe was not improved in cases with a positive oestrogen 
receptor (p=0.341), progesterone receptor (p=0.522) or HER2 (p=0.264) status. The 
time between injection and applying the probe on the excised tissue did not impact on 
the accuracy of the probe but the dose did (Table 7.8). Controlling for doses ≥80MBq 
increased accuracy by 2.5% to 97%. 
 
Table 7.8: Accuracy of PET probe on the excised tissue controlling for time since 
injection and injected dose. 
Variable Accuracy* 95% CI Sensitivity Specificity 
No control 94.5 89.9 – 99.1 92.0 93.5 
Time ≤150 minutes 94.5 89.9 – 99.1 92.0 93.5 
Dose ≥80MBq 97.0 93.7 – 100 97.4 90.6 
* all values p≤0.001 
CI, confidence interval; MBq, megabecquerels 
 
A multiple regression analysis found both CPS in the cavity (β=0.006, p<0.001) and the 
excised tissue (β=0.006, p<0.001) significantly correlated with the margin width when 
controlling for dose, grade, size and necrosis (Tables 7.9 and 7.10).  
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Table 7.9: Multiple linear regression in cavity results (margin width ≥10mm) 
Variable Coefficient (β) 95% CI p-value 
CPS 0.006 0.005 – 0.006 <0.001 
Dose -0.001 -0.002 – 0.000 0.285 
Grade 0.038 -0.033 – 0.109 0.295 
Size 0.002 -0.003 – 0.006 0.404 
Necrosis -0.043 -0.135 – 0.049 0.354 
CI, confidence interval; CPS, counts per second; mm, millimetre. 
 
Table 7.10: Multiple linear regression on the excised tissue results (margin width 
≥10mm) 
Variable Coefficient (β) 95% CI p-value 
CPS 0.006 0.005 – 0.007 <0.001 
Dose -0.001 -0.002 – 0.000 0.022 
Grade -0.010 -0.070 – 0.050 0.738 
Size 0.000 -0.004 – 0.004 0.956 
Necrosis -0.003 -0.081 – 0.076 0.946 
CI, confidence interval; CPS, counts per second; mm, millimetre. 
 
Multiple regression analyses were next performed for margin widths ≥1, 2, 5 and 10mm 
(Table 7.11). CPS in the cavity and the excised tissue for all widths significantly 
correlated with the margin width. Size also significant at ≥1mm in the cavity (p=0.001), 
dose significant at ≥10mm (p=0.022) and ≥5mm (p=0.022). Necrosis was significant at 
≥1mm (p=0.047) and grade significant at ≥2mm (p=0.057). 
 
Table 7.11: Multiple linear regression for varied margin widths 
 Margin 
width ≥ 
(mm) 
Variable p-value 
CPS Dose Grade Size Necrosis 
In cavity 
 
10 <0.001 0.285 0.295 0.404 0.354 
5 <0.001 0.197 0.768 0.315 0.414 
2 <0.001 0.348 0.103 0.301 0.322 
1 <0.001 0.116 0.811 0.001 0.560 
Excised tissue 
 
10 <0.001 0.022 0.738 0.956 0.946 
5 <0.001 0.022 0.738 0.956 0.946 
2 <0.001 0.096 0.057 0.751 0.624 
1 <0.001 0.122 0.943 0.082 0.047 
CPS, counts per second; mm, millimetre. 
 
An analysis of the thirteen cases classified as false positive or negative is presented in 
Table 7.12. In the case where there was a false negative the injected dose was only 
55.99MBq. In four cases where the in cavity results were false positive but the excised 
tissue result agreed with pathology, all occurred in the left breast and the injected dose 
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was 113-154MBq. The other eight cases were false positive but a breast cancer event subsequently occurred four months or longer following final 
surgery.    
 
Table 7.12: False positive and negative cases 
ID Age Breast Dose Grade Size(a) Necrosis ER PR HER2 FUP Status Comment 
1 54.77 Left 105.31 3 20 + - - - 2.93 Excised FP (superior) Recurrence 23/52 
2 47.30 Left 158.80 2 9 - + + NS 3.59 In cavity & excised FP (superior) Recurrence 67/52 
3 67.19 Left 153.57 2 15 - - - - 3.95 In cavity & excised FP (lateral) Recurrence 63/52 
4 53.12 Left 142.85 3 15 + - - - 3.85 In cavity & excised FP (superficial) Recurrence 147/52 
5 67.78 Right 147.19 2 40 - + + NS 3.60 In cavity & excised FP (superior) Recurrence 147/52 
6 48.62 Left 157.86 2 15 + - - - 3.04 In cavity & excised FP (superficial) Recurrence 42/52 
7 63.61 Left 143.51 3 14 - - - - 4.12 In cavity & excised FP (lateral) Recurrence 47/52 
8 66.62 Right 74.06 3 18 + - - + 4.11 Excised FP (inferior & medial) Invasion 203/52 
9 65.14 Left 125.00 3 14 + - - NS 4.51 In cavity FP Paget’s disease 
10 54.73 Left 113.00 3 11 + + - NS 4.31 In cavity FP No  subsequent BCE 
11 64.83 Left 154.77 3 14 + - - + 3.88 In cavity FP No  subsequent BCE 
12 56.21 Left 127.22 3 7.2 + - - - 4.28 In cavity FP No  subsequent BCE 
13 56.93 Right 55.99 2 4 - - - - 4.34 In cavity & excised FN Injected dose 
55.99MBq 
(a) in millimetres 
+, positive; -, negative; BCE, breast cancer event; ER, oestrogen receptor; FN, false negative; FP, false positive; FUP, follow-up; HER2, human epidermal growth factor 2; ID, identification number; MBq, megabecquerels; NS, 
not specified; PR, progesterone receptor. 
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The radiation dose to the surgeon was measured using a finger dosimeter worn in 29 of 
the cases, with the absorbed radiation dose ranging from 0.003 to 0.030 mSv and a 
mean 0.009mSv (±0.006). The average dose per hour was 0.021mSv/h and the average 
surgical time was 29 minutes. For cases with an injected dose ≥100MBq the average 
dose per hour was 0.025mSv/h. Based on 30 minutes per patient injected ≥100MBq and 
50 patients per year, the surgeon’s total absorbed radiation would be 0.625mSv, which 
is a fifth of the natural background radiation.  
 
 
7.5 Discussion 
Breast conserving therapy (BCT) is the preferred method of treatment for DCIS as it is a 
non-palpable, pre-invasive cancer, but the therapy is associated with a high risk of 
subsequent breast cancer events.4 The ability to accurately identify positive margins 
with a high level of sensitivity whilst aiming for the best cosmetic outcome in DCIS 
surgery is essential.5,6 Accurate intraoperative margin assessment can reduce the 
number of patients requiring a second operation.7 This is important because second 
operations impact on the patient, including additional recovery time, time off work and 
possible need for additional care, decreased quality of life and psychological impacts, 
potential adverse events from complications, worse cosmetic outcomes and a delay in 
commencing radiotherapy. They also affect the health care system, including additional 
staff, theatre and resource requirements and cost.8  
 
There is no universal standard margin measurement, with most surgeons aiming for 
between 2 to 10mm and second operation rates as high as 72%.1,5,9,10 The site of DCIS, 
or the tumour bed, is frequently the site of subsequent breast cancer events and therefore 
complete excision of DCIS is required to reduce the risk of recurrence or invasion.11 
This presents a dilemma, whereby the surgeon needs to ensure adequate margins are 
obtained whilst achieving the best cosmetic outcome and reducing the need for a second 
operation. 
 
Chapter 3 reported that pathological measures, such as frozen section, touch smear and 
imprint cytology, performed best among the intraoperative methods, but added 
considerable time to the length of the operation (often between 20-30 minutes). 
Ultrasound was the only other method identified through the systematic review of the 
literature with a good accuracy and short time duration to return results, yet it has 
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limitations where there is multifocal disease or calcifications. Whilst a number of other 
technologies (radiofrequency spectroscopy, optical coherence tomography, gamma 
camera/probe and mammography) were identified, their accuracy, sensitivity and 
specificity were much lower or the sample size was very small. 
 
The PET probe in this study demonstrated a high level of accuracy, particularly on the 
excised tissue with 94.5% accuracy when compared to a margin width less than 10mm 
and 96.5% accuracy when compared to a margin width less than 2mm. Sensitivity and 
specificity was also good. The average additional surgical time was 4 minutes and 5 
seconds. The probe did not perform differently with different hormonal receptor status, 
but there was a significant negative association between CPS and margin width when 
dose, tumour size and necrosis were controlled. Controlling for dose increased accuracy 
by 2.5% to 97%. 
 
Table 7.13 compares the accuracy of the PET probe against the accuracy of 
intraoperative margin assessment methods reported in Chapter 3. A number of these 
studies examined the use of the IMA method with invasive breast cancer, without 
specifying the results for DCIS alone. This may have improved the statistical results for 
the method due to the pathology of invasive breast cancer. The PET probe performed 
well, with a high level of accuracy found with pathological assessment without the long 
additional surgical time. Whilst the accuracy of the PET probe was 3.1% lower than 
ultrasound at a ≥2mm margin width, the additional surgical time was not reported for 
ultrasound making it difficult to draw a conclusion. The PET probe performed better in 
accuracy than other types of probe technology, namely radiofrequency spectroscopy and 
the gamma probe, both in the cavity and on the excised tissue.  
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Table 7.13: Comparison of accuracy of various intraoperative margin assessment 
methods 
IMA method Author Optimal 
margins 
(mm) 
In cavity 
or on 
excised 
tissue 
Accuracy 
(%) 
Average 
additional 
time 
PET probe Investigator ≥10 Excised 94.5 4 minutes 
≥5 92.0 
≥2 96.5 
≥1 97.2 
Ultrasound Ramos12 ≥2 Both 99.6 Not reported 
Frozen section Jorns7 ≥3 Excised 98.3 27 minutes 
Sabel8 ≥2 Excised 94.0 30 minutes 
Weber13 ≥1 Excised 83.8 Not reported 
Olson14 NR Excised 98.0 Not reported 
Radiofrequency spectroscopy 
probe 
Thill15 ≥5 Cavity 73.0 Not reported 
≥2 86.0 Not reported 
Imprint cytology Martin16 >0 Excised 77.8 22 minutes 
Creager17 >0 Excised 85.0 20 minutes 
Touch smear cytology Sumiyoshi18 >0 Excised 93.8 Not reported 
Optical coherence tomography Nguyen19 ≥2 Excised 90.0 Not reported 
Gamma camera & probe Paredes20 ≥5 Both 60 5 minutes 
Gross tissue inspection Cabioglu21 ≥2 Excised 87.4 Not reported 
IMA, intraoperative margin assessment; mm, millimetre; NR, not reported; PET, positron emission tomography. 
 
The sensitivity and specificity rates are equally important measures for evaluating an 
intraoperative margin assessment method. Table 7.14 compares the sensitivity and 
specificity of the PET probe against the other methods reported in Chapter 3. Any 
intraoperative margin assessment should be able to correctly identify a positive margin 
at a high level. Ultrasound, as reported by Doyle22, and optical coherence tomography, 
as reported by Nguyen19, appeared to possess a higher sensitivity than the PET probe. 
With a similar small sample size to this study, the OCT specificity was lower than the 
PET probe. Although ultrasound was 100% sensitive in Doyle’s study, other studies 
reported sensitivity as low as 25%. 
 
Specificity is equally important to enable surgeons to achieve full resection whilst 
aiming for the best cosmetic outcome for the patient, as recommended by the National 
Breast Cancer Centre.5 It is therefore important to identify negative tissue so additional 
shavings are not unnecessarily taken. Pathological measure, frozen section and imprint 
cytology, reported a higher specificity than the PET probe, however the additional time 
in surgery for their application was much higher than the PET probe. Whilst one study 
for ultrasound only reported 25% sensitivity, the specificity was 95%.  
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Table 7.14: Comparison of sensitivity and specificity of various intraoperative 
margin assessment methods. 
IMA method Author Optimal 
margins 
(mm) 
In cavity 
or on 
excised 
tissue 
Sensitivity 
(%) 
Specificity 
(%) 
Average 
additional 
time 
PET probe This study ≥10 Excised 92.0 93.5 4 minutes 
≥5 90.2 89.1 
≥2 93.3 90.1 
≥1 97.5 87.4 
Ultrasound Ramos12 ≥2 Both 80 86.6 NR 
Olsha23 ≥2 Excised 25 95 
Doyle22 NR Both 100 74 
Frozen section Jorns7 ≥3 Excised 91.1 100 27 minutes 
Weber13 ≥1 Excised 80 87.5 NR 
Olson14 NR Excised 73.1 99.6 NR 
Imprint cytology Martin16 >0 Excised 71.4 100 22 minutes 
Creager17 >0 Excised 80 85 20 minutes 
Touch smear 
cytology 
Sumiyoshi18 >0 Excised 70 97.1 NR 
Optical coherence 
tomography 
Nguyen19 ≥2 Excised 100 82 NR 
Gross tissue 
inspection 
Cabioglu21 ≥2 Excised 91.7 77.8 NR 
Microscopic 
margin 
assessment 
Fleming24 ≥5 Excised 73 88 NR 
Radiofrequency 
spectroscopy 
probe 
Karni25 ≥1 Excised 71 68 7 minutes 
Digital specimen 
mammography 
Kaufman26 NR Excised 36 71 NR 
Standard 
specimen 
mammography 
Kaufman26 NR Excised 31 74 NR 
McCormick27 NR Excised 54.6 87.8 15 
IMA, intraoperative margin assessment; mm, millimetre; NR, not reported; PET, positron emission tomography. 
 
Overall, the PET probe performed better in sensitivity and specificity than all of the 
other methods assessed in Chapter 3 except frozen section where PET has a higher 
sensitivity but frozen section was reported to have a higher specificity and accuracy. 
 
The PET probe performed better when the dose was ≥80MBq. The data showed no 
statistically significant improvement in accuracy when the time between injection and 
using the probe intraoperatively was shorter. But accuracy, sensitivity and specificity 
were improved when the probe was used on the excised tissue as opposed to in the 
cavity. This may have been due to the time available to slowly examine the excised 
tissue whilst the surgeon continued with the surgery, however the in cavity results 
shows the method still has a high level of accuracy, sensitivity and specificity. It 
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appears that when time is a factor to act upon results from the probe on the excised 
tissue, accuracy would not be greatly compromised. 
 
Piert3 reported a lower radiation exposure burden than this study, however they used a 
smaller injected dose. In this study, for cases with an injected dose ≥100MBq, the 
average dose was 0.025mSv/h compared to Piert’s 0.0025 to 0.0086 mSv/h where 41.4 
to 47.0MBq of FDG was injected. 
 
A major limitation of this study is the small sample size and results from the probe were 
not acted upon, not allowing the impact on second operation rates to be calculated. It is 
recommended that a large, multi-centre study be undertaken using the PET probe in 
DCIS surgery, where results are acted upon in the study. The injected dose for patients 
should be ≥80MBq, the probe be used both in the cavity and the excised tissue (but only 
the excised tissue where time is a factor) and it is recommended surgery be performed 
within 2 hours of injection. The probe should also be tested on a range of breast 
carcinomas. It is also recommended an economic feasibility study be undertaken to 
determine the cost-benefits of the PET probe. 
 
 
7.6 Conclusion 
In order to achieve adequate margins during breast conserving therapy for DCIS, an 
intraoperative margin assessment method that can be utilised during surgery to return 
immediate results with a high accuracy and sensitivity whilst not significantly extending 
the time of surgery is ideal. The literature has demonstrated that pathological methods, 
such as frozen section or imprint or touch smear cytology, have a high level of 
accuracy, sensitivity and specificity, yet they can add an additional 20 to 30 minutes to 
the surgical time. Ultrasound has demonstrated in some studies to perform well, whilst 
not incurring too much time to the operation, yet other studies have shown a poor 
sensitivity for ultrasound and it has limitations where multifocal disease or 
calcifications are present. 
 
This is the first reported study using a PET probe in DCIS breast conserving therapy. 
The study findings from 234 surgical margins indicate 94.5% accuracy at ≥10mm and 
97.2% accuracy at ≥1mm when used on the excised tissue. The sensitivity and 
specificity of the probe on the excised tissue was also high, being 92.0% and 93.5% at a 
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margin width of ≥10mm and 97.5% and 87.4% at ≥1mm, respectively. Ideally the probe 
should be used within two hours of an injected dose of ≥80MBq and can be used in the 
cavity or on the excised tissue, but is easier to apply to the excised tissue. It is 
recommended that this technology be tested in a large multi-centre study to obtain a 
larger sample size and further test the probe’s capacities. 
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CHAPTER 8 CONCLUSION AND RECOMMENDATIONS 
 
8.1 Conclusion 
Ductal carcinoma in situ (DCIS) is a heterogeneous disease characterised as a 
proliferation of neoplastic cells confined to the mammary duct system of the breast.1 
Research has shown when left untreated, approximately a third of low grade, 
noncomedo DCIS cases will within 15 years develop into invasive breast cancer.2 Given 
these findings the risk of progression for high grade DCIS is much higher. A study 
identified that 96% of recurrences following complete resection of DCIS were at or near 
the initial surgical site, and concluded that there was inadequate resection of the primary 
DCIS.3 Inadequate margin width can result in a patient requiring a second operation. 
This rate can vary from 5-72%, with most studies reporting a 20-25% second operation 
rate.4 Therefore, the review of DCIS in Chapter 2 concluded that accurately assessing 
margins intraoperative would reduce the number of second operations required to obtain 
adequate margins and potentially reduce the subsequent breast cancer event rate. 
 
Intraoperative pathological methods have a high level of accuracy in assessing the 
surgical margin in breast cancer. However, these methods significantly increase 
operation time, reported between 20-30 minutes on average. In addition, touch smear 
and imprint cytology methods only assess the direct surgical margin and do not identify 
where there may be residual disease deeper than the surface. Ultrasound is often used to 
guide surgery but the literature showed a high accuracy when used to assess the surgical 
margins. The advantages of ultrasound is its utilisation in the operating theatre and that 
it produces results immediately, allowing the decision to take further shavings with 
minimal impact on operating times. Ultrasound does not generally perform well where 
there are calcifications or multifocal disease, thus limiting its applicability in DCIS 
surgery, and a low sensitivity has been reported in the literature.5 Radiofrequency (RF) 
spectroscopy reports a statistically significant level of concordance with the standard 
assessment (pathology) but half of the studies examined used small sample sizes making 
it difficult to generalise results. Mammography technologies and optical coherence 
tomography (OCT) have shown promising results, but further research in both of these 
technologies is required. A review of the literature in Chapter 3 concluded 
intraoperative pathological methods, including frozen section or imprint/touch smear 
cytology, and ultrasound currently offer the best means for accurately assessing the 
surgical margins in DCIS surgery but they have significant limitations.  
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Chapter 4 reported the epidemiology of DCIS in Western Australia (WA). Between 
1996 to 2005 there was 1356 cases of newly diagnosed DCIS in WA, with an age-
standardised incidence rate (ASR) of 15.4 cases per 100,000 females in 2005. There 
was 18.07% of cases that required a second operation and 17.3% of cases reporting a 
subsequent breast cancer event (recurrence or invasion) by the 31 December 2010. An 
8-fold increased risk for women under 40 years, relative to those over 40 years, to have 
a subsequent BCE was determined. And there was a 5-fold increased risk where the 
DCIS was grade 3, relative to grade 1-2 DCIS. There was an increased risk of a 
subsequent BCE (p<0.001), and specifically invasion (p<0.001), where a second 
operation was not performed. Given the second operation rate reported in WA is lower 
than that reported in the literature, and the significant rate of subsequent BCEs, Chapter 
4 concludes that under the WA protocol, sufficient margins may not be taken during the 
primary surgery and residual DCIS is remaining in the breast. 
 
Based on the background review of existing technology and the WA epidemiology, 
there clearly is the need for an intraoperative method that can accurately assess the 
margins during surgery for DCIS, returning results immediately and therefore 
decreasing the need for a second operation and potentially reducing subsequent breast 
cancer event rates. Therefore, a validation study was conducted to (1) identify a suitable 
radiopharmaceutical tracer for DCIS, and (2) determine the accuracy of a positron 
emission tomography (PET) probe to evaluate the margin status during BCT for DCIS. 
 
In Chapter 5 two case studies using PET to diagnose DCIS were performed to determine 
the appropriate radiopharmaceutical to use with the PET probe in DCIS surgery. In both 
patients the 18F-fluorodeoxyglucose (FDG) reported a better tumour to background ratio 
over 18F-fluoromethylcholine (FCH) and therefore appeared to be the preferred 
radiopharmaceutical to use with the PET probe. In addition FDG is clinically available 
more widely than FCH.  
 
Laboratory testing of the PET probe in Chapter 6 concluded that it was able to 
accurately identify tumours smaller than 10mm in diameter with a good sensitivity and 
detect tumours beneath a small margin of tissue. The experiments assisted in 
establishing the performance of the probe. The recommended dose for surgery (100-
150MBq), uptake time (~45 minutes with a 120 minutes post injection window) and 
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count limits (>50 counts per second) were determined through these experiments, which 
had not previously been reported in the literature.  
 
The PET probe was used in surgery for 39 patients with primary DCIS. The study 
findings reported in Chapter 7 from the examination of 234 surgical margins showed an 
accuracy of 94.5% at a ≥10mm clearance of margins and 97.2% accuracy at a ≥1mm 
clearance of margins when used on the excised tissue. The sensitivity and specificity of 
the probe on the excised tissue was also excellent, 92.0% and 93.5% respectively at a 
clearance margin width of ≥10mm and 97.5% and 87.4% at ≥1mm, respectively. The 
PET probe performed better in accuracy than other types of probe technology, namely 
RF spectroscopy, OCT and the gamma probe, both in the cavity and on the excised 
tissue. Intraoperative pathological methods and ultrasound reported a higher accuracy, 
but have a number of limitations which was not the case for the PET probe. Overall, the 
PET probe performed better in sensitivity and specificity than all other IMA methods, 
except frozen section where PET has a higher sensitivity and returned results 
immediately whereas frozen section reported a higher specificity and accuracy but took 
approximately 20 – 30 minutes to return a result. 
 
Overall, the PET probe performed better when the dose was 80MBq or higher and when 
the time between injection and using the probe was under one hour. Although the probe 
performed better on the excised tissue, the in cavity results shows the method still has a 
high level of accuracy, sensitivity and specificity.  
 
In conclusion the PET probe has a high level of accuracy in determining the margin 
status in DCIS surgery when FDG is injected. Application of the probe added an 
average four minutes to surgical time and returned results immediately through the 
control unit. As results were not acted upon, it is difficult to state with certainty the 
impact this method would have on second operation rates and potentially on subsequent 
breast cancer events. However, if action were taken, the number of second operations 
and subsequent breast cancer events could be greatly reduced in the future. Therefore 
this method has the potential to alter breast conserving surgery for DCIS. 
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8.2 Recommendations 
Subsequent to this research, the following recommendations are made: 
 
1. Undertake a 10 year follow-up for the 39 patients from this study to determine 
the subsequent BCE rate for comparison against the PET probe result, especially 
in false positive cases. This will allow identification of cases where there is a 
subsequent BCE and examine if there is an association to the PET probe results. 
 
2. Conduct further research with a larger sample size and acting on PET probe 
result in surgery to determine true effect on second operation rates and 
subsequent breast cancer event rates. It is recommended a multicentre study be 
conducted to achieve a larger sample size, with a longer recruitment period, to 
obtain a minimum sample size of 200 patients. Comparisons can be then made to 
evaluate variation in results with different operators. 
 
3. Conduct a randomised control trial against intraoperative frozen section, with 
subjects matched by age, cell type and grade as determined by biopsy. As OCT 
is currently being trialled in Western Australia,6 there is also the potential to trial 
this technology with the PET probe. This will allow a comparison of properties 
such as accuracy, sensitivity and specificity, additional surgical time, second 
operation rate and BCE rates between methods. 
 
4. With recommendations two and three above, include other in situ and invasive 
breast cases to determine the accuracy of the PET probe across breast cancer 
surgical cases. This would potentially widen the application of this technology. 
 
5. Perform an economic evaluation of the above recommendations to identify the 
cost-benefit of using PET probe technology in breast surgery. This would 
provide greater information as to the suitability of this technology in routine 
clinical use. 
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(f) Indicate number of participants with missing data for each variable of interest 
(g) Cohort study—Summarise follow-up time (eg, average and total amount) 
Cohort study—Report numbers of outcome events or summary measures over time 
Case-control study—Report numbers in each exposure category, or summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary measures 
(h) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted 
for and why they were included 
7 
Discussion (a) Summarise key results with reference to study objectives 
(b) Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias 
(c) Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence 
(d) Discuss the generalisability (external validity) of the study results 
3 
Funding Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based 1 
 Overall score 20 
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APPENDIX B: HUMAN RESEARCH ETHICS COMMITTEE CURTIN 
UNIVERSITY LETTER OF APPROVAL 
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APPENDIX C: HUMAN RESEARCH ETHICS COMMITTEE ROYAL PERTH 
HOSPITAL LETTER OF APPROVAL 
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APPENDIX D: RADIOLOGICAL COUNCIL OF WESTERN AUSTRALIA 
LETTER OF APPROVAL 
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APPENDIX E: ROYAL PERTH HOSPITAL PATIENT INFORMATION SHEET 
AND INFORMED CONSENT (CHAPTER 5) 
 
 
THIS PATIENT IS ELIGIBLE FOR THE DCIS & PET 
(PART A) TRIAL. 
 
TRIAL INVESTIGATORS: 
BREAST ASSESSMENT CENTRE: 
   Dr Christobel Saunders 
   Dr Lee Jackson 
   Dr Peter Willsher 
PET SERVICE: 
   Dr Nat Lenzo 
RESEARCH OFFICER: 
   Kerryn Butler-Henderson (043 899 3067) 
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Royal  Perth Hospi tal  
 
PATIENT INFORMATION SHEET 
Version 1 
DATE 1st February 2005 
 
Positron Emission Tomography (PET) and Beta Probe in the Staging of Ductal 
Carcinoma In Situ of the Breast (Part A). 
 
Principal Investigator: Dr Nat Lenzo 
 
Introduction 
You are being invited to take part in a research study for patients who are being 
investigated for ductal carcinoma in situ (DCIS) of the breast.  In order for you to 
decide whether you should agree to be part of this study, you should understand enough 
about its risks and benefits to make an informed decision. This process is known as 
informed consent. 
 
DCIS is an increase of abnormal cells within the mammary ducts of the breast.  Normal 
breasts contain lobules where the milk is produced, and tubes called ducts that take the 
milk from the lobules to the nipple.  DCIS are said to be “pre-cancerous” and develops 
inside the lobules and may spread along the ducts.  We have been informed that your 
biopsy results indicate DCIS and you are planned to have surgery to remove and test the 
tissue. 
 
Both research and clinical experience indicates that approximately 20% of patients will 
need to have a second operation (re-excision) when some of the DCIS remains in the 
breast after the first operation.  We wish to see how well positron emission tomography 
(PET) imaging could stage your DCIS before surgery.  There have been a small number 
of animal and human studies that show PET is very good at providing the important 
information to your surgeon as to where exactly your DCIS is located. 
 
We would like you to have two PET studies before you have surgery.  The reason for 
the two studies is because we wish to know which of two different PET isotopes, 
fluorodeoxyglucose (FDG) and fluorocholine (FCH) is better at staging your DCIS.  
This information is important because should one isotope be better at staging your DCIS 
then the other, and it provided more information than your mammogram or ultrasound, 
then this could reduce the number of times a patient needs to have a second operation.  
Participating in this trial will not delay your surgery. 
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What will happen in this study? 
As part of this trial you will be asked to undergo a number of standard assessments.  
These include: 
- Mammogram (which you have already had), 
- Biopsy (which you have already had), 
- Ultrasound (which you may or may not already had). 
 
You will then be required to undergo an FDG-PET scan.  A PET scan is similar to a CT 
scan.  For the FDG PET scan, you will need to fast for 6 hours before your appointment 
time.  You will then receive an injection of the FDG in your arm.  After the injection 
you will rest for about an hour. You may be given a small amount of muscle relaxant 
prior to the FDG-PET scan. The muscle relaxant may impair your ability to drive and 
you should arrange to have someone come with you who can take you home. The scan 
itself takes about 45 minutes, during which time you will be lying comfortably under 
the camera. 
 
In the following days, you will undergo a FCH PET scan.  You do not need to fast for a 
FCH PET scan.  Again, you will be given a small injection in your arm, but this time 
you will be scanned immediately.  This scan will be for one hour, with no rest period 
before being imaged.  Your PET results will not be shared with your surgeon until after 
your surgery.  This is because the accuracy of PET to stage DCIS has yet to be validated 
and to provide this information to your surgeon to make a decision on would be 
irresponsible. 
 
Alternatives 
If you decide not to take part in this study, you will still receive the standard 
assessments. 
 
Possible Risks 
You will need to fast for 6 hours before having the FDG-PET scan. If you have 
unstable diabetes or are unable to fast for other reasons you should not enter this 
study. 
 
Complications related to insertion of the intravenous catheter (IV line) used to give the 
PET tracer can occasionally occur. These mainly involve slight bruising but very 
infrequently, infections can occur. You will be given appropriate treatment at the 
Hospital if a reaction or complication occurs. 
 
The study will involve the use of approximately 300MBq of FDG or 200 MBq of FCH, 
which gives an estimated dose of 13mSv effective dose of radiation. The amount of 
extra radiation exposure from the PET scan is equal to about six and a half years of 
natural background radiation. This has a probability for the induction of fatal cancer of 
one in 1500. The risk of this occurring is about one half of the risk of being killed on 
WA roads in the next 10 years.  Other than the radiation exposure there are no 
documented side effects associated with the administration of the PET isotope. 
 
Women who are pregnant or breast-feeding and women who may become pregnant, but 
who are not taking adequate contraceptive measures, must not participate in this trial.  
Participants are strongly advised to use effective contraception if appropriate during the 
course of the study. You should discuss methods of effective contraception with your 
doctor. 
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There may be additional risks that are unforeseeable at this time. You will be informed 
of any new and significant information that could affect your willingness to continue 
participation. In the case of an unforeseen side effect, prompt treatment will be initiated. 
 
Possible Benefits 
As your results will not be discussed with your surgeon until after your operation, you 
may not receive any benefits from participating in this trial.  Because PET is an imaging 
tool that is used to diagnose a number of different cancers, you should be aware that 
there might be an incidental finding when you have your PET scan, which may have 
otherwise gone undetected.  There is also the possibility that PET may detect invasion 
into the breast tissue, which would indicate breast cancer.  Should either of these 
circumstances arise, you will be withdrawn from the trial and the PET findings will be 
released immediately to your surgeon. 
 
The knowledge gained from patients participating in the study will assist us in 
determining the role of PET scans in the staging of DCIS.  Should this technique be 
validated, then in the future the information will be shared with the surgeon, who can 
use it when planning your surgery.  This has the potential of reducing the re-excision 
rate in women in the future who have a PET scan before surgery for DCIS. 
 
Confidentiality and Disclosure of Information 
Any information obtained in connection with this project that can identify you, 
including information from medical practitioners, other health professionals, hospitals, 
diagnostic imaging services or laboratories outside this hospital, will remain 
confidential.  It will only be disclosed with your permission, except as required by law.   
 
It is anticipated that results will be published in a relevant medical journal.  In any 
publication, information will be provided in such a way that you cannot be identified. 
 
All data collected will be kept in a safe and secure location.  All hardcopy data will be 
kept in a locked cabinet in the WA PET/Cyclotron Service and electronic data will be 
password protected.  Only authorised staff will have access to your information.  All 
data will be kept for the minimum 15 years retention period. 
 
Participation is Voluntary 
Participation in any research project is voluntary.  If you do not wish to take part you 
are not obliged to.  If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage.  
 
Your decision whether to take part or not to take part, or to take part and then withdraw, 
will not affect your routine treatment, your relationship with those treating you or your 
relationship with the WA PET/Cyclotron Service. 
 
Before you make your decision, a member of the research team will be available so that 
you can ask any questions you have about the research project.  You can ask for any 
information you want.  Sign the Consent Form only after you have had a chance to ask 
your questions and have received satisfactory answers. 
 
If you decide to withdraw from this project, please notify a member of the research team 
before you withdraw.   
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In the event that you suffer an adverse event or a medical accident during this study that 
arises from your participation in the study, Royal Perth Hospital will offer you all full 
and necessary treatment.   
 
New Information Arising During the Project 
During the research project, new information about the risks and benefits of the project 
may become known to the researchers.  If this occurs, you will be told about this new 
information.  This new information may mean that you can no longer participate in this 
research.  If this occurs, the person/s supervising the research will stop your 
participation.  In all cases, you will be offered all available care to suit your needs and 
medical condition. 
 
Further Information or Any Problems 
If you require further information or if you have any problems concerning this project 
(for example, any side effects), you can contact: 
 
Principal Investigator     Dr Nat Lenzo (PET Service)  Phone: 9346 2656 
Co-Investigator              Dr Lee Jackson (Breast Surgeon)  Phone: 9224 2294 
Research Coordinator    Kerryn Butler-Henderson (PET Service) Phone: 9346 7483 
 
If you want to discuss the study with someone who is not directly involved in it 
(about the information you have received, the conduct of the study, your rights as 
a participant, or a complaint you have), please contact Associated Professor A 
Millar, Chairman of the Royal Perth Hospital Ethics Committee (9224 2292). 
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CONSENT FORM 
Positron Emission Tomography (PET) and Beta Probe in the Staging of Ductal 
Carcinoma In Situ of the Breast (Part A). 
 
Principal Investigator:  Dr Nat Lenzo 
 
Subject Name:____________________________   Date of Birth: _______________ 
 
1. I have been given clear information (verbal and written) about this study and have 
been given time to consider whether I want to take part. 
2. I have been told about the possible advantages and risks of taking part in the study 
and I understand what I am being asked to do. 
3. I have been able to have a member of my family or a friend with me while I was 
told about the study.  I have been able to ask questions and all questions have been 
answered satisfactorily. 
4. I know that I do not have to take part in the study and that I can withdraw at any 
time during the study without affecting my future medical care.  My participation in 
the study does not affect any right to compensation, which I may have under statute 
or common law. 
5. I hereby give permission for medical practitioners, other health professionals, 
hospitals, diagnostic imaging services or laboratories outside this hospital to release 
information concerning my disease and treatment that is needed for this study to the 
WA PET/Cyclotron Service and I understand that such information will remain 
confidential. 
6. I agree to take part in this research study and for the data obtained to be published 
provided my name or other identifying information is not used. 
7. I do not wish to participate in the substudy (delete should you consent to participate 
in the substudy). 
 
If you are unclear about anything you have read in the Patient Information Sheet 
or this Consent Form, please speak to your doctor before signing. 
 
 
Name of Patient   Signature of Patient                                     Date 
 
 
Name of Witness to Patient Signature Witness to Signature            Date 
 
 
Name of Investigator   Signature of Investigator           Date 
 
The Royal Perth Hospital Human Research Ethics Committee has given ethics approval 
for the conduct of this project.  If you have any ethical concerns regarding the study you 
can contact Associated Professor A Millar, Chairman of the Royal Perth Hospital Ethics 
Committee (9224 2292). 
 
All study participants will be provided with a copy of the Information Sheet and 
Consent Form for their personal records. 
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CONSENT FORM for women of child-bearing potential 
 
 
………………………………. (Doctor's name) has reviewed information on pregnancy 
prevention for women of childbearing potential in clinical trials with me. I understand 
that I should not become pregnant while I am participating in this study. 
 
I understand that I should immediately telephone Kerryn Butler-Henderson at WA 
PET/Cyclotron Service, telephone number 9346 7483 in case: 
 
 I am pregnant or think I might be pregnant. 
 I have missed my period or it is late, or I have a change in my usual menstrual 
cycle (for example, heavier bleeding during my period or bleeding between 
periods). 
 
I should also telephone if I have changed or plan to change my birth control method, or 
if I need to take any prescription drug or other medication not given to me or known by 
Kerryn Butler-Henderson. 
 
 
Patient's name (in print)……………………………………………………. 
 
Patient's signature………………………………………………………….  
 
Date………………………………………………………………………….  
 
 
 
Doctor's name (in print)………………………………………………….  . 
 
Doctor's signature…………………………………………………………   
 
Date…………………………………………………………………………   
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APPENDIX F: HUMAN RESEARCH ETHICS COMMITTEE MOUNT 
HOSPITAL LETTERS OF APPROVAL 
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APPENDIX G: NOTIFICATION FORM (CHAPTER 7) 
 
ATTENTION KERRYN BUTLER-HENDERSON 
Please fax to: 9266 2958 
Please notify that fax has been sent: 0408956082 
 
DCIS TRIAL FORM A 
 
Inclusion Criteria 
To be eligible for inclusion, a patient must satisfy ALL of the following: 
 Newly diagnosed DCIS, 
 Planned to undergo wide local excision of DCIS, and 
 Able to provide informed consent. 
Exclusion Criteria 
Patients will be excluded from the study if ANY of the following apply: 
 Planned mastectomy or neoadjuvant therapy for DCIS; 
 Invasive component detected by biopsy; 
 Previous history of invasive breast disease; 
 Uncontrolled diabetes mellitus; 
 Pregnant at the time of surgery. 
 
 
Patient name:  ________________________________________________________ 
  First Name  Middle Name   Last Name 
 
Date of Birth: ___________________________________ 
 
Breast:  Left  Right    Please ensure patient has: 
        *  Mammography 
Date of surgery: ______________________  *  Positive biopsy 
 
Time of hookwire: _____________________   am    /    pm 
 
Planned time of surgery: _____________________   am    /    pm 
 
Surgeon: PW  DI 
Height: ______________ cm 
Weight: ______________ kg 
Patient must fast for 6 hours prior to injection 
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APPENDIX H: MOUNT HOSPITAL PATIENT INFORMATION SHEET AND 
CONSENT FORM (CHAPTER 7) 
 
Mount  Hospi tal  
 
PATIENT INFORMATION SHEET 
Version 3 
DATE 8th March 2010 
 
Positron Emission Tomography (PET) and Beta Probe in the Staging of Ductal 
Carcinoma In Situ of the Breast. 
 
Principal Investigator: Dr Peter Willsher & Kerryn Butler-Henderson 
 
Introduction 
You are being invited to take part in a research study for patients who are being 
investigated for ductal carcinoma in situ (DCIS) of the breast.  In order for you to 
decide whether you should agree to be part of this study, you should understand enough 
about its risks and benefits to make an informed decision. This process is known as 
informed consent. 
 
DCIS is an increase of abnormal cells within the mammary ducts of the breast.  Normal 
breasts contain lobules where the milk is produced, and tubes called ducts that take the 
milk from the lobules to the nipple.  DCIS are said to be “pre-cancerous” and develops 
inside the lobules and may spread along the ducts.  We have been informed that your 
biopsy results indicate DCIS and you are planned to have surgery to remove and test the 
tissue. 
 
Both research and clinical experience indicates that approximately 20% of patients will 
need to have a second operation (re-excision) when some of the DCIS remains in the 
breast after the first operation.  We are testing a new technology called the positron 
emission tomography (PET) probe. This probe can detect radioactivity attached to a 
substance called fluorodeoxyglucose (FDG) which is taken up by the DCIS cells. In the 
study the probe will be used to try and accurately assess the extent of the DCIS in the 
breast during surgery.  The true microscopic extent of DCIS is difficult to assess with 
our currents tests (i.e. clinical examination, mammography and ultrasound) and 
microscopic (minute or tiny) disease is, of course, not visible to the naked eye. At the 
time of surgery we aim to remove all of the DCIS with a margin of surrounding normal 
breast tissue (the margin).  The PET probe is being tested to see if it can accurately 
identify if all DCIS cells have been removed (i.e. the margins are clear of DCIS cells). 
In the future we are optimistic that this technique will improve the chances of getting 
clear margins at the first operation, meaning fewer women will need to have further 
surgery.  
 
What will happen in this study? 
As part of this trial you will be asked to undergo a number of standard assessments.  
These include: 
- Mammogram (which you have already had), 
- Biopsy (which you have already had), 
- Possibly an ultrasound (which you may or may not have already had). 
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On the day of your surgery, an hour before your operation, you will be injected with a 
small amount of FDG through an intravenous line in your arm. We are testing to see if 
the PET probe can find DCIS cells which have taken up the FDG. During your surgery, 
the surgeon will use the PET probe inside the breast after your tissue has been removed 
to see if there is any residual activity (or cells still containing the FDG). The surgeon 
will also use the probe to test the surface of the tissue that has been removed to see if 
there is any activity. Recordings will be made of the amount and location of any FDG 
activity and this will then be correlated with the pathology results after the surgery. We 
will then be able to see if FDG activity corresponds to the presence of DCIS cells at the 
margins.  
 
Your surgeon will perform the standard recommended surgery to the breast as you have 
discussed pre-operatively - no changes to the surgical plan will be made based on the 
presence of FDG activity.  
 
Alternatives 
If you decide not to take part in this study, you will still receive the standard 
assessments. 
 
Possible Risks 
Complications related to insertion of the intravenous catheter (IV line) used to give the 
FDG can occasionally occur. These mainly involve slight bruising but very 
infrequently, infections can occur. You will be given appropriate treatment at the 
Hospital if a reaction or complication occurs. 
 
The study will involve the use of approximately 100 - 150 MBq of FDG pre-surgery, 
which gives an estimated dose of 2.847mSv effective dose of radiation. The amount of 
extra radiation exposure from this injection is equal to about eleven months of natural 
background radiation. This is about the same amount of radiation as that from a 
mammography and about half that from a chest CT. Other than the radiation exposure 
there are no documented side effects associated with the administration of the PET 
isotope. 
 
Women who are pregnant or breast-feeding and women who may become pregnant, but 
who are not taking adequate contraceptive measures, must not participate in this trial. 
Participants are strongly advised to use effective contraception if appropriate during the 
course of the study. You should discuss methods of effective contraception with your 
doctor. 
 
There may be additional risks that are unforeseeable at this time. You will be informed 
of any new and significant information that could affect your willingness to continue 
participation. In the case of an unforeseen side effect, prompt treatment will be initiated. 
 
Possible Benefits 
As your results will not be discussed with you or your Surgeon until after your 
operation, you may not receive any benefits from participating in this trial.  The 
knowledge gained from patients participating in the study will assist us in determining 
the role of a PET probe in the treatment of DCIS.  Should this technique be validated, 
then in the future the information will be shared with the Surgeon, who can use it during 
surgery.  This has the potential of reducing the number of women who may need second 
operations in the future. 
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Confidentiality and Disclosure of Information 
Any information obtained in connection with this project that can identify you, 
including information from medical practitioners, other health professionals, hospitals, 
diagnostic imaging services or laboratories outside this hospital, will remain 
confidential.  It will only be disclosed with your permission, except as required by law.   
 
It is anticipated that results will be published in a relevant medical journal.  In any 
publication, information will be provided in such a way that you cannot be identified. 
 
All data collected will be kept in a safe and secure location.  All hardcopy data will be 
kept in a locked cabinet at Curtin University of Technology and electronic data will be 
password protected.  Only authorised staff will have access to your information.  All 
data will be kept for the minimum 15 years retention period. 
 
Participation is Voluntary 
Participation in any research project is voluntary.  If you do not wish to take part you 
are not obliged to.  If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage.  
 
Your decision whether to take part or not to take part, or to take part and then withdraw, 
will not affect your routine treatment, your relationship with those treating you or your 
relationship with the Mount Hospital. 
 
Before you make your decision, a member of the research team will be available so that 
you can ask any questions you have about the research project.  You can ask for any 
information you want.  Sign the Consent Form only after you have had a chance to ask 
your questions and have received satisfactory answers.  If you decide to withdraw from 
this project, please notify a member of the research team before you withdraw.   
 
In the event that you suffer an adverse event or a medical accident during this study that 
arises from your participation in the study, Mount Hospital will offer you all full and 
necessary treatment.   
 
New Information Arising During the Project 
During the research project, new information about the risks and benefits of the project 
may become known to the researchers.  If this occurs, you will be told about this new 
information.  This new information may mean that you can no longer participate in this 
research.  If this occurs, the person/s supervising the research will stop your 
participation.  In all cases, you will be offered all available care to suit your needs and 
medical condition. 
 
Further Information or Any Problems 
If you require further information or if you have any problems concerning this project 
(for example, any side effects), you can contact: 
 
Principal Investigator     Dr Peter Willsher (Breast Surgeon)           Phone: 9481 4522 
Co-Investigator              Kerryn Butler-Henderson (PET Probe)      Phone: 9266 7531 
           040 895 6082 
If you want to discuss the study with someone who is not directly involved in it 
(about the information you have received, the conduct of the study, your rights as 
a participant, or a complaint you have), please contact Dr Ross Baker, Chairman 
of the Ethics Committee, telephone (08) 9483 2841. 
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MOUNT HOSPITAL 
CONSENT FORM 
Positron Emission Tomography (PET) and Beta Probe in the Staging of Ductal 
Carcinoma In Situ of the Breast. 
 
Principal Investigator:  Dr Peter Willsher & Kerryn Butler-Henderson 
 
Subject Name:_________________________________________ 
 
Date of Birth: _______________ 
 
1. I have been given clear information (verbal and written) about this study and have 
been given time to consider whether I want to take part. 
2. I have been told about the possible advantages and risks of taking part in the study 
and I understand what I am being asked to do. 
3. I have been able to have a member of my family or a friend with me while I was 
told about the study.  I have been able to ask questions and all questions have been 
answered satisfactorily. 
4. I know that I do not have to take part in the study and that I can withdraw at any 
time during the study without affecting my future medical care.  My participation in 
the study does not affect any right to compensation, which I may have under statute 
or common law. 
5. I hereby give permission for medical practitioners, other health professionals, 
hospitals, diagnostic imaging services or laboratories outside this hospital to release 
information concerning my disease and treatment that is needed for this study to 
Curtin University of Technology and I understand that such information will remain 
confidential. 
6. I agree to take part in this research study and for the data obtained to be published 
provided my name or other identifying information is not used. 
 
If you are unclear about anything you have read in the Patient Information Sheet 
or this Consent Form, please speak to your doctor before signing. 
 
 
Name of Patient  Signature of Patient                                     Date 
 
 
Name of Witness to Patient Signature Witness to Signature          Date 
 
 
Name of Investigator  Signature of Investigator           Date 
 
The Mount Hospital Human Research Ethics Committee has given ethics approval for 
the conduct of this project.  If you have any ethical concerns regarding the study you 
can contact Dr Ross Baker, Chairman of the Ethics Committee, telephone (08) 9483 
2841. 
 
All study participants will be provided with a copy of the Information Sheet and 
Consent Form for their personal records. 
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CONSENT FORM for women of child-bearing potential 
 
 
………………………………. (Investigator’s name) has reviewed information on 
pregnancy prevention for women of childbearing potential in clinical trials with me. I 
understand that I should not become pregnant while I am participating in this study. 
 
I understand that I should immediately telephone Kerryn Butler-Henderson at Curtin 
University of Technology, telephone number 9266 7531 in case: 
 
* I am pregnant or think I might be pregnant. 
* I have missed my period or it is late, or I have a change in my usual menstrual 
cycle (for example, heavier bleeding during my period or bleeding between 
periods). 
 
I should also telephone if I have changed or plan to change my birth control method, or 
if I need to take any prescription drug or other medication not given to me or known by 
Kerryn Butler-Henderson. 
 
 
Patient's name (in print)……………………………………………………. 
 
Patient's signature………………………………………………………….  
 
Date………………………………………………………………………….  
 
 
 
Investigator’s name (in print)………………………………………………….  . 
 
Investigator’s signature…………………………………………………………   
 
Date…………………………………………………………………………   
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APPENDIX I: DATA COLLECTION FORM (CHAPTER 7) 
 
PET PROBE STUDY  
DEMOGRAPHIC DATA  
Patient ID: __________ DOB:  ______________ Date of Surgery:  ___________ 
Weight:  ____________ Height:  _____________ BMI:  ___________ 
Surgeon:   PW  DH  
Breast:  Left  Right Diabetes:  Yes  No 
 
INJECTION DATA 
Time of injection:  _________________________  am  pm 
Comments:  _______________________________________________________________ 
_______________________________________________________________ 
_______________________________________________________________ 
_______________________________________________________________ 
 
PRE-SURGERY DATA 
Monitoring Device 
Reading 
Surgeon:  ___________ Investigator:  ______________ 
 
SURGERY 
Time of surgery:  __________________________  am  pm 
 
 Time Superior Inferior Medial Lateral Superficial Deep 
In cavity 
CPS 
       
Excised 
CPS 
       
Shaving        
 
Gamma Excised Time:  _____________ CPS:  ____________________ 
 
POST-SURGERY 
Monitoring Device 
Reading 
Surgeon:  ___________ Investigator:  ______________ 
 
COMMENTS:  ________________________________________________________ 
 
